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INTRODUCCIÓN 
El sistema respiratorio es el encargado de suministrar oxígeno al organismo para la 
respiración celular. Para ser eficiente, la principal estructura donde se produce el intercambio 
gaseoso, el epitelio alveolar, presenta una gran superficie de contacto con la atmósfera (1). 
Por ello, los alveolos están continuamente expuestos a partículas inhaladas potencialmente 
dañinas, como alérgenos, contaminantes o patógenos. Para proteger al huésped frente a 
patógenos que colonizan los alveolos durante la respiración, el epitelio alveolar está equipado 
con una efectiva defensa inmune (2). 
El sistema inmune innato en el pulmón está compuesto por un componente celular, 
formado por células inmunes con capacidad fagocítica, principalmente macrófagos alveolares 
e intersticiales; y un componente soluble, con proteínas y péptidos antimicrobianos (AMP) 
capaces de eliminar patógenos (3). Los AMPs, tales como β-defensinas (HBD) o el péptido 
derivado del extremo N-terminal de la proteína B del surfactante pulmonar (SP-BN) (4-6), son 
péptidos catiónicos (HBD) o aniónicos (SP-BN) de bajo peso molecular, evolutivamente 
conservados, que forman el principal sistema de defensa en la mayoría de organismos vivos 
(7, 8). Por otra parte, las proteínas antimicrobianas son factores solubles de mayor peso 
molecular, que presentan actividad bactericida y, además, son capaces de modular la 
respuesta inflamatoria del huésped (9, 10). Entre éstas se encuentran la lisozima, lactoferrina 
y las proteínas del surfactante pulmonar A y D (SP-A, SP-D) (10-12). 
SP-A es la proteína más abundante en el fluido alveolar (en peso) y pertenece a la familia 
de colectinas, caracterizadas por la presencia de un dominio tipo lectina y un dominio tipo 
colágeno (11, 12). Esta familia es capaz de reconocer y facilitar la eliminación de patógenos a 
través del reconocimiento de patrones moleculares asociados a patógenos (13). Se ha 
demostrado que tanto la SP-A, como los AMPs, pueden matar directamente algunos 
microorganismos aumentando la permeabilidad de su membrana (13-15). La mayoría de los 
estudios in vitro con SP-A indican que se une y actúa preferentemente sobre bacterias Gram-
negativas que expresan lipopolisacárido (LPS) truncado en su membrana externa (OM) (LPS 
rugoso), aunque también ha mostrado actividad frente a bacterias con la estructura completa 
del LPS (LPS liso) (16, 17). Esto podría sugerir la expresión de factores o mecanismos de 
resistencia a SP-A por parte de algunos patógenos pulmonares. Por otro lado, estudios in vivo 
con ratones SP-A -/- han demostrado que ratones silvestres presentan una mayor eliminación 
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bacteriana que ratones KO (18), incluso frente a bacterias que han sido resistentes a la acción 
bactericida de la SP-A in vitro (19, 20), indicando un papel más complejo de la SP-A in vivo. 
De este modo, nuestra hipótesis es que la SP-A actúa sinérgicamente y/o cooperativamente 
con diferentes AMPs presentes en el espacio alveolar para reforzar la actividad microbicida 
de cada factor por separado.  
Esta hipótesis se basa en el hecho de que ya se han descrito previamente actividades 
sinérgicas en el fluido alveolar entre lisozima, lactoferrina y HBD-2 (21), así como 
actividades aditivas entre HBD-2 y la catelicidina LL-37 frente E. coli (22). El estudio de las 
interacciones entre la SP-A y diferentes factores solubles alveolares, y entre factores solubles 
y patógenos, permitiría avanzar en el conocimiento del papel de la SP-A en la inmunidad 
innata del pulmón. Además, ayudaría al desarrollo de nuevas terapias adyuvantes frente a 
infecciones por bacterias Gram-negativas, debido a la actual incidencia de bacterias multi-
resistentes sin ningún antibiótico efectivo (23).  
OBJETIVOS 
El principal objetivo de esta tesis fue estudiar la actividad antimicrobiana de la SP-A, 
tanto individual como en colaboración con AMPs, en la defensa inmune innata del pulmón. 
Para ello, se usaron diferentes patógenos respiratorios, incluyendo Klebsiella pneumoniae, 
Pseudomonas aeruginosa y Haemophilus influenzae, así como mutantes isogénicos de 
Klebsiella en su membrana externa, a fin de aclarar el mecanismo de resistencia bacteriana a 
SP-A, así como dilucidar la posible acción sinérgica de SP-A con AMPs, tanto endógenos 
(HBD, SP-BN) como exógenos como la polimixina B (PMB) o colistina. Además, también se 
investigó el mecanismo cooperativo o sinérgico entre la SP-A y AMPs responsable de su 
actividad antimicrobiana. 
Esta tesis está compuesta de 3 capítulos con los siguientes objetivos concretos: 
1. Estudiar el potencial efecto protector de la SP-A frente a diferentes cepas lisas y 
rugosas del patógeno pulmonar Klebsiella pneumoniae K2; así como su habilidad para 
modular la actividad antimicrobiana de diversos péptidos antimicrobianos frente a 
varios patógenos respiratorios. 
2. Determinar in vivo el potencial efecto terapéutico de SP-A y SP-BN frente a una 
bacteria que es causa común de neumonía. 
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3. Evaluar los mecanismos mediante los cuales la SP-A y un derivado nonapeptídico de 
PMB (PMBN), son capaces de matar bacterias Gram-negativas sinérgicamente, 
cuando ni la proteína SP-A ni el péptido PMBN presentan actividad bactericida por 
separado. 
RESULTADOS PRINCIPALES Y CONCLUSIONES 
Para evaluar el papel protector de la SP-A frente a infecciones, determinamos su 
habilidad antimicrobiana frente al aislado clínico Klebsiella pneumoniae K2 (Kp wt), el cual 
expresa LPS liso (S-LPS) en su membrana externa (OM) y cápsula (CPS); y diferentes 
mutantes isogénicos de esta cepa con diferentes fenotipos de LPS rugoso, desde LPS rugoso 
(R-LPS) con CPS hasta LPS rugoso profundo Rc o Re sin CPS. Encontramos que la SP-A fue 
capaz de agregar, inhibir el crecimiento y matar mutantes descapsulados de K. pneumoniae 
con LPS rugoso profundo (Rc y Re). Por el contrario, SP-A no mostró ningún efecto 
antimicrobiano frente a Kp wt, mutantes rugosos descapsulados (Ra o Rb) o mutantes rugoso 
profundo con CPS. Además, SP-A opsonizó y aumentó la fagocitosis del mutante Rc sin CPS, 
y no de Kp wt, por macrófagos alveolares MH-S. Mediante experimentos de unión en fase-
sólida, demostramos que la SP-A no tuvo ningún efecto frente a Kp wt, porque fue incapaz de 
unirse a esta bacteria. Por el contrario, SP-A sí se unió, de manera dosis-dependiente, a las 
cepas que fueron sensibles a ella (Rc y Re sin capsula). Estos resultados conjuntamente 
destacan la importancia del LPS liso y la CPS en la resistencia bacteriana a SP-A, a la vez que 
confirman estudios previos que indicaban la preferencia de esta proteína por bacterias que 
expresan LPS rugoso profundo (16, 24). 
Además, evaluamos la capacidad de la SP-A para modular la actividad antimicrobiana 
microbicida de diferentes péptidos antimicrobianos frente a patógenos respiratorios resistentes 
a ella, como K. pneumoniae K2, Pseudomonas aeruginosa O1 (PAO1) and Haemophilus 
influenzae no tipable (NTHi). Para ello, se utilizaron distintos tipos de AMPs endógenos 
catiónicos y aniónicos, así como AMPs exógenos catiónicos. Nuestros resultados mostraron 
que la SP-A fue capaz de actuar sinérgicamente con concentraciones crecientes de AMPs 
exógenos catiónicos, como polimixina B (PMB) y colistina (PME), aumentando así la acción 
de dos potentes, pero citotóxicos, péptidos antibióticos de uso clínico (25, 26). Esta acción 
sinérgica también se vio con un derivado nonapeptídico de PMB (PMBN), que no presenta 
actividad bactericida, pero retiene la capacidad de unirse y alterar la estructura de la 
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membrana externa de bacterias Gram-negativas (27). Así, la acción sinérgica entre SP-A y 
PMBN derivó en una alta acción bactericida, cuando ninguno de estos factores tuvo actividad 
por separado. 
Por otro lado, SP-A también aumentó significativamente el efecto bactericida de los 
AMPs catiónicos endógenos (β-defensina 2 y 3), ambos presentes en el fluido alveolar, que 
han sido ampliamente investigados debido a su habilidad para matar bacterias MDR (28, 29). 
Además, encontramos que la SP-A fue capaz de matar Kp wt en la presencia del péptido 
antimicrobiano aniónico, específico de pulmón, SP-BN, a pH neutro. SP-BN proviene del 
procesamiento proteolítico de la proteína del surfactante SP-B y mata bacterias a pH ácido, 
pero no neutro (6). Asimismo, a través de experimentos de recuento de colonias 
intracelulares, encontramos que la pre-incubación de macrófagos alveolares (MH-S) y 
peritoneales (Raw 264.7) con SP-A y SP-BN aumentó la fagocitosis de Kp wt, comparado con 
células sin tratar o tratadas con SP-A o SP-BN por separado. Estos resultados juntos sugieren 
que la acción sinérgica de la SP-A con AMPs podría aumentar la defensa del pulmón frente a 
infecciones en el espacio alveolar. 
Para confirmar estos resultados en condiciones fisiológicas y evaluar el posible potencial 
terapéutico de la SP-A en combinación con SP-BN, comprobamos la actividad cooperativa 
entre estas proteínas in vivo. De este modo, 10.000 CFUs de K. pneumoniae K2 fueron co-
administrados intratraquealmente con SP-A, SP-BN o ambos, en ratones FVB/N wt. Tras 
diferentes tiempos de infección, los pulmones fueron extraídos y homogeneizados para  
determinar la carga bacteriana por recuento de CFUs y la expresión de citoquinas por ELISA. 
Igualmente, se analizó el estado de los pulmones mediante histopatología, así como el numero 
total y el tipo de células presentes en el lavado broncoalveolar mediante tinción de 
centrifugados celulares. Encontramos que en los ratones tratados con SP-A/SP-BN: i) la carga 
bacteriana pulmonar se redujo 9 veces; ii) aumentó el reclutamiento temprano de neutrófilos; 
y iii)  mejoró la histopatología del pulmón; comparado con ratones sin tratar o ratones 
tratados con SP-A o SP-BN solamente. Además, se incrementó la concentración de 
mediadores solubles inflamatorios (TNF-α, IL-1β, -6, -17 y MIP-2) en los homogeneizados de 
pulmón en comparación con ratones sin tratar. De esto modo,  SP-A fue capaz de cooperar 
con SP-BN in vivo para aumentar la defensa del pulmón. La acción cooperativa de SP-A/SP-
BN fue consistente con: 1) una aumentada actividad microbicida de SP-A/AMP; 2) un 
incremento de la fagocitosis de bacterias por macrófagos alveolares inducido por SP-A/SP-
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BN; 3) un incremento en el reclutamiento temprano de neutrófilos en el fluido broncoalveolar 
inducido por SP-A/SP-BN; y 3) un aumento en la respuesta inflamatoria temprana del huésped 
promovido por SP-A/SP-BN.  
Una vez que la cooperación entre SP-A y SP-BN se demostró in vivo, evaluamos el 
potencial tratamiento terapéutico de SP-A/SP-BN. Para ello, se infectaron ratones con K. 
pneumoniae, y tras 6h o 24h de la inoculación del patógeno, fueron tratados con SP-A más 
SP-BN. Nuestros resultados indican que el tratamiento terapéutico de SP-A y SP-BN protegió 
significativamente a los ratones frente a la infección por K. pneumoniae K2. 
Finalmente, determinamos algunos de los mecanismos por los cuales SP-A mata 
bacterias sinérgicamente con AMPs. Para ello, estudiamos las interacciones moleculares entre 
SP-A y AMPs, y empleamos modelos de membranas bacterianas para investigar posibles 
cambios en la estructura y permeabilidad de membrana inducida por SP-A/AMPs.  
Mediante experimentos de unión en fase-sólida, de dispersión de luz dinámica y cambios 
en la fluorescencia intrínseca de la proteína, encontramos que la SP-A es capaz de 
interaccionar con beta-defensina humana-3 (HBD-3), SP-BN (Kd=0.39±0.3 µM), PMB (0.32 ± 
0.04 µM), and PMBN (Kd =0.26 ± 0.02 µM) de manera dosis-dependiente. Además, esta 
interacción proteína-proteína facilita la unión de SP-A a K. pneumoniae K2 (con la que SP-A 
sola es incapaz de interaccionar).  
Por otro lado, utilizamos un derivado nonapeptídico de la PMB, PMBN, sin capacidad 
bactericida, para estudiar el mecanismo de acción sinérgico de estas dos proteínas sobre 
membranas modelo de bacterias Gram-negativas. Primeramente, la acción sinérgica entre SP-
A y PMBN frente a bacterias Gram-negativas (Klebsiella pneumoniae K2 and Pseudomonas 
aeruginosa O) se confirmó in vitro, donde ninguna de estas proteínas fue capaz de matar estas 
bacterias por separado. Dado que los modelos de membrana externa bacteriana se hacen 
normalmente con Re-LPS, en vez de S-LPS, también evaluamos la actividad sinérgica de SP-
A y PMBN frente al mutante descapsulado isogénico de K. pneumoniae K2, que expresa LPS 
rugoso profundo y es susceptible a la acción de la SP-A. Encontramos que ni PMBN, ni SP-A 
a bajas concentraciones, fueron capaces de matar esta cepa de K. pneumoniae K2. Sin 
embargo, PMBN y SP-A (a bajas concentraciones de SP-A) juntas, fueron capaces de matar 
el mutante descapsulado de K. pneumoniae K2, que expresa LPS rugoso profundo. 
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Para identificar los mecanismos de la acción bactericida de PMBN/SP-A, medimos la 
capacidad de estas proteínas de insertarse en la membrana externa bacteriana mediante 
mediciones en la presión superficial de monocapas de Re-LPS tras la adición de las proteínas 
en la subfase acuosa. Encontramos que PMBN y PMBN/SP-A, pero no SP-A, fueron capaces 
de insertarse en estas monocapas, y que la inserción de la PMBN incrementó en presencia de 
SP-A. Además, mediante cambios en la fluorescencia de la sonda anfipática LAURDAN, así 
como por calorimetría diferencial de barrido, demostramos que la inserción de SP-A/PMBN 
aumentó la fluidez de membranas externas bacterianas compuestas por Re-LPS/fosfolípidos 
bacterianos (PL)(8/2 w/w). Estas alteraciones de membrana provocadas por las dos proteínas 
fueron suficiente para permeabilizar la membrana externa bacteriana, como demostramos 
mediante cambios en la fluorescencia del DPH (sonda hidrofóbica de membrana) y la 
liberación del fluoróforo hidrofílico ANTS, que fue co-encapsulado con su inactivador 
colisional dentro de vesículas unilamelares grandes de Re-LPS/PL (8/2 w/w). Por el contrario, 
la presencia de SP-A no tuvo ninguna influencia en la permeabilidad de membrana inducida 
por PMBN en membranas internas bacterianas compuestas por fosfolípidos bacterianos 
(PE/PG/CL). Analizando los resultados en conjunto, parecen indicar que la SP-A y PMBN 
cooperan conjuntamente para matar bacterias, porque ambas juntas son capaces de perturbar y 
permeabilizar la membrana externa bacteriana. 
Basándonos en los resultados de la actividad sinérgica entre SP-A y PMBN, y otros 
AMPs, proponemos el siguiente mecanismo de acción: 
i. La unión de la SP-A a AMPs permitiría el acceso de la SP-A a bacterias que 
expresan LPS liso en su membrana externa y/o cápsula. 
ii. SP-A y AMPs inducen la perturbación de la estructura de la OM y, así, SP-A es 
entonces capaz de extraer moléculas de LPS de la membrana, como ha sido 
previamente publicado (30). Esto provoca una pérdida de LPS de la membrana, 
produciendo defectos transitorios en la membrana de LPS. 
iii. El incremento de la fluidez de membrana y su desestabilización inducidos por SP-
A/AMPs produce un incremento de la permeabilidad de la OM, que permitiría el 
acceso de los AMPs a la membrana interna bacteriana (IM).  
iv. La perturbación de la IM bacteriana por los AMPs provocaría la muerte 
bacteriana y/o la translocación de los AMPs al citoplasma y su interacción con 
dianas intracelulares.  
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Basándonos en los resultados de esta tesis, concluimos que la SP-A es capaz de 
incrementar la actividad microbicida de AMPs catiónicos y aniónicos. De este modo, la SP-A 
es capaz de fortalecer la acción antimicrobiana de AMPs frente bacterias Gram-negativas. 
Más estudios sobre actividades sinérgicas entre factores antimicrobianos con potencial uso 
clínico deberían ser considerados para el desarrollo de nuevas terapias adyuvantes o 
alternativas para el tratamiento de infecciones respiratorias. 
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INTRODUCTION 
The respiratory system is mainly involved in providing oxygen to the organism for 
cellular respiration. To be efficient, the alveolar epithelium constitutes a large contact surface 
with the atmosphere (1). As a consequence, alveoli are constantly exposed to inhaled particles 
such as allergens, contaminants, and pathogens. Therefore, the alveolar epithelium is 
equipped with an effective immune defense in order to protect the host against pathogens 
reaching the alveoli during inspiration (2).  
Innate immune defense in the alveolar space is composed of a cellular component, 
comprising immune phagocytic cells, mainly alveolar macrophages; and a soluble 
component, consisting of antimicrobial peptides (AMPs) and proteins able to eliminate 
pathogens (3). AMPs, like β-defensins (HBD) or the peptide derived from N-terminal domain 
of pulmonary surfactant protein B (SP-BN) (4-6), are small cationic (HBD) or anionic (SP-BN) 
conserved peptides of the innate immune response and the principal defense system for the 
majority of living organisms (7, 8). Alveolar antimicrobial proteins such as lysozyme, 
lactoferrin, SP-A, and SP-D are host soluble factors of higher molecular weight (10-12). They 
have direct antimicrobial activity and are able to modulate the inflammatory response of the 
host (9, 10). 
SP-A is the most abundant protein of the alveolar fluid (by weight) and belongs to the 
collectin family, whose members are characterized by the presence of a lectin-like domain 
and a collagen-like domain. This family is able to recognize and facilitate the clearance of 
pathogens through interaction with pathogen-associated molecular patterns (11, 12). SP-A, 
like AMPs, has been proven to directly kill some microorganisms by increasing membrane 
permeabilization (13-15). Most in vitro studies of SP-A antimicrobial activity indicate that it 
binds to and acts preferably on Gram-negative bacteria expressing truncated LPS on their OM 
(rough LPS), but shows also activity against bacteria expressing the entire structure of LPS 
(smooth LPS) (16, 17).  These findings suggest the expression in some respiratory pathogens 
of factors with bacterial resistance to SP-A. On the other hand, in vivo studies with SP-A -/- 
mice show much greater microbial clearance in SP-A wt than SP-A -/- mice after infection 
(18), even on bacteria resistant to the bactericidal activity of SP-A (19, 20); thereby 
suggesting more complex mechanisms of the antimicrobial activity of SP-A in vivo. We 
hypothesize that SP-A acts synergistically or cooperatively with different AMPs present in 
the alveolar fluid to strengthen the microbicidal activity of each factor alone.  
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This hypothesis is based on the facts that synergistic activity between lisozime, 
lactoferrin and HBD-2 has already been described in the alveolar fluid (21), and HBD-2 and 
cathelicidin LL-37 exhibit additive activities against E. Coli (22). The study of SP-A 
interaction with several alveolar soluble factors and between soluble factors and pathogens 
would further advance understanding of SP-A’s role in innate immunity. It would also help to 
develop new adjunctive therapies against Gram-negative infections, due to the emergence of 
multi-drug resistant (MDR) bacteria without any effective antibiotic (23).  
 
OBJECTIVES 
The main objective of this thesis was to study both individual and cooperative 
antimicrobial activities of SP-A in airway host defense. To accomplish this task, several 
respiratory Gram-negative pathogens, including Klebsiella pneumoniae, Pseudomonas 
aeruginosa and Haemophilus influenzae, as well as isogenic mutants of Klebsiella in its OM, 
were used to clarify the mechanism of bacterial resistance to SP-A and the synergistic activity 
of SP-A with cationic and anionic AMPs, either endogenous or exogenous. In addition, the 
mechanism by which SP-A kills bacteria in conjunction with these factors was investigated. 
 
This thesis is composed of three chapters with the following concrete objectives: 
1. To study the potential protective effect of SP-A against different smooth and rough 
strains of the lung pathogen Klebsiella pneumoniae K2, as well as its ability to 
modulate the antimicrobial activity of exogenous and endogenous cationic AMPs 
against several respiratory pathogens. 
2. To investigate the potential cooperative therapeutic action of SP-A and the lung 
anionic antimicrobial peptide SP-BN against a common bacterial cause of pneumonia 
in vivo. 
3. To determine the mechanism by which SP-A and PMBN, a derivative of polymyxin B, 
are able to kill Gram-negative bacteria synergistically, when neither of these proteins 
has microbicidal activity alone. 
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MAIN RESULTS AND CONCLUSIONS 
To evaluate the protective role of SP-A against infection, we tested its antimicrobial ability 
against the clinical isolate Klebsiella pneumoniae K2 (Kp wt), which expresses smooth LPS (S-
LPS) in its outer membrane (OM) and capsule (CPS), and different isogenic mutants 
expressing several LPS phenotypes, from rough LPS (R-LPS) with CPS to deep rough Rc- or 
Re-LPS without CPS. We found that SP-A was able to aggregate, inhibit the growth and kill 
isogenic decapsulated Klebsiella pneumoniae K2 mutants expressing deep rough LPS (Rc-LPS 
and Re-LPS). In contrast, SP-A did not have any antimicrobial effect against Kp wt, 
decapsulated rough mutants (Ra or Rb) or deep rough mutants expressing CPS. In addition, SP-
A opsonized and enhanced phagocytosis of the Rc-LPS mutant, but not Kp wt, by alveolar 
macrophages. By employing solid-phase binding assay, we demonstrated that SP-A did not 
have any effect on Kp wt because it was unable to bind this bacterium. On the contrary, SP-A 
bound in a dose-dependent manner to decapsulated deep rough mutants. Together, these results 
highlight the importance of smooth LPS and CPS in bacterial resistance to SP-A, and confirm 
previous studies that indicate SP-A’s preference for bacteria expressing deep rough LPS (16, 
24).  
Next, we evaluated whether SP-A was able to modulate the microbicidal action of different 
antimicrobial peptides against respiratory pathogens resistant to SP-A such as capsulated 
Klebsiella pneumoniae K2 (Kp wt), Pseudomonas aeruginosa O1 (PAO1), and non-typeable 
Haemophilus influenzae (NTHi). For this purpose, several kinds of cationic and anionic 
endogenous AMPs and cationic exogenous AMPs were used. We found that SP-A acted 
synergistically with increasing concentrations of exogenous cationic AMPs, such as polymyxin 
B (PMB) and colistin (PME), thus enhancing the action of these potent, but cytotoxic, clinical 
antibiotics (25, 26). This synergistic action was also found with a nonapeptide derivative from 
polymyxin B (PMBN) which does not have bactericidal activity but is able to bind and disturb 
the structure of the outer membrane of Gram-negative bacteria (27). Therefore, the synergistic 
action between SP-A and PMBN resulted in high bactericidal action against Gram-negative 
bacteria, when neither SP-A nor PMBN exhibited microbicidal activity alone.   
On the other hand, SP-A significantly increased the bactericidal effect of endogenous 
cationic AMPs (human β-defensins 2 and 3) present in the alveolar fluid, which has been 
widely investigated due to their ability to kill MDR bacteria (28, 29). Furthermore, we found 
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that SP-A was able to kill Kp wt in the presence of the lung-specific anionic antimicrobial 
peptide SP-BN at neutral pH. SP-BN comes from the proteolytic processing of the surfactant 
protein SP-B and kills bacteria at acidic, but not neutral, pH (6). We found that pre-incubation 
of alveolar and peritoneal macrophages with SP-A and SP-BN resulted in a dramatic uptake of 
Kp wt, compared with untreated cells or cells treated with SP-A or SP-BN alone. Taken 
together, these results suggest that synergistic action of SP-A with AMPs in the alveolar space 
might enhance lung host defense against infection. 
Next, we proved the cooperative action of SP-A and SP-BN in vivo in physiological 
conditions, and evaluated the potential therapeutic treatment of SP-A in combination with SP-
BN. Therefore, 10,000 CFUs of K. pneumoniae K2 were intratracheally co-administered with 
SP-A, SP-BN or both, in wt FVB/N mice. After several infection times, the lungs were 
harvested and homogenized to determine the lung bacterial burden by CFU count, and cytokine 
expression by ELISA. In addition, lung condition was analyzed by histopathology and the 
broncoalveolar lavages were used to evaluate the number and type of alveolar cells by staining 
of cytospin preparations. We found that in SP-A/SP-BN-treated mice: i) lung bacterial burden 
was reduced 9-fold; ii) early neutrophil recruitment was enhanced; and iii) lung histopathology 
was ameliorated in comparison with untreated mice or mice treated with SP-A or SP-BN alone. 
In addition, the concentrations of soluble inflammatory mediators (TNF-α, IL-1β, -6, -17 and 
MIP-2) in lung homogenates increased early in infection in comparison with untreated mice. 
Consequently, SP-A was able to cooperate with SP-BN in vivo to enhance lung defense. This 
SP-A/SP-BN’s action was consistent with: 1) enhanced SP-A/SP-BN microbicidal activity; 2) 
SP-A/SP-BN-induced increase of bacterial phagocytosis by alveolar macrophages; 3) SP-A/SP-
BN-induced increase of neutrophil recruitment in the alveolar fluid; and 4) SP-A/SP-BN-
induced enhance of host early inflammatory response. 
Once the cooperation between SP-A and SP-BN in vivo was demonstrated, we evaluated 
the potential therapeutic treatment of SP-A/SP-BN. To this end, mice were infected with K. 
pneumoniae, and after 6h or 24h of bacterial challenge, they were treated with SP-A plus SP-
BN. Our results indicate that therapeutic treatment of SP-A and SP-BN conferred a significant 
protection against K. pneumoniae K2 infection. 
Finally, we studied some of the mechanisms by which SP-A kills bacteria synergistically 
with AMPs. To accomplish this, we studied molecular interactions between SP-A and AMPs, 
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and we used bacterial model membranes to investigate possible changes in membrane structure 
and permeability induced by SP-A/AMP.  
We found that SP-A is able to interact with human-beta-defensin-3 (HBD-3), SP-BN 
(Kd=0.39±0.3 µM), PMB (0.32 ± 0.04 µM), and PMBN (Kd =0.26 ± 0.02 µM) in a dose-
dependent manner as demonstrated by solid-phase binding assay, dynamic light scattering and 
changes in the intrinsic fluorescence of SP-A. This protein-protein interaction facilitates SP-A 
binding to K. pneumoniae K2 (which cannot be recognized by SP-A alone). 
Next, we used a nonapeptide derivative from PMB (PMBN) without antimicrobial activity 
to study the mechanisms of synergic action of these proteins on bacterial model membranes. 
The synergic action of SP-A and PMBN against Gram-negative bacteria (Klebsiella 
pneumoniae K2 and Pseudomonas aeruginosa O) was first confirmed using an in vitro 
bacterial killing assay. Neither SP-A nor PMBN was able to kill these bacteria alone. Given 
that model membranes of the bacterial OM are usually made of Re-LPS instead of S-LPS, we 
also tested the synergic activity of SP-A and PMBN against the decapsulated isogenic mutant 
of Klebsiella pneumoniae K2 expressing deep rough LPS, which is susceptible to SP-A action. 
We found that neither PMBN nor SP-A at low concentrations was able to kill this strain of K. 
pneumoniae K2. However, PMBN and SP-A (at low SP-A concentrations) were jointly able to 
kill decapsulated Klebsiella pneumoniae K2 mutant, expressing deep rough LPS. 
To identify the mechanism of PMBN/SP-A killing, we measured the capability of these 
proteins to insert into bacterial outer membranes by measuring the surface pressure of Re-LPS 
monolayers after protein injection into the aqueous subphase. We found that PMBN and SP-
A/PMBN, but not SP-A, were able to insert into these monolayers, and PMBN insertion 
significantly increased in the presence of SP-A. SP-A/PMBN membrane insertion enhanced 
membrane fluidity of outer bacterial membranes composed of Re-LPS/bacterial phospholipids 
(PL) (8/2 w/w), as demonstrated by changes in the steady-state anisotropy of DPH (membrane 
hydrophobic probe), fluorescence of LAURDAN amphipathic probe, as well as by differential 
scanning calorimetry. These membrane disturbances induced by SP-A/PMBN, but not by SP-A 
or PMBN alone, resulted in membrane permeabilization, as demonstrated by changes in DPH 
fluorescence (membrane hydrophobic probe) and the leakage of the hydrophilic fluorophore 
ANTS, which was co-encapsulated with its collisional quencher DPX inside Re-LPS/PL (8/2 
w/w)	  large unilamellar vesicles. In contrast, the presence of SP-A did not have any influence on 
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PMBM-induced permeability of the inner bacterial membrane composed of bacterial 
phospholipids (PE/PG/CL). Taken together, these results indicate that SP-A and PMBN 
cooperate in killing bacteria because they are jointly able to disturb and permeabilize the outer 
bacterial membrane. 
	  	  Based on our results on the synergistic activity between SP-A and PMBN, and other 
AMPs, we propose the following mechanism of action:  
i. SP-A binding to AMPs would allow SP-A access to bacteria that express smooth 
LPS in its outer membrane and/or capsule. 
ii. SP-A and AMP induce perturbation of OM structure and SP-A would then be able 
to extract LPS molecules from the membrane as previously reported (30). This 
results in a loss of LPS from the membrane. As a consequence, transient defects are 
produced, rendering the LPS membrane leaky. 
iii. SP-A/AMP-dependent increase of bacterial OM fluidity and destabilization result 
in increased OM permeability, which would allow AMPs access to the bacterial 
inner membrane (IM).  
iv. AMP-induced leakage of bacterial IM would promote cell death and/or AMP 
translocation into the cytoplasm, and AMP interaction with intracellular targets.  
Overall, based on results of this thesis, we conclude that SP-A is able to increase the 
microbicidal activity of cationic and anionic AMPs. Therefore, SP-A is able to strengthen the 
antimicrobial action of AMPs against Gram-negative bacteria. Further studies of synergistic 
activities between antimicrobial factors with potential therapeutic use should be considered to 
develop new alternative or adjuvant therapies to treat respiratory infections.  
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1. RESPIRATORY SYSTEM 
The main function of the respiratory system is providing continuous gas exchange between 
inspired air and blood in the pulmonary circulation. Survival is dependent upon this process 
being reliable, sustained and efficient, because cells of the organism require oxygen to 
generate the chemical energy necessary for the maintenance of various metabolic essential 
processes taking place in tissues and organs. Additionally, CO2 generated from these 
processes is a metabolic waste, which has to be removed from the organism. 
The respiratory system extends from mouth and nose to the alveoli and it is classically 
divided into upper and lower respiratory tract (Fig. 1) (31): 
A. Upper respiratory tract: it consists of nose, pharynx and larynx and serves to filter 
airborne particles as well as to humidify and warm the inspired gases	  before they reach 
the lower respiratory zone. 
B. Lower respiratory tract: it starts with the trachea and is followed by the bronchial-tree, 
which is progressively branched into right and left bronchi, bronchioles, alveolar sacs, 
and finally, into the main structure where gas exchange takes places, the alveoli.  
 
 
Figure 1. A) Schematic representation of the human respiratory system. B) Grouped alveoli forming 
two alveolar sacs. C) Schematic representation of gas exchange in the lungs. 
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Another classification of the respiratory tract is based most exactly on its functions and 
according to this, it can be divided into two zones: the conducting zone, comprising the nasal 
cavity, pharynx, larynx, trachea, bronchi, and bronchioles; and the respiratory zone, which is 
composed of the terminal and respiratory bronchioles, alveolar ducts, alveolar sacs and the 
alveoli, where gas exchange occurs (32). 
The lung has the largest area of the body in contact with the external environment, which 
is necessary for gas exchange between the alveoli and pulmonary capillaries through passive 
diffusion. Once gas exchange occurs, oxygen enters into the blood capillaries from the alveoli 
and is distributed to the entire body by bloodstream. On the other hand, CO2 is moved into the 
alveoli, where is removed to the atmosphere.  
Consequently, the alveolar-capillary unit is the main structure involved in gas exchange 
(Fig. 2). It comprises three layers: 
A. Capillary endothelium: composed of endothelial cells, which line the inner surface of 
the pulmonary capillaries and form an interface between bloodstream and alveoli. They 
exert critical gas exchange and metabolic functions. 
B. Interstitial layer: it is made up of an intermediate connective tissue of elastic and 
collagen fibers where mesenchymal cells (fibroblasts) and immune system cells 
(lymphocytes, interstitial macrophages and mast cells) are found. It is placed between 
the capillary endothelium and the alveolar epithelium and support alveolar structure 
through the secretion of extracellular matrix proteins.   
C. Alveolar epithelium: it is considered to be a physical and functional barrier, which is 
also involved in the clearance of environmental agents. It is found above interstitial 
layer and covers the entire surface of each alveolus. The alveolar epithelium (Fig. 2) is 
mainly composed of two types of cells, type I and type II pneumocytes or alveolar 
epithelial cells (1):  
• Type I pneumocytes: these cells cover 90% of the airway surface due to their 
large flattened phenotype and whose main function is gas exchange. 
• Type II pneumocytes: constitute the remaining 10% of the alveolar surface. 
They display proliferative and innate immune functions and are responsible for 
the synthesis and secretion of pulmonary surfactant, a lipid-protein complex that 
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is involved in reducing surface tension at the air/liquid interface of the alveoli. 
Hence, these pneumocytes exhibit a cubic morphology typical of secretory cells 
with microvilli on its apical area.  
 
 
Figure 2. Schematic representation of the alveolar-capillary unit showing their three layers and their 
components: alveolar epithelium, interstitial layer and capillary endothelium.  
 
Additionally, pneumocytes are covered by a thin layer of aqueous fluid, called alveolar 
fluid, which contains immune cells, mainly resident alveolar macrophages that coordinate 
host defense, as well as soluble proteins and peptides with antimicrobial and 
immunomodulatory activity (2). Moreover, in the alveolar fluid is also found pulmonary 
surfactant, which is located at the air-liquid interface allowing gas exchange while 
maintaining alveolar homeostasis. Thus, pulmonary surfactant keeps the structure of the 
alveoli against possible pressure differences and protects the body from potential pathogen 
invasion. 
1.1. PULMONARY SURFACTANT 
Pulmonary surfactant is a complex network of protein-containing extracellular membranes 
that overlies the alveolar epithelium and is involved in surface tension reduction and lung 
defense (33, 34). Since it was discovered by Clements and colleagues in the early 1960s (35), 
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pulmonary surfactant has been widely studied to discern its functions, composition, 
metabolism and importance in pulmonary diseases. 
Surfactant membranes are synthesized by type II pneumocytes and form a stable 
monolayer at the air–liquid interface with bilayer structures attached to it (Fig. 3) (11). After 
its biosynthesis and prior to secretion, surfactant components are assembled into complexes 
stored as tightly packed membranes, called lamellar bodies. Once secreted, the lamellar 
bodies components transform into tubular myelin, an unusual ordered network of membranes 
with lattice-like structure that finally forms the surfactant film by its rapid adsorption and 
spreading over the air-liquid alveolar interface (Fig. 3) (33). Because of surfactant is 
continuously suffering compression and expansion cycles, it is constantly secreted by and 
recycled into the type II pneumocytes, in order to maintain constant surfactant pool size (Fig. 
3) (36).  
 
 
Fig. 3. Schematic representation of pulmonary surfactant secretion and recycling. After synthesis by 
type II pneumocytes, pulmonary surfactant is stored as tightly packed bilayer membranes called 
lamellar bodies (LB) (a) that are then secreted by exocytosis (b) to the alveolar fluid, where 
spontaneously unravel in a lattice-like structure termed tubular myelin (TM) (c) and large surfactant 
aggregates (LA). They have high surface activity and adsorb very rapidly to the air–liquid interface. 
These structures form a surface film at the alveolar air/liquid interface consisting of a phospholipid 
monolayer with bilayer structures attached to it (d). With surface compression and expansion cycles, 
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small surfactant aggregates (SA) with poor surface activity are generated, which are taken up and 
degraded by alveolar macrophages and type II cells for recycling. Taken from (11) 
Pulmonary surfactant contains about 90 % of lipids and 10 % of proteins (by weight) (Fig. 
4A). The lipid composition of mammalian extracellular surfactant is remarkably similar 
among diverse species (37). Lipids consist mainly of phospholipids (90-95 weight %) with a 
small amount of neutral lipids (5-10 weight %), mostly cholesterol, which could play a 
membrane structural role (11). The main lipid comprising pulmonary surfactant is 
dipalmitoylphosphatidylcholine, molecular species of saturated phosphatidylcholine. This 
lipid can be highly and densely packed at the air–water interface, becoming the main factor 
implicated in surface tension reduction (33).  
The surfactant contains about 10% of acidic phospholipids, especially phosphatidyl 
glycerol and phosphatidylinositol, and also, minority fractions of sphingomyelin, 
phosphatidylserine or phosphatidylethanolamine (38). The presence of anionic phospholipids 
appears to be important in specific interactions with hydrophobic proteins, while unsaturated 
lipids are related to fluidizing surfactant membranes. 
 
 
Figure 4. A) Pulmonary surfactant composition. B) Hydrophobic surfactant proteins. C) Hydrophilic 
surfactant proteins. PL: Phospholipid; DPPC: dipalmitoylphosphatidylcholine; PC: 
phosphatidylcholine; PG: phosphatidylglicerol; SP-: surfactant protein-. 
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Regarding the protein component of the pulmonary surfactant, four surfactant-associated 
proteins have been described: the hydrophobic lipoproteins surfactant protein B and C (SP-B 
and SP-C) (Fig. 4B); and the hydrophilic pulmonary collectins, surfactant protein A and D 
(SP-A and SP-D) (Fig. 4C). SP-B and SP-C are small and extremely hydrophobic proteins 
mainly involved in surface activity (39). On the other hand, SP-A and SP-D are large, 
hydrophilic glycoproteins that belong to the collectin mammalian super family (40). SP-A is 
the most abundant protein of pulmonary surfactant, comprising 50-70% of the surfactant 
proteins (w/w), and is mostly associated with surfactant membranes, although it is also 
soluble in the alveolar fluid. In contrast, SP-D is the most soluble surfactant protein, since 
approximately 75% of SP-D is found in the alveolar fluid, non-associated with surfactant 
lipids (41). Because of their ability to bind multiple ligands, they are mainly involved in host 
defense (12).  
Pulmonary surfactant, besides permitting gas exchange, is able to maintain normal 
respiratory mechanics by reducing the surface tension at the air/liquid interface in the alveolar 
fluid; thus preventing lung collapse at the end of expiration (36). Moreover, it contributes to 
avoid pulmonary edema because it is able to keep alveolar fluid out from alveolar space. In 
addition, as pulmonary surfactant is the last structure that is found by the inspired air before 
entry into the body, it plays an essential role in lung defense (34).  
 
2. DEFENSE MECHANISMS IN THE RESPIRATORY SYSTEM 
To have an effective gas exchange in the lungs, respiratory system needs a large contact 
surface with the atmosphere. Thereby, it is continuously exposed to inhaled particles such as 
pathogens, allergens and contaminants. To protect the host against inhaled microbes and 
dangerous particles reaching the alveoli during inspiration, there are effective innate defense 
mechanisms (2).  
2.1. PHYSICAL BARRIERS 
The first defense mechanisms of the respiratory system are structural and physiochemical 
adaptations of the respiratory tract, which act as a mechanical barrier to block the entry of 
INTRODUCTION 
	  
37 
microorganism and particles. Physical defenses are then mainly conducted by the upper 
airway filtering systems, the airway epithelium and the mucociliary system.  
The upper airway filtering system is a mechanism by which the upper respiratory tract 
reduces the access of gases and particulates to the lung by physical means. Nose and 
nasopharinx are the structures mainly involved in this defense (42). They are remarkably 
efficient mechanisms that remove most airborne particles and water-soluble gases from 
inspired air. In addition, this anatomic mechanism is augmented by the upper airway reflexes, 
mostly sneezing and coughing reflexes, which clear unwanted substances from the nose, 
pharynx, and large airways (43). 
Another physical defense is conducted by the airway epithelium, which forms a complex 
physicochemical barrier between the human body and the atmosphere (32). Infections occur 
only when pathogens can overpass these barriers. Epithelial cells are, therefore, held together 
by tight, adherents, and gap junctions, as well as desmosomes, in order to form an effective 
impermeable and mechanical barrier against the external environment (44). Consequently, in 
the absence of wounding or disruption, pathogens normally have to cross epithelial barriers 
by adhering to and colonizing these surfaces. To minimize bacterial attachment and 
colonization, the airway epithelia have another mechanism of defense, the mucociliary 
escalator, which is conducted by mucus and cilia (45).  
The mucus is continuously secreted by submucosal glands and goblet cells that exist in the 
upper and lower airways. Therefore, epithelium is covered by an overlying mucus layer, 
which creates a semipermeable barrier that enables the exchange of nutrients, water, and 
gases while being impermeable to most pathogens (32). The airway mucus is mainly 
composed of mucins, which are large highly charged glycoproteins that cross-link to form the 
structural framework of the mucus (46). In addition, almost 200 different proteins have been 
identified in the mucus, such as antimicrobial substances, cytokines, and antioxidant proteins, 
which, along with mucins, allow this layer to also participate in the immune response of the 
lung (47).  
 Ciliated epithelial cells of the mucosal epithelia complete the mucociliary escalator 
defense by facilitating removal of particles and microorganism from the lung (48). The 
pseudostratified columnar respiratory epithelium consists of ciliated cells, non-ciliated 
secretory cells, and basal cells, which vary in size and ratio from the upper respiratory 
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epithelium to the lower respiratory epithelium (32). Therefore, ciliary movements direct 
overlying mucus-containing particulates and absorbed gases toward the pharynx where it is 
swallowed or expectorated. The efficacy of mucus flow in clearing infection is illustrated by 
people with defective mucus secretion or inhibition of ciliary movement, since they 
frequently develop lung infections caused by bacteria that colonize the epithelial surface (42).  
2.2. INNATE IMMUNTY IN THE ALVEOLAR SPACE  
The main protective role of the upper respiratory tract is avoiding the entrance of large 
inhaled particles to the respiratory zone (32). However, smaller microorganisms or allergen 
can escape this defense and reach the alveolar space, the last protective barrier before enter 
into the organism. Nevertheless, the alveoli contain a potent innate immune system, which is 
specialized in the non-sterile conditions of the alveolus (2).  
The innate immune system in the alveolar space can be divided into the soluble 
component, which comprises ubiquitous and secreted antimicrobial peptides and proteins able 
to neutralize and eliminate microbial components and pathogens, and the cellular component, 
composed of resident and recruited specific cells that participate actively in host defense (3). 
2.2.1 SOLUBLE/HUMORAL COMPONENT 
Humoral response in the lungs is conducted by antimicrobial peptides (AMPs) and 
proteins present in the airways, which have an essential role in innate immunity in the lungs.  
I. Antimicrobial Peptides or Host Defense Peptides 
AMPs are evolutionarily conserved components of the innate immune response and the 
principal defense system for the majority of living organisms (49). They comprise 
polypeptides of fewer than 100 amino acids that are involved in defense against 
microorganisms, as seen by extensive research in the last decades. For example, mice lacking 
the endogenous beta-defensin 1 have shown increased susceptibility to Staphylococcal 
infections (50). In addition, overexpression of the human cathelicidin antimicrobial peptide 
LL-37 in mice protected animals against infection by Pseudomonas aeruginosa PAO1 (51). 
These peptides exert potent antimicrobial activity and are rapidly mobilized to neutralize 
a broad range of microbes, including viruses, bacteria, fungi and eukaryotic parasites (52). In 
addition, AMPs are able to neutralize endotoxins and increase phagocytosis as well as 
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chemokines expression to aid in overcoming infection (53). In humans, the main innate AMPs 
of the lungs are cathelicidins and defensins, which are produced by leukocytes and epithelial 
cells (54). Currently, more than 2000 natural AMPs with several different sequences have 
been isolated from a wide range of organisms (Antimicrobial Peptide Database, http:// 
aps.unmc.edu/AP/main.php). Due to this extensive repertory, AMPs can be classified in many 
different manners. They can be classified as gene coded and non-gene coded (i.e. multiple 
enzyme systems), as well as depending on their biological source (bacteria, plants, animal,...). 
Furthermore, they can be categorized according to its microbial target functions 
(antibactericidal, antifungical, antiviral and antiparasitic peptides) or based on molecular 
target (cell surface targeting peptides and intracellular targeting peptides). However, the most 
extended classifications are based on their secondary structures (β-sheet, α-helix, extended, 
and loop) and/or on their net charge (cationic and anionic peptides) (55). 
II. Antimicrobial proteins 
Antimicrobial proteins are host soluble factors of high molecular weight, compared to 
AMPs, which have antimicrobial activity against Gram-negative and positive bacteria, virus 
and fungi (56). Among their activities, they are able to: i) increase phagocytosis by 
opsonization or direct phagocytic cells stimulation; ii) kill directly microbes; iii) direct 
chemotaxis; and iv) modulate cytokine expression (10). Lysozyme and lactoferrin are among 
the most abundant and important proteins in the alveolar fluid. Both proteins are produced by 
neutrophils, monocytes, macrophages, and epithelial cells and can kill directly bacteria (9). 
Finally, as another important antimicrobial proteins are the pulmonary collectins SP-A and 
SP-D, which participate actively in lung host defense against infection, displaying 
antimicrobial and immunomodulatory activities (10).  
2.2.2 CELLULAR COMPONENT 
Cellular response of the lung innate immunity is coordinated by alveolar epithelial cells 
and phagocytic leukocytes, mostly, alveolar macrophages (AMs) and neutrophils.   
I. Alveolar Epithelial Cells: besides acting as a physical barrier to block microbial infection 
and entry into the host, they are able to eliminate microbes by induction of immune 
effectors by chemokines and cytokines, as well as secretion of soluble components, 
which directly kill pathogens (57).  
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II. Alveolar Macrophages (AM): they make up approximately 95% of the leukocytes in the 
human airspaces and 100% of the leukocytes in the lungs of pathogen-free mice (2).  
AMs reside on the epithelial surface of the lung, and, in contrast to other resident 
macrophage populations, are in direct contact with the environment, including 
commensal bacteria and inhaled particles, while interacting with host-epithelial-derived 
factors such as surfactant components. These conditions determine their unique 
phenotype evolved to maintain the homeostasis and protect the lung from infection (58).  
One of the main characteristics of macrophages is that they are able to promote 
different responses, depending on their differentiation state and microenvironment 
factors, in order to perform the best response to a particular inciting stimulus (59). 
Resident AMs are, therefore, tolerant to their continuous challenging environment, thus 
producing poor inflammatory responses when they are exposed to harmless antigens, and 
removing them by phagocytosis (60). However, if the inhaled agent is highly dangerous 
and exceeds the threshold response of AMs, they can initiate an inflammatory response to 
recruit more potent immune cells (including peripheral monocytes and neutrophils) that 
will help to eliminate the potential injurious agent (58). 
III. Neutrophils: they are polymorphonuclear cells and the most abundant type of leukocytes 
in the human circulation, forming one of the main defensive cells against infection (61). 
In non-infectious conditions, neutrophils constitute 1-2% of the alveolar leukocytes (Fig. 
5A). However, during respiratory infection, neutrophils are recruited to the lungs, 
reaching up to 80-90% of the immune cells in the air space (Fig. 5A). Once there, 
neutrophils are able to eliminate pathogens by phagocytosis or by the expression of 
reactive oxygen species, antimicrobial proteins and peptides (like bactericidal 
permeability-inducing protein and defensins), and degradative enzymes (like elastase) 
(62). Neutrophils also extrude neutrophil extracellular traps (NETs), which are composed 
of a chromatin meshwork containing antimicrobial proteins that ensnare and kill 
extracellular bacteria (Fig. 5B) (63). Additionally, neutrophils generate a variety of 
immune mediators to direct immune responses, influencing other innate and adaptive 
immunity cells (64).  
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Figure 5. A) Cell types in the bronchoalveolar fluid from uninfected and infected mice. Alveolar 
macrophages constitute ≈95% of the leukocytes in the airspaces in non-infectious conditions. After 
infection, neutrophils are recruited and they can constitute up to 80-90% of the immune cells in the air 
space. B) Neutrophil activity at the site of infection. When encountering infectious particles, 
neutrophils (PMN) are able to fight against infection by several mechanisms, including phagocytosis 
and intracellular bacterial killing; secretion of neutrophil extracellular traps (NETs); and production of 
reactive oxygen species (ROS) and AMPs. In addition, they are able to produce cytokines, which 
contribute to the inflammatory reaction. Once infection is cleared, neutrophils die by apoptosis and 
trigger an active program to resolve inflammation. Taken from (61).  
 
Neutrophil recruitment during early acute inflammation is critical for host defense 
against infection. However, an exacerbated inflammatory response resulting in neutrophil 
accumulation for a long time can injure the lung. The neutrophil products generated to 
kill microbes, such as reactive oxygen species and proteases, also kill host cells and 
damage host tissues (65). Therefore, host needs to subvert inflammation as soon as 
possible to not damage the own tissue. Thus, anti-inflammatory mediators released by the 
same cells that initiated the pro-inflammatory response are responsible for this subversion 
and coming back to non-infection conditions (66).  
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3. RESPIRATORY INFECTIONS 
Even though the lungs have effective mechanisms of defense, several microbes overcome 
these mechanisms, surviving within the host and colonizing the respiratory tract. Persistence 
of a specific exogenous microorganism in the different parts of the respiratory system is 
mentioned as respiratory infection, and microorganisms involving this kind of infectious 
disease are known as respiratory pathogens.    
 
Respiratory infections are normally classified as upper respiratory tract infection or lower 
respiratory tract infection. Upper respiratory tract infections comprise tonsillitis, pharyngitis, 
laryngitis, sinusitis, otitis media, and the common cold, which are frequent presenting 
conditions in primary care. Lower respiratory tract infections are generally more serious than 
upper ones. According to the European Respiratory Society, adult lower respiratory tract 
infections are an acute illness (present ≤ 21 days); with cough as the main symptom and ≥ 1 
other respiratory tract symptom (sputum production, dyspnoea, wheeze, and/or chest 
discomfort/pain), and no alternative explanation (e.g. sinusitis, asthma, lung edema, or lung 
embolism). The two most common infections are bronchitis and pneumonia, which are an 
inflammatory condition of the lower respiratory tract promoted by virus and/or bacteria (67). 
 
3.1. ACUTE LOWER RESPIRATORY TRACT INFECTION 
Lower respiratory tract infections cause more disease than better-recognized threats to the 
public’s health such as cancer, heart attacks, HIV/AIDS or malaria; as well as a greater 
burden than any other infectious disease (Figure 6A) (68). Consistent with the World Health 
Organization, ischemic heart disease, stroke, chronic obstructive pulmonary disease and lower 
respiratory tract infections have remained the top major cause of death during the past decade 
(Fig. 6B) (69). Consequently, respiratory infections are a persistent and pervasive public 
health problem. 
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G L O B A L B U R D E N  O F  D I S E A S E S  THE 10 LEADING CAUSE OF DEATH IN THE WORLD 
 
Figure 6. A) The Global Burden of Selected Diseases in 2002, as Measured by Disability-Adjusted 
Life Years. COPD: chronic obstructive pulmonary disease (68). B) The 10 leading causes of death in 
the world in the past decade, according to World Health Organization. Ischemic heart disease, stroke, 
lower respiratory tract infections and COPD have remained the top major killers. Taken from (69). 
 
Among these infections, pneumonia remains as an important cause of morbidity and 
mortality (70). Pneumonia is an inflammatory condition of the lung affecting primarily 
alveolar sacs, which is mainly produced by bacteria or virus. It can be classified among 
community- or hospital-acquired infections, according to the place of acquisition. Hospital-
acquired pneumonia is usually associated with invasive medical devices, mechanical 
ventilation, surgical procedures or immunodeficient patients, being the most common life-
threatening hospital-acquired infection (71). The outcome of pneumonia is an exacerbated and 
persistent inflammatory condition, resulting in lung injury (72). In addition, pneumonia, 
especially in high-risk groups (older or inmunodeficient adults), may have complications such 
as bacteremia, a serious disease that occurs when infection moves into the bloodstream and 
quickly spread to and infect other organs. 
Hospital-acquired pneumonia may be caused by a wide spectrum of bacterial pathogens, 
and can be polymicrobial, with organisms ranging in severity (67). Common bacterial 
pathogens include Gram-negative bacteria, such as Pseudomonas aeruginosa, Escherichia 
coli, Klebsiella pneumoniae, Haemophilus influenzae and Acinetobacter species; and Gram-
positive bacteria, mainly Staphylococcus aureus and Streptococcus pneumoniae (70, 73). 
Among these organisms, infections caused by Gram-negative bacteria are a major challenge, 
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since these kinds of bacteria exert a broad spectrum of virulence factors (including adherence 
or invasion factors, endotoxins and exotoxins) and are highly efficient to acquire resistance to 
antimicrobial drugs or immune system factors (71, 74). 
4. BACTERIAL VIRULENCE FACTORS  
Infection is regarded as an imbalance between microbial pathogenicity factors and the host 
defense systems. Bacterial pathogenicity degree reflects its capacity to infect the host, and is 
measured by the virulence of the bacterium (75). Virulence is affected by numerous variables 
such as the number of infecting bacteria, host defense mechanisms, and virulence factors of 
the bacterium (76).   
Virulence factors are, therefore, molecules and components produced by a microorganism 
to establish itself within a specific host and to cause disease (77). Bacteria have developed a 
great variety of virulence factors, which are difficult to group, because some categories can 
overlap (77). However, the most extended ones can be classified as following: 
I. Adherence Factors: as explained in mechanical defense mechanisms, bacteria have to 
firstly attach to mucus and epithelial surfaces in order to cross them and invade the host. 
Adhesins are the main adherence factor of bacteria. They are usually hair-like 
appendages of the bacterium called pili or fimbriae that extend out from the bacterial 
surface and mediate adhesion to these surfaces (78). In addition, adhesins can be also 
associated with the microbial cell surface, forming the so-called nonpilus adhesins, 
which recognize many different elements of host-cell surfaces, such as collagens, 
proteoglycans, or fibrinogen (79). 
II. Invasion Factors: bacteria have developed several molecular strategies to induce their 
invasion into target cells (intracellular invasion) or into the epithelial barriers 
(extracellular invasion) for colonization and/or dissemination to other host tissues (80).  
Extracellular invasion occurs when bacteria break down host barriers through secretion 
of enzymes to degrade host cell molecules, such as elastases or proteases by P. 
aeruginosa, which degrade extracellular molecules for tissue invasion (81). On the 
other hand, intracellular invasion include surface components and secreted proteins, 
which lead to rearrangements of the plasma membrane architecture in the host cell in 
order to induce pathogen engulfment (78). Several pathogens, for example, bind to 
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integrin receptors in eukaryotic cells not only to adhere but also to trigger actin 
cytoskeleton rearrangements leading to bacterial uptake. 
III. Exotoxins: toxins can be defined as bacterial molecules that produce tissue and cell 
damage in host. Exotoxins are secreted proteins by the bacterium (generally enzymes) 
that destroy certain cellular structures (80). They are secreted into the surrounding 
milieu or injected into the target cell. There is a wide variety of exotoxins with several 
biologic effects on host cells (cytotoxins, neurotoxins or enterotoxins) and diverse sites 
of action (extracellular matrix, cell membrane, nucleus) (74). Exotoxin activity leads to 
the characteristic clinical manifestations of the infectious disease. 
IV. Siderophores: the growth of bacteria in host tissue is limited not only by the host 
defense mechanisms but also by the presence of available iron. Iron is not usually free 
in solution into the host, since most of it is bound to proteins, such as hemoglobin in 
blood or lactoferrin in mucus or saliva (74). To overcome this, bacteria express the so-
called sidephores, which are iron-binding factors that allow bacteria to compete with the 
host for iron (82). These factors bind to iron with a higher affinity than the iron-binding 
proteins of the host, thus facilitating the acquisition of this metal ion for bacterial 
growth (83). 
V. Bacterial cell wall: as eukaryotic cells, both Gram-negative and positive bacteria are 
surrounded by a lipid membrane or cytoplasmic membrane, which acts as a barrier to 
separate essential cytoplasmic components from the environment. In addition, a cell 
wall is present on their outside, in which several components have been shown to be 
virulence and resistant bacterial factors. 
Bacterial cell wall is composed of peptidoglycan, a polymer consisting of sugars and 
amino acids that forms a mesh-like layer (84). In case of Gram-positive bacteria, they present 
a thick cell wall containing many layers of peptidoglycan and lipoteichoic and teichoic acids, 
which are polysaccharides of glycerol phosphate or ribitol phosphate linked via 
phosphodiester bonds. Regarding Gram-negative bacteria, they are characteristically 
surrounded by other lipid membrane, which makes their cell wall substantially thicker than 
that of Gram-positive bacteria (Fig 7).  
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Figure 7. Schematic representation of the bacterial cell wall structure from Gram-negative and 
positive bacteria. LPS: lipopolysaccharide; LTA: lipoteichoic acid; TA: teichoic acid. Figure modified 
from (85). 
 
Therefore, apart from the cytoplasmic membrane and peptidoglycan layers, instead of 
teichoic acids, Gram-negative bacteria present other lipid bilayer with polysaccharides 
attached to it, called the outer membrane (OM) (86). OM is an asymmetric bilayer in which 
the inner leaflet is composed of phospholipids and the outer leaflet comprises the bacterial 
lipopolysaccharide (LPS). LPS typically contains (from inside to outside) the lipid A, the 
oligosaccharide core, and the O-antigen, which are covalently attached to one another (Fig. 8) 
(87):  
• Lipid A: is the hydrophobic component of the OM, which is highly conserved. Lipid A 
generally consists of diglucosamine phosphates attached to five or six fatty acyl chains. 
These hydrophobic chains anchor the LPS into the bacterial outer membrane, whereas the 
rest of the LPS projects from the cell surface. Thus, lipid A makes up the outer 
monolayer of the bacterial outer lipid bilayer.  
• Oligosaccharide core: the oligosaccharide core can be divided into the outer and inner 
core. The inner region is usually highly conserved and is typically constructed from a few 
heptose residues bound to a 3-deoxy-D-manno-oct-2-ulosonic acid (KDO) residues 
attached to the lipid A. Inner core, beside lipid A, are commonly sprinkled with anionic 
groups, such as Kdo molecules, phosphate groups and, sometimes, phosphoethanolamine 
or pyrophosphoethanolamine substituents, which confer negative net charge to LPS. On 
INTRODUCTION 
	  
47 
the other hand, the outer region is a more variable domain, which is mainly formed by 
hexose residues. 
• O-antigen: consist of a variable number of repeating saccharide units comprising the 
outermost domain of the LPS molecule. It is the most variable domain of the OM and is 
the portion of the molecule, which usually determines serotype specificity.   
There are two serotypes of LPS in nature: Smooth LPS (S-LPS), which contains the entire 
structure, and Rough LPS (R-LPS), which lacks the O-antigen, and has the oligosaccharide 
core progressively shorter, depending on the rough phenotype (Ra, Rb, Rc, Rd and Re LPS) 
(Fig. 8) (87). The minimal LPS required for the growth of E. coli consists of the lipid A and 
Kdo domains, i.e., expressing Re LPS. In addition to LPS, some Gram-negative bacteria 
usually develop a prominent polysaccharide capsular (CPS), above the LPS, composed of 
complex repeating subunits of anionic polysaccharides (Fig. 8) (88).                          
 
 
 
 
Figure 8. Chemical structure of bacterial LPS. LPS contains three different regions: i) lipid A, which 
contains the hydrophobic, membrane-anchoring region of LPS; ii) oligosaccharide core, comprising a 
variable outer core and an invariable inner core; and 3) O-antigen. Additionally, bacteria can express a 
capsular polysaccharide. LPS is usually named as smooth LPS when contains the entire structure or 
rough LPS, when lacking the O-antigen, and can be designated as Ra, Rb, Rc, Rd, and Re in order of 
decreasing core length. Figure modified from (89). 
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Besides the adhesion and invasion factors, which are usually present in the bacterial 
surface, other components of the bacterial cell wall are well-known virulence factors: 
• Endotoxin: The LPS complex is properly and commonly referred to as endotoxin. LPS, is 
a potent immune response inductor, mainly because the presence of the lipid A, which is 
detected at picomolar levels by Toll-like Receptors (TLR) (90, 91). The 
lipopolysaccharide endotoxin of Gram-negative bacteria causes fever, changes in blood 
pressure, inflammation, septic shock, and many other toxic events. Consequently, 
endotoxin exerts profound biologic effects, which can be lethal for the host. 
• Lipoteichoic acid: it is considered a potential virulence factor, which shares with LPS 
many of its pathophysiological properties. Like LPS, lipoteichoic acid strongly stimulates 
generation of pro-inflammatory mediators by host immune cells, and is thought to be 
involved in the pathophysiology of septic shock, adult respiratory distress syndrome, and 
toxic shock syndrome (92). In addition, lipoteichoic acid can also mediate bacterial 
adhesion by binding to fibronectin, membrane phospholipids or Toll-like receptors in 
target cells (93). 
• Peptydoglican: peptidoglycans have been shown to exert cytotoxic and pyrogenic 
activities in mammalian hosts, and they have been implicated as mediators of septic 
shock (94). 
• Capsular polysaccharide: capsule formation has been long recognized as a protective 
mechanism for bacteria within the host. K. pneumoniae and P. aeruginosa are well-
recognized encapsulated strains that develop prominent capsule, which have been shown 
to be involved in their pathogenesis. Thus, encapsulated strains are more virulent and 
more resistant to phagocytosis and intracellular killing than nonencapsulated strains (95, 
96). In addition, capsule can prevent killing of the bacteria by bactericidal nonimmune 
serum factors, one of the main soluble host defense mechanism against invading 
microorganisms (97).  
As mentioned above, infection results from an imbalance between bacterial virulence 
factors and host defense mechanisms. When high virulent bacteria are able to resist host 
immunity and promote host infection, exogenous treatments with antimicrobials are necessary 
to overcome infection. Even though these treatments are very efficient to treat respiratory 
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infection, microorganisms have also developed mechanisms of resistance against the majority 
of antimicrobials. 
5. ANTIMICROBIAL RESISTANCE: 
Antimicrobial resistance is the capability of one microorganism to avoid the antimicrobial 
drug activity that was originally effective for the treatment of infections caused by it. The 
evolution of resistant strains is a natural phenomenon that occurs when microorganisms 
replicate erroneously or when resistant traits are exchanged between them. From the 
discovery of penicillin (1921), by Sir Alexander Fleming, to the present, conventional 
antibiotics have been the treatment of choice for infections. 
5.1. CONVENTIONAL ANTIBIOTICS: 
Antimicrobials are agents that kill microorganisms or inhibit their growth. They include 
antibiotics, antifungals, antiviral and antiparasitic drugs. Regarding antibiotics, they are 
currently defined as a chemical substance derivable from a microorganism or produced by 
chemical synthesis that kills or inhibits microorganisms and cures infections. Antibiotics 
more commonly used to treat infections can be classified, according to their structure, in: β-
lactams, glycopeptides, fosfomycin, aminoglycosides, macrolides, tetracyclins, ansamycins, 
sulfonamides and quinolones (98, 99) In turn, they can be divided depending on their mode of 
action, which is based on targeting of components or functions necessaries for bacterial 
growth (Table 1). Accordingly, they are classified as (98, 99): 
1. Cell wall synthesis inhibitors: they work by targeting penicillin binding proteins that 
are implicated in the synthesis of the bacterial cell wall and are present in the 
cytoplasmic bacterial membrane. They comprise the antibiotics β-lactams (penicillin, 
ampicillin, amoxicillin or carbapenems); glycopeptides (vancomycin and 
teicoplanin); and fosfomycin. They are all bactericidal from narrow to broad 
spectrum. 
2. Protein synthesis inhibitors: the main target of these antibiotics is the bacterial 
ribosome in the cytoplasm in order to inhibit the synthesis of bacterial proteins. They 
include aminoglycosides (like streptomycin, kanamycin or gentamycin); macrolides 
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(erythromycin); tetracyclines, and ansamycins (rifampicin). These antibiotics are 
bactericidal or bacteriostatics (macrolides). 
3. Anti-metabolites: also called folate pathway inhibitors, they act as competitive 
inhibitors of the enzyme dihydropteroate synthetase, an enzyme involved in folate 
synthesis, which is essential for the synthesis of adenine and thymine nucleobases. 
This group is composed of sulfonamides and co-trimoxazole, which are specially 
used for urinary tract infection treatment, although they present a high incidence of 
side effects. 
4. Nucleic acid synthesis inhibitors: these antibiotics inhibit DNA synthesis by blocking 
bacterial topoisomerases, which are implicated in DNA supercoiling, replication, 
transcription and recombination. They comprise quinolones and their modern 
substitutes fluoroquinolones. They are broad-spectrum antibiotics that play an 
important role in hospital-acquired infections and others in which resistance to older 
antibacterial classes is suspected. 
 
Table 1. Antibiotic classification, including their activity and common usages. LRTI: lower 
respiratory tract infection; URTI: upper respiratory tract infection; UTI: urinary tract infection. 
 
Mechanism of 
action Structure Activity Common usage Examples 
Cell wall 
synthesis 
inhibitors  
β-lactams  
Bactericidal 
Community- and 
hospital-acquired 
infections  
LRTI 
Penicilin, Amoxicilin,  
Carbapenems, Vancomicin  
Glicopeptides 
Fosfomycin  
Protein synthesis 
inhibitors  
Macrolides  Bacteriostactic 
Hospital-acquired 
infections  
Serious LRTI 
Streptomycin , Gentamycin,  
Erythromycin, Rifampicin  
Aminoglycosides 
Bactericidal Tetracyclines  
Ansamycins  
Anti-metabolites  
Sulfonamides Bactericidal UTI, LRTI and URTI 
Community- and 
hospital-acquired 
infections  
Sulfisoxazole, sulfamethizole, 
Sulfamethoxazole Co-trimoxazole  Bacteriostatic 
Nucleic acid 
synthesis 
inhibitors  
Quinolones  
Bactericidal 
Community- and 
hospital-acquired 
infections  
UTI and LRTI 
Ciprofloxacin, Gemifloxacin, 
Levofloxacin, moxifloxacin  Fluoroquinolones  
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5.2 MULTIDRUG RESISTANCE  
The use and misuse of antimicrobial drugs have produced the emergence of multi-drug 
resistant (MDR) strains (100). The repeated and successful response to emerging resistance 
was to discover new antibacterial drugs (100). However, in recent years this strategy has 
failed, with resistance accumulating faster than new antibiotics are being developed (23, 101) 
OM and CPS are thought to be among the main resistance factors of bacteria. As 
described above, the majority of the main classes of antibiotics have to cross the cell wall to 
reach their intracellular targets (102). Structurally, OM appears to be an effective protective 
barrier to the diffusion of many hydrophobic antibiotics and host antimicrobial proteins, since 
lost of O-antigen and outer core in deep rough mutants confer susceptibility to a number of 
these antimicrobials (86, 103). Thus, pathogenic bacteria usually express a more complex OM 
and CPS in order to increase resistance to hydrophobic antibiotics. On the other hand, 
reductions in the number of anionic phosphates in lipid A are common membrane 
modifications of bacteria to decrease the binding and action of cationic antibiotics such as 
aminoglycosides or polymyxins, which disrupt bacterial cell wall by electrostatic interaction 
with anionic groups in the LPS (103).  
Another common mechanism of resistance is the production of β-lactamases that 
inactivate β-lactam antibiotics by hydrolyzing the β-lactam ring (104). They include 532 
distinct enzymes, where extended-spectrum β-lactamases are the most potent. Carbapenems 
are considered to be the agents of choice for the treatment of serious infections due to 
majority of extended-spectrum β-lactamases do not hydrolyze carbapenems (104). However, 
recent reports have found several enterobaciae bacteria, mostly Klebsiella pneumoniae strains, 
that are capable to hydrolyze them (105).  
An additional mechanism of bacterial resistance is due to the presence of the so-called 
bacterial efflux pumps. They are active protein transporters localized in the cytoplasmic 
membrane, which are able to move compounds, like toxic substances or antibiotics, out of the 
cell (96, 106). Finally, mutational changes in enzymes targeted by antibiotics also contribute 
to bacterial resistance by evading the action of these selective antibiotics (107). 
MDR pathogens have developed many of these resistance mechanisms against the 
existing antibiotics. Consequently, multidrug resistance reduces the effectiveness of 
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treatment, resulting in prolonged illness, higher health care expenditures, and an increase in 
mortality and morbidity rates (71). At this moment, the Antimicrobial Availability Task Force 
has identified six particularly problematic pathogens (108), including three Gram-negative 
organisms: Acinetobacter baumannii, extended-spectrum β-lactamase-producing 
Enterobacteriaceae, and Pseudomonas aeruginosa; two Gram-positive pathogens: 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus 
faecium; and the filamentuous fungi Aspergillus spp (109). Among MDR Gram-positive 
bacteria, being MRSA the most important one (110), a handful of novel antibiotics have been 
recently approved for the treatment of infections caused by these organisms (111, 112). 
However, MDR Gram-negative bacteria are currently becoming a higher challenge, since few 
new antibiotics are in the drug development pipeline for their treatment (Fig. 9) (100). 
 
 
 
 
Figure 9. Number of approved antibiotics from 1980 to 2011. Since 2000, only three new classes of 
antibiotics have been introduced to the market for human use and one of those is limited to topical use. 
Taken from (100). 
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5.3 MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA 
Resistance rates are increasing among several problematic Gram-negative pathogens, 
mainly those that usually promote serious nosocomial infections. Gram-negative bacteria are 
responsible for more than 30% of hospital-acquired infections, becoming hospital-acquired 
pneumonia one of the most difficult challenges in the treatment of infectious diseases. 
Additionally, in intensive care units, Gram-negative bacteria account for about 70% of these 
types of infections (71).  
Among emergent MDR bacteria, Enterobacteriaceae is a large family of Gram-negative 
bacteria, which are able to produce hospital-acquired pneumonia, bloodstream infections and 
urinary tract infections (71, 113). They include pathogens such as E. coli and K. pneumoniae 
that usually develop large LPS molecules and can express prominent CPS on their OM. P. 
aeruginosa is another invasive opportunistic Gram-negative pathogen that is responsible for a 
wide range of severe nosocomial infections, especially in patients undergoing cystic fibrosis 
(114). Both families acquired resistance via multiple mechanisms, including production of β-
lactamases and carbapenemases, upregulation of multidrug efflux pumps, complex OM, and 
cell wall mutations leading to a reduction in porin channels, which are proteins present in 
both lipid bilayers that are used by several antibiotics to cross the OM (96, 107). Additionally, 
P. aeruginosa strains produce loosely anionic CPS of alginate (115) that are able to bind 
themselves to form biofilms, thus providing another resistance mechanism by physical 
exclusion of antibiotics during infection (116). Moreover, this kind of CPS make P. 
aeruginosa intrinsically susceptible to only a limited number of antibiotics, due to its low 
permeability (96). 
Finally, H. influenzae is a human-restricted respiratory pathogen, which has emerged as 
an important opportunistic pathogen causing infection in adults suffering obstructive lung 
diseases (117, 118). H. influenzae commonly colonizes upper respiratory tract and rarely 
produces severe lower respiratory infection because host immune responses can prevent its 
spreading to the lower respiratory tract (118). However, H. influenzae has developed a 
number of resistance mechanisms to adapt and exploit the already-impaired host immunity in 
patient suffering COPD, including lost or gain of resistance surface components, high number 
of adhesion and invasion factors or biofilm formation (118, 119). Most Haemophilus strains 
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remain susceptible to carbapenems. However, antibiotic resistance mechanisms, such as β-
lactamases or bacterial efflux pumps, seem to be currently spreading in this bacterium (120). 
6. NOVEL ALTERNATIVE THERAPIES TO TREAT INFECTIONS 
MDR bacterial infections have emerged as one of the world's greatest health threats. 
Current antibiotics are becoming inefficient against several bacterial pathogens and the 
development of novel antibiotics, especially to treat MDR Gram-negative bacterial infections, 
has stagnated over the last half century. Thus, current research is focused on new alternative 
or adjuvants therapies to treat infections that would be able to substitute or help the classical 
antibiotic treatments. 
Due to this emergence, components of the host immune system are being currently widely 
investigated as one of these alternative therapeutic strategies. Since antimicrobial peptides and 
proteins were discovered, extensive research has shown that these naturally occurring 
components are evolutionarily ancient weapons from the majority of living organisms that are 
highly efficient in killing microorganisms (7). Therefore, both endogenous (belonging to the 
human immune system) and exogenous antimicrobial peptides and proteins, as well as 
synthetic peptides based on these components, are becoming promising novel antimicrobial 
therapies (121).  
6.1. SURFACTANT PROTEIN A: AIRWAY NATURAL ANTI-INFECTIVE 
PROTEIN 
SP-A is the most abundant protein of the alveolus, by weight, representing approximately 
3-5% of the total mass of pulmonary surfactant (122). It is synthesized and secreted by type II 
pneumocytes and nonciliated bronchial epithelial cells (Clara cells). SP-A participates 
actively in surfactant adsorption, recycling, and subsequent homeostasis, because of its lipid-
binding ability (123). Additionally, it has been shown that together with SP-D, is a pattern-
recognition molecule belonging to the pulmonary collectin family that recognizes, binds and 
facilitates the clearance of infectious microorganisms from the lung (18).  
On the other hand, although the major site of SP-A synthesis is the lung, it has been also 
detected in extrapulmonary mucosal tissues as well (40). Thus, SP-A has been also found in 
gastric, intestinal, vaginal, skin, middle ear, Eustachian tube and renal tube epithelia; 
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suggesting that this collectin plays a general role in innate host defense, not only in the lungs 
(124).  
6.1.1. STRUCTURE 
SP-A belongs to the collectin family, which includes calcium-dependent carbohydrate 
binding proteins that are characterized by the presence of an N-terminal collagen-like region 
and a C-terminal lectin domain, comprising a carbohydrate recognition domain (CRD) (40). 
Together with SP-A and SP-D, 9 different members have been identified in the collectin 
family: mannose-binding lectin (MBL), conglutinin, collectin liver 1, collectin placenta 1 
(CL-P1), collectin kidney 1 (CL-K1), collectin of 43 kDa (CL-43) and collectin of 46 kDa 
(CL-46). Apart from CL-L1 and CL-P1, all collectins are soluble and secreted proteins (125).  
SP-A shows the typical structure of the collectin family, characterized by the presence of 
four structural domains and a supratrimeric oligomerization, which varies in several degrees 
depending on the collectin (Fig. 10) (40). 
 
 
Figure 10. Collectin oligolimerization. Three monomers oligomerize to form a triple coiled-coil 
structure, leading to the formation of trimeric subunits. Trimeric subunits multimerize subsequently 
into higher oligomeric forms. MBL: mannose-binding lectin. 
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Each monomer of SP-A (36 kDa) is composed of (Fig. 11): an N-terminal domain (~ 8 
aa), a collagen domain (~73 aa), a coiled-coil neck domain (~34 aa) and a globular or C-type 
lectin domain (~123 aa), comprising the carbohydrate recognition domain (CRD) (41). Once 
monomers are synthetized, SP-A multimerizes to form trimers, which, in turn, associate into 
hexamers to yield the complete protein, an octadecamer of 650 kDa and 20 nm in length, 
which has the appearance of a bouquet of tulips (Fig. 10) (126). It has been shown that the 
oligomerization of SP-A is essential for the maintenance of many of its functions (127, 128). 
I. N-terminal domain:  
This segment contains between 8 and 11 aminoacids, depending on species and 
variation in N-terminal processing. There are two cysteines residues present in this region 
(positions -1 and -6) that have been shown to participate in intermolecular disulfide bound 
formation, which stabilizes the oligomer (127, 129). The interchain disulfide bridge 
formed by the Cys6 has been shown to be necessary for the interaction of the protein with 
surfactant lipids and type II pneumocytes (130). 
 
 
 
Figure 11. Structural domains of SP-A. 
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II. Collagen domain: 
The collagen domain or collagen-like region of collectins consists of repeating motifs 
of Gly-X-Y, where X and Y are generally proline or hydroxyproline (40). It is usually N- 
or O-glycosylated. From each monomer, collagen helices are coiled between them in order 
to form a stable tensile domain that is relatively resistant to proteases. In SP-A, this domain 
has 23 Gly-X-Y repeats and is interrupted close to the middle. This interruption introduces 
a kink in the region that gives flexibility to the protein, allowing SP-A to fold in a bouquet-
like structure (126). This domain is thought to be involved in several functions of SP-A, 
including protein oligomerization, chemotaxis, receptor-mediated effects, pathogen 
agglutination, increased phagocytosis, and binding to target ligands (41, 128, 131). 
III. Neck domain: 
This domain is localized between the collagen-like and globular domains and 
comprises a segment of 34 aa with α-helical structure. It is directly involved in the 
trimerization of monomers, since three neck domains associate to form a triple coiled-coil 
structure, maintained by hydrophobic interactions (40). These structures have been also 
observed in other proteins of the collectin family such as SP-D or mannose-binding lectin 
(40). In addition, this domain is critical for the selective binding of SP-A to various 
ligands, since it can guide the globular domains of SP-A trimers (126). 
IV. Globular domain or carbohydrate recognition domain (CRD): 
It is composed of 123 aa, which make up the C-terminal segment of the protein. This 
domain has 4 cysteines that form two intrachain disulfide bridges (Cys204-Cys218 and 
Cys135-Cys266). It also has 18 highly conserved residues, which are common among C-
type lectins (132). This domain resembles a globe-like structure, which is suitable for the 
interaction of SP-A with a range of ligands and lipid membranes (133). 
In this domain there are at least two calcium-binding sites (133, 134). Near these 
domains are two conserved tryptophan residues at positions 191 and 213 that serve as 
conformational change markers of this region (135). The binding of calcium to the 
globular domains of SP-A causes an increase in the intrinsic fluorescence of the protein, 
as well as a blue-shift of the maximum of emission, indicating a conformational change 
that locates tryptophans in a more hydrophobic environment. This conformational change 
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increases the binding of SP-A to lipids, allows the binding to carbohydrates (as N-
acetylmannosamine or 1-fucose) and self-aggregation of the protein (12, 135, 136). 
6.1.2. FUNCTIONAL ROLES: 
To date, SP-A has been shown as a multifunctional protein involved in multiple 
important processes of the host. Studies involving SP-A gene-deleted mice showed that SP-A 
is not essential for live (137). However, SP-A-/- mice displayed several complications 
consistent with SP-A roles in vivo, including lack of tubular myelin (TM) or susceptibility to 
lung infections (18). Therefore, in vitro and in vivo studies have shown that SP-A is 
implicated in homeostasis and biophysical activity of pulmonary surfactant, as well as lung 
innate host defense (12). 
SURFACTANT-RELATED FUNCTIONS: 
The ability of SP-A to bind to lipids and induce their aggregation in the presence of 
calcium seems to be related to its ability to modulate the biophysical properties of pulmonary 
surfactant.  
SP-A is required to keep the tubular myelin structure, since TM is reduced in SP-A gene-
deleted mice (137, 138). Thus it is responsible for maintaining a reservoir of functionally 
active fraction of surfactant in the alveoli (139). 
SP-A increases the adsorption of phospholipids at the air-liquid interface, encouraging 
the formation of interfacial monolayer (140), improves the surface tension of surfactant in 
collaboration with SP-B (141), and favors the enrichment of the monolayer 
dipalmitoylphosphatidylcholine, the main factor implicated in surface tension reduction (140). 
SP-A prevents surfactant membranes inactivation by serum proteins and inflammatory 
mediators that invade the alveolar space in many respiratory pathologies (142-144) (145). We 
have determined that pulmonary surfactant function can be also inactivated by factors derived 
from microorganisms, such as LPS and β-glucans from fungal wall (unpublished results). It 
has been suggested that the ability of SP-A to protect surfactant could be related to the 
formation of the TM, and its participation in the adsorption and maintenance of a stable 
interfacial monolayer (143). Recently it has been shown that SP-A might bind to different 
inhibitors blocking its action and maintaining the lung surfactant (144). 
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Additionally, SP-A participates in the regulation of pulmonary surfactant metabolic 
cycle, enhancing uptake and subsequently clearance of pulmonary surfactant by type II 
pneumocytes and alveolar macrophages for surfactant recycling (146). This function is 
important for the maintenance of a fully functional surfactant, because it is continuously 
subjected to compression and expansion cycles that generate less surface-active small 
aggregates, which have to be removed and replaced (139).  
ROLE IN IMMUNE DEFENSE OF THE ALVEOLI: 
Agglutination and Enhancement of Phagocytosis:  
SP-A is able to interact through its C-terminal domain with a variety of ligands, such as 
allergens, LPS, and saccharides found in glycoproteins and glycolipids of bacterial, viral or 
fungal surfaces. This feature allows SP-A to agglutinate molecules or microorganisms (Fig. 
12) enhancing mucociliary removal of inhaled dangerous particles, preventing the attachment 
of pathogens to cell surfaces, and/or inhibiting microbial colonization, invasion and 
dissemination (40). 
On the other hand, SP-A is able to enhance phagocytosis of microorganisms by different 
mechanisms (Fig. 12) (12). The ability of SP-A to aggregate microorganisms would facilitate 
its uptake without an obligate interaction of SP-A with the phagocytic cell (147, 148). In 
addition, SP-A is capable of interacting with membrane receptors located in alveolar immune 
cells, such as scavenger receptor A or SP-A receptor 210 (149), resulting in enhanced 
phagocytosis of pathogens. SP-A can also act as an activation ligand, enhancing the 
phagocytosis of pathogens that have been previously coated and opsonized by an opsonin 
other than SP-A (e.g. IgG) (150). Finally, SP-A also stimulates phagocytosis by up-regulating 
the expression of immune cell-surface receptors that are involved in microbial recognition, 
like the macrophages cell receptors scavenger receptor A (151), complement receptor 3 (152) 
or mannose receptor (153), thus augmenting indirectly phagocytosis of pathogens.  
Modulation of the inflammatory response: 
Studies involving SP-A KO mice showed that these mice exhibited an augmented 
inflammatory response to a variety of stimuli, suggesting an anti-inflammatory role of SP-A 
(18). Thus, numerous later studies in alveolar macrophages have shown that SP-A mainly 
play an important anti-inflammatory role by modulating the threshold of LPS activity of these 
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cells towards an anti-inflammatory phenotype, via direct interaction with LPS or with 
immune cell receptors, mostly TLRs (Fig. 12) (154-157). 
On the other hand, another studies (mainly involving nonresident alveolar 
macrophages) have shown that SP-A is also able to promote or subvert inflammation through 
regulation of the expression of numerous pro- and- anti-inflammatory mediators, suggesting 
that SP-A modulates the inflammatory response (Fig. 12) in a context-dependent manner (34). 
This modulation depends on several factors, such as: a) presence and type of pathogen or 
stimulus, b) type and state of activation of the responding cell, and c) period of exposure to 
the stimulus.  
 
SP-A has been shown to regulate inflammatory response through the TLR family. SP-A 
can suppress NF-κB activation and pro-inflammatory cytokine production induced by SP-A 
nonligands (such as S LPS, peptidoglycan or zymosan) (156, 158), but enhances the pro-
inflammatory response of TLRs to SP-A-ligands like R LPS (159). SP-A increases murine 
and human macrophage cytokine expression through TLR (160), but is also able to reduce 
indirectly cytokine expression through up-regulation of negative regulators of TLR-mediated 
NF-κB activation (161). SP-A differentially regulates the expression of TLR2 and TLR4 
during primary human monocyte differentiation into macrophages, receptors that typically 
mediate pro-inflammatory responses. In contrast, SP-A diminishes TNFα secretion from these 
cells stimulated with TLR2 ligands (162).  
 
Consistent with the dual role of SP-A, in an inflammatory model in the murine 
peritoneum, SP-A was reported to bind to the signal-inhibitory regulatory protein-α (SIRP-α) 
or the complex calreticulin/CD91 depending on the ligand bound to SP-A, thus promoting 
pro- or anti-inflammatory response (163). Additionally, SP-A was shown to inhibit the 
production of nitric-oxide metabolites by cells that have been pre-activated with IFN-γ and 
exposed to M. pneumoniae (164). By contrast, SP-A enhanced the production of nitric-oxide 
metabolites and TNF-α in response to the Mycobacterium bovis bacillus Calmette-Guérin 
(165). 
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Figure 12. SP-A functions in lung innate defense against infection. SP-A displays multiple functions 
to add in overcome infection. Thus, SP-A is able to agglutinate and increase phagocytosis of microbes, 
as well as to kill directly microorganism by increasing membrane permeabilization. In addition, SP-A 
modulates immune system through interaction with several immune cells receptors.  MR: mannose 
receptor; TLR: toll-like receptor; CD91: cluster of differentiation 91; SP-R210: SP-A receptor 210. 
 
On the other hand, SP-A has also shown chemoattractive properties. SP-A enhances 
chemotaxis of alveolar macrophages (166) and inflammatory alveolar neutrophils (167) 
whereas it has the opposite effect on peripheral neutrophils (167). SP-A enhances chemotaxis 
through the stimulation of neutrophil chemotactic factors release (168). In addition, 
exogenous administration of SP-A in mechanically ventilated preterm lambs, which are 
characterized by defects in both immune and innate host defenses, stimulates the recruitment 
of neutrophils in the lungs (169).       
Although the majority of SP-A functions are involved in innate immune response, 
numerous studies have shown that SP-A is also implicated in adaptive immunity in the lungs 
(170). Thus, SP-A is able to modulate several functions of dendritic cells and T cells, both 
involved in adaptive response (171). SP-A has been shown to prevent hypersensitivity in 
allergic response (124) and inhibit IgE binding to Aspergillus fumigatus, thus blocking 
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histamine release from human basophils (172). In addition, SP-A inhibits mast cell 
degranulation in vitro and in vivo, decreasing susceptibility to allergic antigens (172, 173).  
C.    Direct Microbicidal Activity 
One of the main characteristics of SP-A as an antimicrobial protein is its ability to 
directly kill microorganisms (Fig. 12) (13). This activity derived from findings showing that 
SP-A KO mice were more susceptible than wt mice to lung infection by Gram-negative and 
positive bacteria like Group B Streptococcus (174), P. aureginosa (20), H. influenzae (175)  
or K. pneumoniae (176), as well as fungal or viral pathogens like Histoplasma capsulatum 
(177) or respiratory syncytial virus (178). In addition, exogenous administration of SP-A was 
able to restore bacterial clearance in mice lungs (174, 178).  
Consequently, direct killing of SP-A has been widely investigated since purified SP-A 
was reported to inhibit the growth of Gram-negative bacteria or fungi (16, 177). Furthermore, 
the microbicidal role of SP-A ex vivo was demonstrated in studies involving macrophage-free 
bronchoalveolar lavages from SP-A -/- mice, which showed lower bactericidal activity against 
E. coli K-12 than those lavages from SP-A +/+ mice (14).  
SP-A performs this activity mainly because its capability to bind to various ligands 
existing on the surface of microbes, such as LPS on Gram-negative bacteria, glycoprotein on 
fungi, lipoarabinomannan on mycobacteria, phospholipids on mycoplasma, and glycoproteins 
on virus surface. Subsequently, even though little is known about the SP-A mechanisms of 
microbicidal activity, SP-A has been shown to kill bacteria and fungi, to inhibit the growth of 
mycoplasma and mycobacteria as well as to neutralize viral infection (13). 
I. Virus 
Direct activity of SP-A on virus can be referred to as viral neutralization or inhibition of 
hemagglutination activity. In the case of influenza A virus, hemagglutinins allows the 
recognition of host cell and facilitates the entry of the viral genome into the target cells (179). 
SP-A can interfere with this process through interaction between sialic acid residues on its 
CRD and (presumably) the sialic acid receptor present on the hemagglutinins (180). 
Additionally, SP-A can also interact with herpes simplex virus type 1 (181), respiratory 
syncytial virus (182) and human immunodeficiency virus (183) in order to neutralize their 
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infectivity, as seen by reduction in the number of host cells expressing viral nucleoprotein 
after infection. 
II. Fungi 
The interaction of SP-A with fungi seems to be directed by two mechanisms: binding to 
structural polysaccharides consisting of repetitions of the same oligosaccharide elements, and 
interaction with glycosylated proteins express by fungi on their surface (40). SP-A has been 
reported to inhibit the growth of Histoplasma capsulatum by altering the cell membrane, as 
seen by proteins leak from the microorganism and enhanced access to the impermeant 
alkaline phosphatase substrate ELF97 after exposure to SP-A (177).  
 
III. Bacteria 
SP-A microbicidal activity has been mainly investigated in Gram-negative bacteria. SP-A 
directly inhibits the growth of Gram-negative bacteria such as E. coli, Bordetella pertussis, 
Legionella pneumophila and P. aeruginosa by increasing bacterial membrane permeability 
(16, 19, 24, 184). In general, rough bacterial mutants containing truncated LPS species were 
more readily permeabilized by SP-A than smooth strains (16, 24, 185). It has been suggested 
that bacterial permeabilization and killing require interaction between SP-A and LPS, most 
likely through the protein binding to the proximal core and/or lipid A moieties of LPS (17). 
This hypothesis is supported by the finding that deletion of the terminal sugar of B. pertussis 
and B. bronchiseptica, the causative agent of whooping cough, renders the organisms 
susceptible to aggregation and permeabilization by SP-A (24).  
On the other hand, although there are no reports about direct killing of SP-A in Gram-
positive bacteria, it has been shown that SP-A is able to inhibit the growth of other bacterial 
groups, as mycoplasma or mycobacteria, which are well-known opportunistic pathogens (186, 
187). SP-A binds Mycoplasma pneumonia or Mycobacterium avium through lipids expressed 
on its OM and decreases metabolic activity and bacterial DNA replication, thus attenuating its 
growth (188, 189). 
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6.1.3. EFFECT OF SP-A ON GRAM-NEGATIVE BACTERIA MODEL 
MEMBRANES   
SP-A has been reported to kill Gram-negative bacteria by increasing membrane 
permeability. However, the mechanisms by which SP-A increases the permeability of the 
bacterial membrane in vivo are still poorly understood. Nevertheless, there are various reports 
comprising model bacterial membranes that help to understand, at least, some of the 
molecular mechanisms involved in SP-A bacterial killing. 
The CRD domain of SP-A is able to recognize and bind various components of the 
bacterial surface. Thus, SP-A has been shown to bind to rough LPS (159), di-mannose 
repeating units of some capsular polysaccharides (147), phospholipids such as 
phosphatidylcholine (which can be found on diverse bacteria) (123), and membrane proteins 
such as P2 outer membrane protein of H. Influenzae (148).  
Bacterial membrane is responsible for mediating many essential functions in microbial 
pathogens, such as selective permeability and maintenance of gradients; energy obtaining by 
electron transport and oxidative phosphorylation; synthesis and cross-linking of 
peptidoglycan or another biopolymers; motility; and processing or display of adhesins or 
other key virulence determinant (190). Consequently, membrane disruption by SP-A might 
interfere with some of these essential bacterial functions, thus resulting on bacterial death. 
Using Re-LPS model membranes, it has been shown that SP-A may disrupt the bacterial 
membranes by extracting Re-LPS molecules thereof. This would make more fluid the 
bacterial membranes and create packing defects that facilitate the interaction of SP-A with its 
main ligand on Gram-negative bacteria, the lipid A. This would cause the membrane 
permeabilization, which would allow the entry or exit of small molecules, such as water, 
through the bilayer of LPS (30). This ability of SP-A to disrupt bacterial membranes is 
dependent on its binding to the LPS, since this does not occur in vesicles containing 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (17).  
Even though a mounting body of evidence seems to support that membrane 
permeabilization alone appears insufficient to cause cell death (191), this effect contributes, al 
least, to mechanisms by which SP-A exerts their antimicrobial activity. Therefore, additional 
or complementary mechanisms could be involved in the mechanism of action of SP-A, such 
as targeting of intracellular components like some AMPs (191). 
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6.1.4. SP-A BACTERIAL RESISTANCE 
Despite SP-A is specialized to target specific and essential molecular patterns expressed 
by pathogens; microorganisms inevitably develop diverse strategies for its own defense.  
The main constitutive resistance strategy of Gram-negative bacteria against SP-A appears 
to be the expression of more complex LPS. Numerous studies have shown the binding 
preference of SP-A by deep rough LPS. SP-A binds to LPS from either the Re-mutant of 
Salmonella minnesota or the J5-mutant of E. coli; but not to E. coli O111 LPS (159, 192). SP-
A interacts with Rb LPS mutant from E. coli strain LCD 25 (131). Consistent with that, SP-A 
has been reported to kill E.coli strains K12 (14) or J5 (16), both expressing deep rough LPS as 
well as rough mutants of B. pertussis (24) or P. aeruginosa O1 (19, 185, 193). In contrast, SP-
A did not increase permeability of E. coli O111, which expresses smooth LPS, wild-type 
strains of B. pertussis or P. aeruginosa, or liposomes containing 
palmitoyloleoylphosphatidylethanolamine and smooth LPS (17).  
Besides LPS, resistance against SP-A may be due to other components of the bacterial 
cell wall, such as the capsular polysaccharide, pili, and flagellum. SP-A binds to specific 
strains of K. pneumoniae expressing the sequence mannose-α-2/3-mannose on its CPS, unlike 
Klebsiella strains expressing CPS lacking this sequence (147). These Klebsiella strains have 
been also found to be resistant to other lectins (194, 195). In fact, it has been proposed that the 
degree of virulence conferred by a particular CPS might be connected to its mannose content, 
since the lack of this oligosaccharide could avoid direct killing and phagocytosis by lectins 
and macrophages (196). This is consistent with the observed predominance of Klebsiella 
expressing capsular serotype K2 infections, one of the most virulent of Klebsiella (97). On the 
other hand, flagellum and type IV pilus expressed by P. aeruginosa have been reported to 
confer resistance to SP-A in this bacterium. Thus, P. aeruginosa mutants in these components 
were preferentially cleared by SP-A +/+ mice, but survived in SP-A KO mice (185, 193). In 
addition, SP-A was able to increase membrane permeability and/or aggregate these mutants, 
unlike wt strain. 
There is another set of mechanisms that make bacteria resistant to the microbicidal action 
of SP-A, like the secretion of exoproteases. Incubation of SP-A with several clinical isolates 
of P. aeruginosa organisms resulted in a concentration- and temperature-dependent 
degradation of SP-A, consistent with the presence of a Pseudomonas elastase B (197). This 
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was also tested in vivo where isogenic mutant strains of P. aeruginosa nonexpressing this 
protease were attenuated in virulence when compared to the wild-type strain during lung 
infection in SP-A +/+ mice (197). Additionally, a secreted serine protease of Pseudomonas, 
called protease IV, was also found to degrade SP-A from cell-free bronchoalveolar lavage 
fluid, thus inhibiting SP-A-mediated bacterial aggregation and macrophages uptake (198).  
6.2. ANTIMICROBIAL PEPTIDES 
As mentioned in this thesis, antimicrobial peptides (AMPs) are among the main 
components of the innate immune response and the principal defense system for the majority 
of living organisms (49). Currently, more than 2000 natural AMPs with several different 
sequences have been isolated from a wide range of organisms (Antimicrobial Peptide 
Database, http:// aps.unmc.edu/AP/main.php), of which only 6% are anionic. Therefore, 
almost all research has been developed with cationic antimicrobial peptides (CAMPs). 
However, anionic antimicrobial peptides (AAMPs) are receiving more attention, since they 
have been shown as another integral and important part of the innate immune system. 
Exogenous and endogenous AMPs are mostly amphipathic molecules, with a high to 
moderate content of cationic or anionic residues, and hydrophobic amino acids (199). These 
characteristics allow them to kill a broad-spectrum of microorganisms as well as to display 
immunostimulatory and anti-inflammatory properties (8).  
Based on peptide secondary structure, AMPs can be classified into (200): α- helical, β-
sheet, extended and loop-structured peptides (Fig. 13).  
• α-helical peptides: are unstructured or disordered peptides that fold into amphipathic 
α-helices when get in contact with a target membrane. Magainins, which are 
expressed on the skin of frogs (201), or human cathelicidins (202), are one of the 
most representative CAMPs of this group. Dermcidin is one of the most studied 
human AAMPs that also adopts a α−helix structure upon contact with lipid bilayer 
surface (203). 
• β-sheet peptides: contain between 2 to 4 disulfide bridges that stabilize β-sheet 
structures and adopt cyclic-like conformations that are thought to be essential for 
antibacterial activity. Defensins are among the main components of this group in 
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mammals (52). Another example is HE2C, which is an anionic β-defensin-like 
peptide expressed in human testis (204). 
 
 
Figure. 13. Protein models of the four classes of antimicrobial peptides according to their secondary 
structure. Taken from (121). 
 
• Linear extended peptides: less common that the above mentioned, these peptides adopt 
an unconventional linear structure, without α- or β-structures. They are characterized 
by the overexpression of one or more amino acids, like histidine residues on histatins 
(205), tryptophan residues on indolicidins (206), or proline and arginine residues on 
the proline-arginine (PR)-rich antibacterial peptide  (207). 
• Loop-structured peptides: this peptides assembly into loops due to the presence of a 
single disulfide bond and/or cyclization of the peptide chain. An example is bactenein 
found in cattle and sheep (208). Another examples are gramicidin S and polymyxins, 
which are cationic decapeptides that adopt cyclic structures in their peptide chains 
(209).  
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6.2.1. MAIN FEATURES FOR ANTIMICROBIAL ACTIVITY 
AMPs share common features, which are responsible for their selective toxicity for the 
microbial target, but not for the host. They are mainly characterized by forming amphipathic 
structures, with cationic net charge at physiological pH (although as mentioned before, there is 
a small group of them that are anionic) and a moderate hydrophobicity, with up to 50% 
hydrophobic amino acids (199). These features allow AMPs to exert its activity against bacteria 
and not the host. Alternatively, AMPs toxicity to potentially vulnerable host tissue may be 
limited by localization and/or highly regulated expression of AMPs (191). 
I. Charge:  
Almost all antimicrobial peptides are cationic. Subsequently, they display a net positive 
charge, ranging from +2, like human α-defensin 1 (HNP-1), to +9, like human β-defensin 3 
(HBD-3) (210). These characteristics are responsible for the initial binding of CAMPs to 
bacterial membrane through electrostatic interactions. In bacteria, outer phospholipid bilayer is 
heavily populated with lipids negatively charged, like phosphatidil-glicerol, -serine and 
cardiolipin. In contrast, the outer one of the animal cells is composed principally of lipids with 
no net charge (zwitteronic), and most of the lipids with negatively charged headgroups are 
facing the cytoplasm, into the inner leaflet. The elevated presence of acidic phospholipids on 
bacterial membrane, together with LPS and/or teichuronic acids (negatively charged), permit 
mutual electroaffinity between AMP and bacterial membrane, and confers selective 
antimicrobial targeting relative to host tissues (191). 
In the case of anionic antimicrobial peptides, they contain aspartic acid residues as the 
main responsible for their negative charge, which generally ranges from -1 to -7 (211, 212). It 
still not clear how these anionic antimicrobial peptides are able to interact with bacterial 
surfaces, but it seems that they use metal ions to form cationic salt bridges with negatively 
charged components of microbial membranes, thereby facilitating interaction with their target 
organisms (212). 
II. Amphipathicity: 
Amphipathicity refers to the existence and polarization of hydrophobic and hydrophilic 
domains within a molecule. In proteins and peptides, it can be achieved by several 
conformations. For α-helical peptides, amphipathicity is often accomplished by a periodicity of 
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polar and apolar residues of about three to four, which can be achieved when the peptides are in 
contact with the target membrane. β-sheet peptides often show spatial separation of polar and 
hydrophobic residues due to the presence of a variable number of β-strands, which are 
frequently antiparallel (213).  
As AMPs, biomembranes are also amphipathic. Cellular membranes are composed of a 
phospholipids bilayer, where hydrophobic acyl chains of phospholipids are placed into the 
membrane, whereas its hydrophilic headpolars are exposed to the outsides of the membrane, in 
contact with water. Consequently, amphiphatic conformation of AMPs seems to be the optimal 
structure for interaction with and insertion into bacterial membranes (191). Hydrophilic 
residues would interact with the polar headgroups of the phospholipids, while hydrophobic 
residues could be inserted into the membrane and interact with the acyl chains. In addition, the 
amphipathic nature of AMPs may enable them to form transmembrane channels and/or to cross 
the membrane for intracellular targeting (15).  
III. Hydrophobicity: 
Hydrophobicity is defined as the percentage of hydrophobic residues within a peptide. For 
most AMPs it is approximately 50%, and the hydrophobic residues more common are alanine, 
leucine, phenylalanine or tryptophan (199). This characteristic enables water-soluble 
antimicrobial peptides to partition into the membrane lipid bilayer and is required for effective 
membrane permeabilization (191). An increase of peptide hydrophobicity is associated with an 
increase in antimicrobial activity. However, increasing levels of hydrophobicity above a 
threshold have been strongly correlated with mammalian cell toxicity and loss of antimicrobial 
specificity (214).  
6.2.2. MECHANISMS OF ACTION IN BACTERIAL KILLING 
Several techniques like circular dichroism, solid-state NMR spectroscopy or microscopic 
analyses as well as studies involving model bacterial membranes have permitted to discern 
the mechanisms of action of AMPs (191). These findings have shown that AMPs exert 
different effects on microbial cells with diverse target sites or mechanisms of activity. 
However, regardless of the specific mechanism, the antimicrobial activity of AMPs has three 
commons steps that, in some cases, have been shown to be independent. These steps are: I) 
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peptide attachment; II) peptide insertion and membrane permeabilization; and III) cell death 
(15).  
I. Peptide attachment: correlation between cationicity and membrane binding ability 
(215), as well as strong conservation of positive charge in CAMPs, seems to indicate 
that the initial binding of CAMPs with bacterial membrane may be initially conducted 
by electrostatic interactions (15, 216). In the OM of Gram-negative bacteria, CAMPs 
promote displacement of divalent cationic ions (Ca2+), which are bound to CPS and 
LPS molecules maintaining the OM closely packed (217). Such displacement is likely 
to be energetically favorable given that the binding affinity of a typical antimicrobial 
peptide for LPS is ≈3 orders of magnitude greater than that of divalent cations (191). 
In Gram-positive bacteria, its envelope is enriched in negatively charged teichoic and 
teichuronic acids, which are responsible for peptide interaction. 
AAMP Attachment is less studied. Many AAMPs, like dermcidin in human sweat, 
show higher activity at acidic pH and high salt conditions, which seem to function 
similar to catonic metal ions, enhancing the binding between the peptide and the 
bacterial membrane (203). On the other hand, AAMPs have been also speculated to 
interact with membranes via the use of receptors to cross the bacterial membrane and 
target intracellular components (212). However, the mechanisms underlying the 
antimicrobial effect of AAMPs are still unclear and remain to be further studied. 
II. Peptide insertion and Membrane permeabilization: once CAMPs cross bacterial cell 
wall, they gain access to the membrane (outer and inner membrane in Gram-negative 
bacteria), which is permeabilized by peptide insertion. It has been suggested that 
peptide insertion into the membrane is sequential and related to peptide concentration 
(218). Peptides begin to bind parallel to the membrane until they arise a threshold 
concentration at which peptide molecules orientate perpendicularly and insert into the 
bilayer, forming transmembrane pores to permeabilize the bacterial membrane [210].  
Several models of insertion have been proposed, according to experimental 
findings with the techniques previously mentioned (Fig. 14): 
a. Barrel-stave model (219): proposed for alamethicin. Peptides aggregate in the 
bilayer surface until they reach a determined concentration where their helices form 
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a bundle in the membrane with a central lumen. Then, the hydrophobic peptide 
regions align with the lipid core region of the bilayer and the hydrophilic peptide 
regions form the interior region of the pore.  
b. Toroidal-pore model (220): proposed for magainins, protegin and melittin. The 
attached peptides aggregate and induce the lipid monolayers to bend continuously 
till peptides connect the two leaflets of the membrane, forming a curved pore.  
 
 
 
Figure 14. Proposed models of the killing induced by AMPs. A) Barrel-stave model. B) Carpet 
model. C) Toroidal model. Hydrophilic regions of the peptides are shown coloured red and 
hydrophobic regions of the peptide are shown coloured blue. Taken from (15). 
 
c. Carpet model (221): peptides disrupt the membrane by orienting parallel to the 
surface of the lipid bilayer (forming an extensive layer or carpet) that, at high 
peptide concentrations, disrupt the bilayer in a detergent-like manner, eventually 
forming micelles.  
III. Cell death: in early studies, AMPs permeabilization was thought as the primary 
mechanism of killing, due to impairment of essential functions of the membranes as 
well as by leakage of ions and metabolites (191). However, there is increasing 
evidence that indicates that AMPs have intracellular targets. Buforin II, a proline α-
helical peptide, penetrates the bacterial outer membrane without permeabilizing it, and 
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accumulates into the cytoplasm, exerting its cytotoxic activity (222). CAMPs rich in 
arginine residues are able to translocate across both the cellular and nuclear 
membranes, where they interact with DNA, RNA and/or proteins to inhibit synthesis 
pathways (223). There is no general mechanism of intracellular killing. Once AMPs 
translocate into the cytoplasm, they are able to inhibit cell-wall synthesis, enzymatic 
activity or DNA, RNA and protein synthesis and/or to activate autolysin (191). 
6.2.3. IMMUNOMODULATION: 
Several AMPs have been found to modulate both innate and adaptive immune systems 
and have been recently renamed (or grouped) as host defense peptides (HDPs) (8). Among 
this function, HDPs exert numerous roles including direct and indirect modulation of pro- and 
anti-inflammatory responses; increase of extracellular and intracellular bacterial killing; 
promotion of polarized dendritic cell maturation and macrophage differentiation; and 
modulation of wound repair, apoptosis and pyroptosis (53).  
HDPs can reduce endotoxin-induced inflammation, because are able to bind to free LPS 
reducing its endotoxicity (224). HDPs decrease the expression of pro-inflammatory 
mediators, such as TNF-α, in human primary cells in response to various host and 
endogenous molecules, while upregulating anti-inflammatory cytokines and pathways (225). 
HDPs also displayed anti-inflammatory properties in vivo in both Gram-negative and Gram-
positive bacterial infection models (226). On the other hand, they promote chemotaxis 
indirectly by stimulating the expression of well-known chemokines (227, 228), like 
CXCL8/IL8 and CCL2/MCP1, and directly by acting as chemokines themselves to recruit a 
variety of immune cells (229).  
 
HDPs have been proposed to link the innate and adaptive immune responses by inducing 
the differentiation of dendritic cells and macrophages (230, 231). Additionally, HDPs have 
been shown to induce autophagy to increase intracellular pathogen clearance (232) and 
promote or inhibit apoptosis, depending on cell type (233) as well as induce pyroptosis (234), 
thus augmenting pathogen clearance and/or decreasing an excessive inflammation (8).  
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7. EXOGENOUS CATIONIC ANTIMICROBIAL PEPTIDES: 
POLYMYXINS AND THEIR NOVEL DERIVATIVES 
Polymyxins are nonribosomal cyclic lipodecapeptides that are strongly cationic, due to 
the presence of five free amino groups (235). They are synthetized by different species of 
Bacillus polymyxia and are able to kill Gram-negative bacteria. They were discovered in 1947 
and were subsequently used in intravenous therapy. However, due to their high toxicity for 
humans and the discovery of better-tolerated drugs, they were largely abandoned in the 1960s 
(236). Nevertheless, polymyxins have the ability to kill the current MDR bacteria. Thus, they 
have been reinstated as the last-line therapy for severe MDR infections (26, 237). 
7.1. POLYMYXIN B AND COLISTIN: 
Polymyxins comprise a group of five chemically different compounds (polymyxins A–
E), but the most studied and the only available for clinical use are polymyxin B (PMB) and E, 
also named colistin (5). They have typical features of CAMPs, including: high cationic 
character (+5), provided by 5 α,γ-diaminobutyric acid residues;  and hydrophobicity and 
amphiphaticity, provided by the presence of phenylalanine and leucine residues and a fatty 
acid tail. PMB and colistin share a common primary sequence, but differ at position 6, which 
is occupied by D-Phe in PMB and D-Leu in colistin. All amino acid residues are of the L-
configuration, except for these D-amino acids at position 6 (Fig. 15) (238). 
L-Dab 
L-Dab 
L-Dab 
L-Dab 
L-Dab 
L-Thr 
L-Dab 
NH3+ 
NH3+ 
D-Phe1 
D-Leu2 
L-Leu 
L-Thr 
NH3+ 
NH3+ 
NH3+ 
CO(CH2)4CHCH2R 
CH3 
Fatty acid tail 
 
Figure 15. Polymyxin structure. Polymyxins are pentacationic lipodecapeptides composed of a 
heptapeptidic ring and a fatty acid tail.  They comprise PMB and colistin, which only differ at position 
6 that is occupied by D-Phe in PMB (1) and D-Leu in colistin (2). Hydrophobic regions are shown 
colored in blue and cationic regions are shown colored in red. Dab: diaminobutyric acid. 
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There are several proposed model for the mechanism of action of polymyxins, but the 
most accepted, consistent with available and extensive experimental data in the literature, is 
the mechanism of “self-promoted uptake” (217). Polymyxins firstly bind to and accumulate 
onto the OM though electrostactic interactions between the positive charges of the 
diaminobutyric acid residues and the negative charges of LPS molecules, thus promoting 
access to the outer lipid bilayer. This initial electrostatic interaction temporarily stabilizes the 
complex and brings the N-terminal fatty acyl chain of the polymyxin molecule into proximity 
with the lipid A of the outer lipid bilayer. Thereby, polymyxins bind to the lipid A monolayer 
through hydrophobic and electrostatic interactions, inserting, subsequently, the lipophilic face 
(fatty acyl chain and the Phe and Leu hydrophobic domain) into the hydrophobic core of the 
bacterial outer membrane. This appears to promote a loose packing of the adjacent lipid A 
fatty acyl chains, causing OM disruption (238). Afterward, the polymyxin molecule inserts 
and disrupts the physical integrity of the inner cytoplasmic membrane (inner membrane of 
Gram-negative bacteria) by forming channels that lead to the leakage of cytoplasmic 
molecules and likely cell death (239). Additionally, as many other AMPs, it is though that 
polymyxins may target intracellular components of bacteria, which also would contribute to 
bacterial death.  
 
Polymyxins exert neurotoxicity and, mainly nephrotoxicity, which is higher in patients 
with abnormal renal function, correlates with the age and varies in the recent literature from 
10% to 30%, reaching up to 45% or 55% in some case (236, 240-242). The nephrotoxicity of 
polymyxins is principally associated with acute tubular necrosis and increased serum 
creatinine concentrations (236). The mechanisms of polymyxin-induced nephrotoxicity are 
not clear, but seem to be related to kidney tubular cell apoptosis, since PMB- and colistin-
induced tubular apoptosis have been reported (243). In addition, toxicity of polymyxins might 
be linked to that of aminoglycosides, another group of cationic antibiotics that produce 
damage renal proximal tubuli by interaction with the brush-border membrane of the proximal 
tubular cells, which are rich on acidic phospholipids (244). Moreover, oxidative stress and 
reactive oxygen species have been suggested to play a key role in their nephrotoxicity (244, 
245).   
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7.2. POLYMYXIN DERIVATIVES: 
Numerous polymyxin derivatives have been developed, in order to reduce the 
polymyxins-associated toxicity for patients or to obtain more potent and efficient 
antimicrobials (246). Thus, derivatives lacking the fatty acid tail or two strategic positions of 
the five cationic charges of polymyxins differ from polymyxins in their renal handling and 
affinity to kidney brush-border membrane, and are in preclinical studies (27). 
 
7.2.1. DES-FATTY ACYL DERIVATIVES 
7.2.1.1. POLYMYXIN B NONAPEPTIDE 
Polymyxin B nonapeptide (PMBN) is a derivate from PMB that lacks the fatty acid tail 
and the N-terminal amino acyl residue Dab (Fig. 16). Its net charge is therefore + 4, instead of 
+5 of PMB. PMBN is less bactericidal or not bactericidal at all, but retains a significant OM-
perturbing action (247). It has been shown to only produce a mild release of periplasmic 
proteins, unlike PMB, which is able to cause a high efficiently periplasmic and cytoplasmic 
protein release (248). However, PMBN is still able to bind to LPS with high affinity, which is 
likely retained by proper three-dimensional conformation and cationicity (249).  
Although PMBN is an extremely poor antimicrobial compound, it has been shown to 
reduce at low concentrations the MICs of many hydrophobic antibiotics for several pathogens 
(250-252), which is consistent with its LPS binding affinity (249). Intraperitoneal treatment of 
PMBN + erythromycin was reported to protect mice infected with K. pneumoniae or P. 
Aeruginosa, whereas PMBN or erythromycin alone were inactive (253). PMBN was also able 
to sensitize various Gram-negative pathogens to the direct bactericidal effect of human serum 
(254, 255) and neutrophils (256). Therefore, PMBN appears to have an effective synergistic 
ability with other antimicrobials by disturbing the bacterial OM, which could establish a 
novel therapeutic direction (250, 253).  
 
 
INTRODUCTION 
	  
76 
 
Figure 16. Primary structures of polymyxin B (PMB), colistin and some of their derivatives. Boxed 
parts indicate locations where the compounds are not identical. MHA/MOA, mixture of methyl 
octanoyl and methyl heptanoyl (fatty acid tail); Dab: diaminobutyryl; Abu, aminobutyryl; Dap, 
diaminopimelyl; OA: octanoyl; Ac, acetyl; cy: cyclic portion indicated with brackets. The positive 
charge of the free α- and γ-amino group is also shown. Modified from (27). 
 
Regarding toxicity, PMBN was 15-fold less toxic than polymyxin in an acute-toxicity 
assay in mice, 25-fold less active in releasing histamine from rat mast cells, and 150-fold less 
active in causing neuromuscular blockade (246). However, PMBN still suffers from being 
nephrotoxic and current research is trying to develop novel derivative less toxic (257).  
Additionally, PMBN has been extensively used for studying the mechanism by which 
polymyxins and CAMPs kill bacteria, showing that three-dimensional conformation of cyclic 
ring of polymyxins seem to be more important than their chirality or LPS binding for their 
antimicrobial activity (249, 258).  
7.2.1.2. DES-FATTY ACYL-PMB ANALOGS 
Recently, more des-fatty acyl derivatives have been developed, which comprise the 
peptide ring portion of PMB and N-terminal moieties (linear peptide portion) that were 
changed to basic or hydrophilic amino acids (Fig. 16) (27). These synthetic peptides have 
smaller amino acid side chains and shortened length of the linear peptide. Unlike PMBN, they 
ha an antimicrobial activity against P. aeruginosa equivalent to that of PMB (259). In 
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addition, their binding activity to E. coli and P. Aeruginosa was comparable with PMB and 
they have lower acute toxicity after intravenous administration in mice (259, 260).  
7.2.2. NAB COMPOUNDS 
These derivatives have their cyclic peptide portion identical to that of PMB, but their 
linear peptide portions are uncharged, thus containing the only three positive charges of the 
peptide ring portion, whereas PMB and colistin contain five (Fig. 16) (27). NAB7061 and 
NAB741 have linear portions consisting of uncharged threonyl-D -serinyl and acetyl-Thr-D-
Ser, respectively (261, 262). NAB739 differs from NAB741 by having an octanoyl group at 
the N-terminus, instead of acetyl (261).   
Both NAB7061 and NAB741 lack potent direct antibacterial activity, but, like PMBN, 
are effective sensitizers by increasing the OM permeability to hydrophobic and large 
hydrophilic antibiotics in Gram-negative bacteria, (262, 263). In addition, combinatorial 
treatment of NAB7061 and erythromycin was effective in an experimental E. coli peritoneal 
infection, unlike the administration of these components individually (264). Both components 
induced less necrosis on renal proximal tubular cells than PMB (257), and showed higher 
renal clearance and less renal accumulation than (262, 265).  
NAB739 exerts bactericidal activity similar or several-fold higher than PMB against 
Enterobacteriaceae or A. baumannii and P. aeruginosa, respectively (263, 266), and has been 
effective in treating mice i.p. infected with E. coli (264). In addition, it has shown 
combinatorial activity with antibiotics, like rifampicin (261). NAB739 was 26-fold less toxic 
than PMB and 7.5-fold less toxic than colistin to human kidney proximal tubular cells (267). 
Consequently, NAB739 is undergoing preclinical studies, although more toxicity and in vivo 
studies are necessaries.  
8. HUMAN CATIONIC ANTIMICROBIAL PEPTIDES 
8.1. DEFENSINS: 
Defensins are small, multifunctional CAMPs, which typically contain 18–45 amino acid 
residues and six conserved cysteines that form three intramolecular disulfide bonds that 
stabilize a large β-sheet structure (Fig. 17) (268). They comprise an evolutionarily conserved 
family of CAMPs divided into three subfamilies: α-defensins, only expressed in mammals; β-
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defensins, expressed in vertebrates; and θ-defensin, only found in certain non-human primates 
(269). α- and β-defensins subfamilies are expressed in humans and differ in the length of 
peptide segments between the six cysteines and the pairing of these cysteines that are 
connected by disulphide bonds (270). 
 
• Human α-defensins: are composed of 
29–35 amino acids and the cysteine 
arrangement is C1–C6, C2–C4 and 
C3–C5 (271). Four members, named 
human neutrophil peptides (HNPs) 1–
4, have been primarily found in the 
azurophilic granules of neutrophils, 
but also in monocites, lymphocytes 
and natural killer cells. The other two 
members, human defensins (HD)-5 
and -6, are located in secretory 
granules of intestinal Paneth's cells 
and in female genital epithelial cells 
(269). HNPs comprise 30–50% of the 
total protein of azurophilic organelles, 
and are expressed constitutionally by 
microbial signals, developmental 
signals or pro-inflammatory cytokines 
(29). When stimulated, both 
neutrophils and Paneth cells 
degranulate, releasing α-defensins 
into the local environment to fight 
against infection (8).  
• Human β-defensins (HBDs): HBDs are 36–42 amino acids in length and have their 3 
disulfide bridges arranged in a C1–C5, C2–C4, C3–C6 pattern (272). More than 28 
HBDs have been identified, but the most studied are HBD-1, -2 and -3. HBD-1 is 
Figure 17. Structures of representative 
defensin and cathelicidin peptides. Residues 
with a net positive charge are in red, those 
with a negative charge are in green, and 
hydrophobic residues are in blue. N termini 
are indicated with NH2. The star at the end 
of LL-37 indicates that the C terminus is 
amidated. HNP-1, human neutrophil peptide 
1; hBD, human β-defensin; SS, disulphide 
bonds. Taken from 77.  
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expressed in respiratory epithelial cells,	  urogenital tract and reproductive tract; HBD-2 is 
expressed in skin, trachea and lung; and HBD-3 is expressed predominantly in the skin 
but is also in the respiratory trachea (273). HBD-1 is constitutively expressed and HBD-2 
and -3 have been also found at very low basal amounts upon noninducible conditions. In 
addition, HBDs are induced by the presence of microorganisms or through pro-
inflammatory cytokines such as TNF-α and IL-1β (274). HBD-3 represents the most 
potent CAMP of HBDs and has a broad-spectrum antimicrobial activity, including MDR 
bacteria. In addition, unlike the other HBDs, HBD-3 retains bactericidal ability upon 
physiological concentrations of sodium chloride or in the presence of various divalent 
cations (275, 276). 
As AMPs, defensins exert microbicidal activity against Gram-negative and positive 
bacteria, fungi and virus as well as immunomodulatory functions into the host (272, 274).  
 
8.2. CATHELICIDINS 
These peptides have a strong cationicity (+ 6 at pH 7.4) and a high content of basic and 
hydrophobic amino acids (277). They are known as cathelicidins, due to their main structural 
feature, consisting on a high-level sequence identity in the 5′ region, named the N-terminal 
cathelin domain, because it is also found in cathelin, a cysteine protease inhibitor. The 
antimicrobial properties of cathelicidins are found in their highly variable C-terminal domain 
(278).  
In humans, there is only one cathelicidin precursor, hCAP-18, which is processed by 
serine protease 3 to generate a 37 amino acid peptide called LL-37 (Fig. 17) (279). The 
structure of LL-37 in aqueous solution is relatively disordered, but adopts a typical α-helical 
assembly of CAMPs upon contact with the bacterial wall (280). LL-37 is expressed in 
immune cells, such as neutrophils, monocytes, dendritic cells, and macrophage, as well as in 
mast and epithelial cells. Its expression can be constitutive or induced by the presence of 
inflammatory mediators and microbial structures (278). 
LL- 37 has been shown to display a broad range of immune functions both in vitro and in 
vivo. It is able to directly kill different microorganisms, including P. aeruginosa, K. 
pneumoniae, and S aureus (281-283). LL-37 has anti-fungal (284) and antiviral activity (285). 
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Moreover, LL-37 displays immunomodulatory activities, including both direct and indirect 
neutrophils, monocytes and T cell recruitment, and regulation of angiogenesis and cell growth 
(286).  
Consequently, cathelicidins, together with defensins, have become a promising 
therapeutic agent to treat infectious and inflammatory diseases (280). 
9. HUMAN ANIONIC ANTIMICROBIAL PEPTIDE: SP-BN 
In humans, AAMPs were firstly discovered in bronchoalveolar lavage fluid and airway 
epithelial cells. These peptides occur in millimolar concentrations, are antimicrobial against 
both Gram-positive and Gram-negative organisms and were shown to require zinc as a 
cofactor for antimicrobial activity (287). Later, a variety of AAMPs have been found in 
plasma and cells of human blood, which are mainly encrypted within the primary structures of 
proteins. Dermcidin is one of the most studied human AAMPs, which is proteolytically 
processed to give rise to 14 dermcidin-derived peptides, from which the anionic peptides 
DCD-1L and DCD-1 show antimicrobial activity (288). Unlike most of AMP, DCD-1L 
maintains antimicrobial activity over a broad pH range and at high salt concentration (289). 
This is consistent with others AAMPs, as the recently discovered human AAMPs surfactant 
protein BN (SP-BN), a soluble segment of the surfactant proprotein SP-B found in human 
airspace, which shares some features with dermcidin and has antimicrobial activity only at 
low pH (6).  
SP-BN is an 80 amino acid, anionic, saposin-like peptide, which comes from the 
proteolytic processing of the NH2-terminal propeptide of SP-B. SP-BN is secreted into the 
airspace with surfactant and exerts robust antimicrobial activity against Gram-positive and -
negative bacteria, but only at acidic pH (6). Processing of SP-B occurs during the surfactant 
secretory pathway, in which is glycosylated in the endoplasmic reticulum, transported to the 
Golgi apparatus and thence to multivesicular bodies and is finally stored in lamellar bodies 
(290). SP-B is firstly translated into a larger precursor protein in which the mature SP-B 
peptide (residues 201–279) is flanked by an N-terminal prepropeptide of 200 amino acids and 
a C-terminal peptide of 102 amino acids; both of them containing saposin-like domains (291). 
Cleavage of both terminal propeptides occurs in the lumen of the multivesicular body, prior to 
or during their fusion with the lamellar body, and it is thought to be performed by proteases 
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such as napsin A and cathepsin H (292). Finally, the saposin-like domain of the N-terminal 
propeptide is also cleaved to obtain the AAMP SP-BN. Moreover, the C-terminal domain 
encodes another saposin-like domain with unknown functions (6). 
SP-BN has been shown not to partition with surfactant lipids and to be secreted into the 
alveolar fluid, since it was recovered in the mouse bronchoalveolar lavage fluid and in 
nonciliated bronchiolar cells, alveolar type II epithelial cells, and alveolar macrophages (6). 
Overexpression of SP-BN in targeted mice protected mice against infection with P. 
aeruginosa and S. aureus. In vitro, SP-BN localized to lysosomes in phagocytic cells and was 
able to increase bacterial phagocytosis and killing by alveolar macrophages. In addition, SP-
BN directly killed K. pneumoniae and S. aureus, but only at acidic pH, which, together with 
lysosomal localization, was consistent with a potential role in intracellular killing by alveolar 
macrophages (6). 
The mechanism of bactericidal action of SP-BN is still unknown. SP-BN shares striking 
structural and functional similarities with amoebapores, other member of the saposin-like 
proteins family. Amoebapores are a family of three cytolytic peptides (amoebapore A, B and 
C) from Entamoeba histolytica that kill ingested bacteria by the amoeba in acidic 
phagolysosomes (293). They are highly hydrophobic and amphipathic and permeabilize 
bacterial membranes in a pH- and oligomerization-dependent manner by forming a stable 
transmembrane pore that disrupts the cytoplasmic membrane (294). Both peptides are 
predicted to have very similar secondary structures and three-dimensional structure according 
with the so-called “saposin-fold”. Thus, by nuclear magnetic resonance, amoebapore A was 
found to contain five helices connected by three disulfide bonds; whereas, SP-BN has been 
predicted to contain four amphipathic helices and three disulfide bridges arising from six 
invariant cysteine residues. This saposin-folding confers them resistance to denaturation and 
proteolysis, and promotes protein stability and likely antimicrobial activity in an acidic 
environment. Moreover, SP-BN has been found to form a coiled coil structure at acidic pH, 
which could be implicated in its pH-dependent antimicrobial activity (295, 296).  
Although still unknown, it is possible that these features allow SP-BN to depolarize 
bacterial membrane via formation of pores, like amoebapores (6). Additionally, since it is 
secreted into the alveolar fluid together with another antimicrobials factors, whether SP-BN 
could kill bacteria in vivo at neutral pH also remains to be determined.  
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10. SYNERGISTIC AND ADDITIVE ACTIVITY OF HOST DEFENSE 
FACTORS  
The innate immune system of higher organism is usually composed of different 
antimicrobial peptides and proteins, which are virtually expressed at a particular site, like skin 
or alveolar space in humans (10). The presence of multiple antimicrobial factors might 
provide redundancy in bacterial killing and increase the spectrum of antimicrobial activity to 
strengthen host defense (22). Consequently, most of these factors might act cooperatively in 
their microbicidal activity (273). Antimicrobial cooperation occurs when two antimicrobial 
factors work in conjunction to reduce the individual concentration of each molecule required 
to kill a microorganism. Whether the combined activity is greater than the sum of the 
individual activities, it is synergistic activity. If it is similar to the sum of both, the 
combination is additive. 
 
Both activities have been observed in AMPs of different organisms, not only between 
them, but also with antimicrobial proteins. Frog peptides, including members of the 
dermaseptin family and magainin, have shown synergistic activity (297, 298). Two peptides 
found in rabbit neutrophil granules, also act synergistically in killing extracellular pathogens 
(299). Peptides representing each of the structural classes found in mammals, protegrin-1 (β-
hairpin), LL-37 (α-helical), bactenecin (loop), and indolicidin (extended), demonstrated 
combinatorial activity against representative human pathogens (300). In addition, HBD-2 and 
LL-37 had additive activity against E. coli, and lactoferrin and lysozyme acted synergistically 
in combination with HBD-2 or in triple combinations with the proteinases inhibitor secreted 
by leukocytes (22). 
On the other hand, AMPs, both exogenous and endogenous, have been studied to 
synergize with antibiotics. Polymyxins showed synergistic and additive activity when 
combined with lipophilic and amphiphilic antibiotics, such as rifampin, macrolide antibiotics, 
fusidic acid and novobiocin (26). Additionally, AMPs like peptide p18, defensins, and 
cathelicidins have been found to act in conjunction with commonly used antibiotics against 
several microorganisms (301). 
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11. THERAPEUTIC POTENTIAL OF HOST DEFENSE FACTORS  
As mentioned throughout the introduction, numerous studies involving SP-A have 
indicated the essential role of SP-A in innate immune defense of the host. In addition to its 
antimicrobial and immunomodulatory activities found in vitro and in vivo, the role of SP-A in 
the pathobiology of several pulmonary diseases has been demonstrated. Varying serum and 
bronchoalveolar lavage fluid levels of SP-A as well as polymorphisms in genes encoding SP-
A have been associated with a range of infectious and non-infectious diseases (which may 
undergo infection), including idiopathic pulmonary fibrosis (302), cystic fibrosis (303, 304), 
pulmonary alveolar proteinosis (305), hypersensitivity pneumonitis (306),  bacterial 
pneumonia (307), acute lung injury/acute respiratory distress syndrome (308, 309) or 
interstitial lung disease (310). Moreover, lower respiratory tract pathogens have been shown 
to impair SP-A function to potentially leave the host vulnerable to develop severe infection 
(311). Consequently, administration of exogenous SP-A might be useful for both delaying 
microbial invasion and increasing host defense mechanism to overcome infection. 
Usage of naturally occurring antimicrobial factors as future therapeutics is being widely 
investigated, not only with SP-A. AMPs are currently great promising alternatives to treat 
respiratory infections (312). Together with SP-A, they are implicated in host defense, 
including microbial clearance, immunomodulation and neutralization of endotoxins (53). In 
addition, are unaffected by classical antibiotic resistance mechanisms and are less likely to 
produce new bacterial resistance (121). Most importantly, one of the main desirable 
characteristics is its ability to kill MDR bacteria, (313).  
With multi-drug resistance accumulation without new effective antibiotics, many 
companies are trying to introduce the antimicrobial peptide products into the market (313, 
314). AMPs have been or are in various stages of development, ranging from early preclinical 
studies to phase III clinical studies. Pexiganan (analog of maganin 2) was the first AMP 
developed commercially, which arrived into phase III clinical trials, but failed to be accepted 
for clinical use, because it was not more effective that other current antibiotics (315). Since 
then, AMPs have been in clinical phases for more than 10 years. However none has been yet 
approved for clinical use for several reasons, including low oral bioavailability, weak activity 
in vivo, nonspecific cytotoxicity, apparent susceptibility to proteolysis, and their propensity to 
be rapidly metabolized (314). Additionally, they are affected by a very expensive synthesis 
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compared to antibiotics, since production of one gram of an AMP can cost up to 400US$, 
whereas for a conventional antibiotic this price can be under 1US$ (313).  
Polymyxins are one of the most promising AMPs that are currently used clinically (5). 
Both polymyxins B and colistin are used for topical treatments of infection by P. aureginosa 
and A. baumannii without side effects and with low bacterial resistance (313). Although these 
AMPs are too toxic to be used systemically as anti-bactericidal or anti-endotoxic reagents; 
both colistin and polymyxin B are increasingly being used as salvage therapy in critically-ill 
patients with MDR Gram-negative infections (26, 316).  
Due to the appearance of these MDR bacteria, functional recombinant proteins of SP-A 
(containing full-length SP-A or some of its domains) as well as synthetics analogs of 
polymyxins or AMPs are being currently developed to reduce their toxicity and/or improve 
their clinical activity for the treatment of several infections, including respiratory infections 
(13, 246). Additionally, some of these factors, as well as their analogs, have shown 
synergistic activity with both antibiotics and other antimicrobial factors of the host (301, 317). 
This feature is particularly interesting, since combinatorial use between these molecules 
and/or with antibiotics could reduce clinical doses of both, thus decreasing associated toxicity 
and/or increasing effectiveness of antibiotics against MDR bacteria. 
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Gas exchange between oxygen and CO2 is essential for the maintenance of metabolic 
processes in the organism, and requires a large contact surface with the atmosphere. The 
alveolar epithelium is continuously exposed to inhaled particles such as pathogens, allergens 
and contaminants. To protect the host against microorganisms reaching the alveoli during 
inspiration, there are some effective defense mechanisms. 
Beside a cellular component, the lung innate immune system is composed of a soluble 
component, consisting of proteins and antimicrobial peptides (AMPs) able to kill, directly or 
indirectly, microorganisms as well as modulate the inflammatory response of the host (3, 8). 
SP-A is a large protein present in the lung with immune defense functions (12, 18).  SP-A 
belongs to the collectin family, and it is the most abundant protein of the alveolar fluid by 
weight. SP-A acts as an opsonin and enhances phagocytosis of several pathogens including S. 
aureus and P. aeruginosa (149, 197). SP-A is able to modulate the alveolar immune cell 
response and also exert direct bactericidal activity against some Gram-positive and Gram-
negative bacteria, virus and fungi in vitro and in vivo (12, 14). It has been reported that SP-A 
enhances lysosomal delivery of GFP-transfected E. coli in alveolar macrophages (318), 
suggesting that SP-A could impair pathogens’ evasion of lysosomal fate. SP-A has also been 
shown to have a protective role in K. pneumoniae infections since SP-A knock-out mice show 
a higher mortality index upon K. pneumoniae challenge (176). Finally, it has been reported 
that pathogen elimination is very deficient in SP-A -/- mice (18), whereas SP-A +/+ mice 
showed a greater microbial clearance, even on bacteria resistant to SP-A killing in vitro (19, 
20). 
Since the alveolar fluid contains other soluble factors able to recognize and eliminate 
pathogens, like AMPs, it is possible that synergistic or cooperative action between several 
airway antimicrobial factors might strengthen the microbicidal activity of each factor alone. 
Therefore, our hypothesis is that SP-A could act in collaboration with AMPs of the alveolar 
space to increase its antimicrobial activity in the alveoli. This would contribute to enhance the 
clearance of respiratory pathogens. In this regard, synergies between lysozyme, lactoferrin 
and human-beta defensin-2 (HBD-2) have been described (21), while cathelicidin LL37 and 
HBD-2 have demonstrated additive action against E. coli (22).  
This is particularly important given the emergence of antibiotic bacterial resistance and 
spread of MDR-bacteria to current antimicrobials. Thus, it has increased urgency to explore 
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alternative means of combating pathogenic assault (23, 109). A better understanding of the 
biological and molecular basis of SP-A-pathogen and SP-A-AMPs interactions opens 
stimulating perspectives on future alternative or adjuvant treatments. 
Therefore, the main objective of this thesis was to study both individual and 
cooperative antimicrobial activities of SP-A in airway host defense. To accomplish this 
task, several respiratory Gram-negative pathogens were used in order to clarify the 
mechanism of bacterial resistance to SP-A, as well as to elucidate the potential synergistic 
activity of SP-A with AMPs. Additionally, the mechanism by which SP-A kills bacteria in 
conjunction with these factors was investigated. 
This thesis is composed of three chapters with the following concrete objectives: 
1. To study the potential protective effect of SP-A against different smooth and rough 
strains of the lung pathogen Klebsiella pneumoniae K2, as well as its ability to 
modulate the antimicrobial activity of cationic AMPs, both exogenous and 
endogenous, against several respiratory pathogens, including Klebsiella pneumoniae, 
Pseudomonas aeruginosa and Haemophilus influenzae. 
2. To determine the potential cooperative therapeutic action of SP-A and the anionic 
peptide SP-BN against a common bacterial cause of pneumonia in vivo. 
3. To evaluate the mechanisms by which SP-A and a nonapeptide derived from 
polymyxin B (PMBN) kill bacteria synergistically. 
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1. Materials 
1.1.  Surfactant Protein A (SP-A) 
Human surfactant protein A was isolated from bronchoalveolar lavage fluid (BALF) of 
patients with alveolar proteinosis using a sequential butanol and octylglucoside extraction 
similar to (319). Aliquots from BALF (1.5 mL) were re-suspended in 25 mM Tris, 150 mM 
NaCl buffer (25 mL) and subsequently added to 1-butanol, HPLC grade (Scharlab) (1:30, 
w/v) according to the amount of total protein in the aliquot determined by lowry protein assay 
(320). After 30 min of stirring at RT, surfactant/butanol mixture was centrifuged at 5000 g for 
30 min at 15ºC to deposit the butanol-insoluble protein. Pellet was dried under nitrogen and 
washed twice with 5 mM Tris, 150 mM NaCl, 20 mM octyl-/3-D-glucopyranoside (Sigma) 
pH 7.4. The obtained pellet was suspended in 5mM Tris pH 7.4 and dialyzed against the same 
buffer for 24h at 4ºC to remove detergent. After that, solution was centrifuged at 100,000 g, 
4ºC, for 30 min. Supernatant, containing soluble protein SP-A, was finally stored in small 
aliquots at -20ºC after evaluating the amount of protein by lowry protein assay (320). The 
endotoxin level of SP-A was measured by the toxinsensor™ chromogenic limulus amebocyte 
lysate endotoxin assay kit according to the manufacturer’s instructions (GenScript, USA). 
Endotoxin levels were less than 0.15 EU/ml.   
Isolated human SP-A was characterized by several experimental approaches:	   
• Polyacrylamide Gel Electrophoresis (PAGE) 
The purity of SP-A was checked by 1-dimensional SDS-PAGE with 12% 
acrylamide/bisacrylamide under reducing conditions, and its oligomerization state was 
assessed by 1-dimensional PAGE in 4-12% acrylamide under non-denaturing conditions 
(131). After electrophoresis in these conditions, SP-A was detected by either coomassie blue 
or silver staining methods (321, 322). Under reducing conditions, SP-A migrated as monomer 
(≈36 kDa) and nonreducible dimer (≈ 72 kDa) (Fig. 1), as previously described for this 
protein (323). Under non-denaturing conditions, SP-A migrated as higher oligomers, mainly 
octadecamers (≈650 kDa), as previously characterized (324). Thus, SP-A consisted of 
supratrimeric oligomers of at least 18 subunits. Each subunit had an apparent molecular 
weight of 36,000 Da.  
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Figure 1. Silver stain of human SP-A analyzed by 1-dimensional SDS-PAGE in 12% acrylamide 
under reducing conditions. Upper bands correspond to SP-A dimer (≈ 72 kDa); and lower bands 
correspond to SP-A monomers (≈36 kDa) after protein reduction. 
 
• Intrinsic Fluorescence Spectroscopy 
Fluorescence measurements of isolated SP-A were carried out in 5 x 5 quartz cuvettes 
using an SLM-Aminco AB-2 spectrofluorimeter equipped with a thermostated cuvette holder 
(±0.1 °C; Thermo Fisher Scientific, Waltham, MA, USA). Fluorescence emission spectra of 
SP-A (10 µg/mL) were measured at 25 °C in 5 mM Tris buffer, pH 7.4. Blanks and protein 
were excited at 295 nm. Emission spectra were recorded from 305 to 400 nm, and the slit-
widths were 4 nm for the excitation and emission beams. The emission spectrum of SP-A is 
dominated by the contribution of two conserved tryptophan residues located at positions 192 
and 213 of the globular COOH-terminal domain (135). The emission spectrum of human 
isolated SP-A had a maximum at 337 nm (Fig. 2A), as previously described (135).  
• Dynamic Light Scattering (DLS) 
DLS, sometimes referred to as Quasi-Elastic Light Scattering, is a technique that allows 
to measure the size distribution of molecules and particles dispersed or dissolved in a liquid 
(325). For this, a laser is focused on a small region of the sample. A certain proportion of the 
incident light is scattered and detected at an angle of 90 °, regarding to the direction of the 
incident beam. The Brownian motion of the scattering particles causes fluctuations in light 
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scattering intensity. The velocity of the Brownian motion of the particles can be calculated 
and related to their hydrodynamic size (326). 
The hydrodynamic diameters of SP-A (Fig. 2B) in 5mM Tris buffer, pH 7, were 
measured at 25°C in a Zetasizer Nano S (Malvern Instruments, Malvern, UK) equipped with a 
633-nm HeNe laser as explain later in section 5.1.2-DLS. The hydrodynamic size of isolated 
human SP-A was around 30-40 nm, as seen previously seen (144).  
 
 
Figure 2. Representative graphs of emission spectra (A) and hydrodynamic size (B) of isolated human 
SP-A. SP-A shows a maximum at 337 nm when excited at 295 nm, and its hydrodynamic size is 
usually around 30-40 nm in 5 mM Tris buffer, pH 7. 
 
• Self-Aggregation Assay 
Self-aggregation of SP-A is one of its main intrinsic abilities, which it is principally Ca2+-
dependent, but also occurs at high-ionic strength or mildly acidic pH (136). Ca2+-dependent 
self-association of SP-A (Fig. 3) was performed at 37 °C by measuring the change in protein 
absorbance at 360 nm in a DU-800 spectrophotometer (Beckman Coulter, Fullerton, USA) as 
previously described (327). Sample and the reference cuvettes were first filled with 0.4 ml of 
5 mM Tris buffer, pH 7.4. After 10 min equilibration at 37 ºC, SP-A (20 µg) was added to the 
sample cuvette and the change in absorbance at 360 nm was monitored at 1-min intervals over 
10 min. Next, Ca2+ (5 mM, final concentration) was added to both the sample and the 
reference cuvette and the change in absorbance was monitored again. Self-association of SP-
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A was finally reversed by adding EDTA  (10 mM, final concentration). 
 
 
Figure 3. Representative graph of self-aggregation of SP-A in the presence of Ca2+. Absorbance of 20 
mg SP-A (red circle) in 0.4 ml of 5 mM Tris buffer, pH 7.4, or buffer alone (white circle) was 
measured at 360 nm before and after addition of Ca2+ (5 mM). Self-aggregation was reverted by 
addition of EDTA (10 mM). 
 
• Ability to aggregate bacteria expressing deep rough LPS. 
SP-A has been shown to aggregate bacteria, preferably expressing deep rough LPS (13). 
Thus, to analyze the biological activity of human isolated SP-A, we performed bacterial 
aggregation assays of SP-A against Escherichia coli J5, a rough mutant of E. coli 0111:B4, 
which express deep rough LPS (328) and has been reported to be bound and aggregated by 
SP-A (192, 329).  
Bacteria were grown at 37ºC in 5 mL of Luria-Bertani (LB) medium and harvested (500 
g for 10 min) on exponential-phase. The pellet was washed twice with 10 mM phosphate 
buffer saline (PBS) pH 7.2 and re-suspended in Hank’s balanced salt solution (HBSS) buffer 
(0.137 M NaCl, 5,4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1 mM 
MgSO4, 4.2 mM NaHCO3). Optical density (OD) of this suspension was measured in a 
spectrophotometer DU-800 (Beckman Coulter, Fullerton, USA) at 700 nm and adjusted to a 
final OD700 = 1. This OD was previously established to be equivalent to a bacterial 
concentration of 109 colony forming units (CFU)/mL by plating serial dilutions on agar plates 
of bacteria growth in the same conditions, and counting the number of CFU after ON 
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incubation at 37°C. SP-A 25 µg/mL was, then, added to 150 µL of this solution and incubated 
for 30 min at 37 ºC with 30 seconds of gentle shaking each 5 min. The aggregation was 
determined by monitoring the changes in absorbance at 700 nm during 2h at 37ºC without 
shaking (Fig. 4A). The results are shown as percentage of absorbance versus absorbance at 
time 0 (100%). Furthermore, E. coli J5 transformed with the plasmid pZsGreen expressing 
GFP was used for visualization of bacterial aggregation by fluorescence microscopy (Leica 
TCS SP2 Confocal System) (Fig. 4B). 
 
Figure 4. A) Representative graph of ability of SP-A (25 µg/mL) to aggregate E. coli J5. Aggregation 
was determined by monitoring the changes in absorbance at 700 nm during 1h at 37ºC without 
shaking. B) Representative images of E. coli J5 expressing GFP aggregated by SP-A.  
 
1.2. Antimicrobial Peptides 
• Polymyxin B (PMB), Polymyxin E or colistin (PME) and polymyxin B nonapeptide 
(PMBN) were obtained from Sigma Aldrich (St. Louis, MO, USA).  
• Recombinant human β-defensins (HBDs) HBD-1, HBD-2 and HBD-3 were obtained from 
PrepoTech (Rocky Hill, NJ, USA).  
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• NH2-terminal propeptide of surfactant protein B (SP-BN) was obtained in the Prof. 
Timothy E. Weaver laboratory (Cincinnati Children's Hospital Medical Centre, OH, USA) 
during a predoctoral stay, as following.  SP-BN cDNA (encoding residues 61–146; Fig. 5A) 
was generated from mouse type II cell RNA by RT-PCR using upstream primer 5’-GGG 
AAT TCC ATA TGC ATG CAG GAG CTA ATG ACC TG-3’ and downstream primer 
5’-CCG CTC GAG CTG CCC ACG TGG GCA CAG GCC-3’; restriction sites for NdeI 
and XhoI were encoded in the upstream and downstream primers, respectively.  
 
 
Figure 5. A) Schematic representation of preproSP-B protein. The boxes indicate the predicted 
location of three saposin-like domains in mouse preproSP-B: N-terminal peptide (SP-BN): residues 
61–146; mature peptide (SP-B): residues 192–270; and C-terminal peptide (SP-BC): residues 292–367. 
Taken from (6). B) Recombinant SP-BN on 10-20% Tricine-SDS PAGE gradient gel stained with 
comassie blue. 
 
 
The amplified 258-bp fragment was cloned into the NdeI/XhoI sites of PET21a vector 
(Novagen, Madison, WI). SP-BN was expressed in Escherichia coli BL21 (DE3). 
Transformed bacteria were grown in LB medium supplemented with 50 µg/ml 
carbenicillin to an OD600 of 0.6; protein expression was induced by the addition of 0.1 mM 
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isopropyl b-d-thiogalactoside (IPTG) for 3 h at 37° C. Ten to 20% tricine–SDS-PAGE of 
bacterial lysates expressing SP-BN detected a band, Mr = 9 kDa, following IPTG induction 
(Fig. 5B). The broth was centrifuged, and the isolated bacterial pellet was lysed by 
sonication in 20 mM Tris buffer, pH 7.4, 4°C. Inclusion bodies were recovered by 
centrifugation, washed in Tris buffer, and solubilized in 20 mM Tris, 6 M urea, 50 mM 
DTT buffer, pH 7.4. Denatured, solubilized inclusion body protein was diluted (1:10) in 20 
mM Tris, 6 M urea, 0.5 M NaCl, 3 mM reduced glutathione, 0.3 mM oxidized glutathione, 
pH 7.4, and dialyzed three times against 10 volumes of the same buffer in which the urea 
concentration was reduced to 2 M followed by dialysis against 10 volumes of 20 mM Tris, 
0.5M NaCl (nickel-nitrilotriacetic acid [Ni-NTA] binding buffer), pH 7.9. After 
centrifugation, the supernatant was applied to a Ni-NTA agarose column (Novagen). The 
column was washed and eluted according to the manufacturer’s protocol. Eluted protein 
was dialyzed against sodium phosphate buffer, pH 7.0, and stored in aliquots at -80°C. The 
endotoxin level of SP-A was measured by the toxinsensor™ chromogenic limulus 
amebocyte lysate endotoxin assay kit according to the manufacturer’s instructions 
(GenScript, USA). Endotoxin levels were less than 0.12 EU/ml. 
 
1.3. Biotynilation Assay 
SP-A and SP-BN were biotynilated by the FluoReporter® Mini-biotin-XX Protein 
Labeling Kit according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). This kit 
contains watersoluble biotin-XX sulfosuccinimidyl ester, which readily reacts with protein 
amines to yield a biotin moiety covalently attached via two aminohexanoic chains (“XX”). 
This 14-atom spacer has been shown to enhance the ability of the biotin moiety to bind to 
avidin’s relatively deep binding sites. Proteins (1 mg/ml) in 100 mM sodium bicarbonate 
buffer, pH 8, were incubated with biotin (biotin/protein molar ratio of 3-8:1) for 90 min in 
darkness at room temperature. To remove unreacted fluorescent reagent, the mixture was 
exhaustively dialyzed against 5 mM Tris-HCl, pH 7.4. After that, protein amount was 
determined by lowry protein assay. The structure and functional activity of biotinylated 
proteins were similar to that of unlabeled SP-A and SP-BN. 
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1.4. LPS and Lipids 
 Rough LPS from Salmonella minnesota (serotype Re 595) were purchased from Sigma 
(St. Louis, MO, USA). Total E. coli phospholipid extract was purchased from Avanti Polar 
Lipids (Birmingham, AL, USA). The organic solvents (methanol and chloroform) used to 
dissolve lipids were HPLC grade (Scharlau, Barcelona, Spain).  
1.5. Fluorescent Probes  
The fluorences probes Rhodamine Phalloidin and 4',6-diamidino-2-phenylindole (DAPI) 
were obtained from Invitrogen (Waltham, MA, USA).  The fluorescent probes propidium 
iodide, 1,6-diphenyl-1,3,5-hexatriene (DPH), 6-lauroyl-2-(N,N-dimethylmino) naphthalene 
(LAURDAN), 8-aminonaphthalene-1,3,6-trisulfonic acid disodium salt (ANTS) and p-
xylene-bis-pyridinium bromide (DPX) were obtained from Molecular Probes Inc. (Eugene, 
OR, USA).  
 
All other reagents were obtained from Sigma Aldrich (St. Louis, MO, USA) or where 
indicated. 
 
2. Mice, Bacteria and Cell lines 
2.1. Bacteria 
Klebsiella pneumoniae 52145 (serotype K2:O1) is a clinical isolate that has been 
described previously (330) (Fig. 6) and was kindly provided by Dr. José A. Bengoechea 
(Fundación Caubet-Cimera, Centro Internacional de Medicina Respiratoria Avanzada, 
Mallorca, Spain) as well as used during a predoctoral stay in his laboratory. The chemical 
structure of its CPS has been reported (331). To obtain K. pneumoniae mutant strains with 
defects in LPS core, chromosomal in-frame nonpolar waa deletions were generated by Dr. JA 
Bengoechea laboratory as described in (95, 332). The isogenic mutants 52145-ΔwabK (Kp 
Rc+CPS), which express Rc-LPS and CPS; 52145-ΔwcaK2-ΔwabK (Kp Rc-CPS), which 
express Rc-LPS and does not express CPS; and 52145-ΔwabC (Kp Re-CPS), which express 
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Re-LPS and does not express CPS have also been described previously (95, 331). All 
Klebsiella strains were grown in LB medium at 37 ºC.  
 
 
Figure 6. Aspects of colonies from a non-mucoid strain of K. pneumoniae  (KP110) (A) and 
the mucoid strain of our strain of study, K. pneumoniae  (52145) (B). Taken from (330).  
 
Pseudomonas aeruginosa O1 (PAO1) wild type is a clinical isolate that has been 
described previously (333) and was kindly provided by Dr. José A. Bengoechea as well as 
used during a predoctoral stay in its laboratory. This bacterium was also grown in LB at 37 
ºC.   
Non-typable Haemophilus influenzae (NTHi) strain 375 is an otitis media isolate (334), 
and was kindly provided by Dra. Junkal Garmendia (Instituto de Agrobiotecnología, Navarra, 
Spain) as well as used during a predoctoral stay in her laboratory. NTHi was grown at 37 °C 
and 5 % CO2 on chocolate agar plates (BioMérieux, Marcy l'Etoile, France) or brain heart 
infusion (BHI) broth supplemented with 10 µg/mL haemin and 10 µg/mL β-Nicotinamide 
adenine dinucleotide hydrate (β-NAD).  
2.1.1.  Bacteria expressing Green Fluorescent Protein 
To obtain fluorescents bacteria, bacteria were made competent using the CaCl2 method 
(335), and subsequently transformed with the plasmid pZsGreen (Clontech Laboratories, CA, 
USA), which encodes a variant of wild-type Zoanthus sp. green fluorescent protein (GFP). 
These variant is flanked by the lac operon and is expressed upon induction of IPTG. In 
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addition, this vector encodes carbenicilin resistance gene, to select transformed bacteria. 
Aliquot of 100 µl of competent bacteria were transformed with 2 ng of plasmid pZsGreen. 
Transformed bacteria were plated on LB-agar with 100 µg/ml of carbenicillin to select 
bacteria expressing GFP. The next day, plates were observed in a STATION Kodak 4000MM 
IMAGE filter equipment using λex 465 nm and λem 535 nm and colonies with greater 
fluorescence intensity were selected. 
2.2. Cell Cultures  
MH-S (mouse alveolar macrophages) and Raw 264.7 (mouse peritoneal macrophages) 
cell lines was purchased from American Type Culture Collection (Rockville, MD) (Fig. 7). 
Both were grown at 37ºC and 5% CO2 in RPMI 1640 medium supplemented with 2mM 
glutamine, 100 units/mL penicillin, 100 units/mL streptomycin and 10% fetal bovine serum 
(FBS). 
 
 
Figure 7. Optic micrograph showing MH-S and Raw 264.7 cells morphology. 
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2.3. Mice 
Five to six weeks old males FVB/N were purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA) for in vivo experimental approaches. All mice were housed in a pathogen-
free barrier facility and were handled according to the Institutional Animal Care and Use 
Committee guidelines at Cincinnati Children’s Hospital Medical Center.  
3. Antimicrobial Activity in vitro Assays 
3.1. Bacterial Aggregation 
Bacteria were grown at 37ºC in 5 mL of LB medium, harvested (500 g for 10 min) on 
exponential-phase and the pellet was washed twice with 10 mM phosphate buffer saline 
(PBS) pH 7.2, re-suspended in Hank’s balanced salt solution (HBSS) buffer (0.137 M NaCl, 
5,4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1 mM MgSO4, 4.2 mM 
NaHCO3), and adjusted to a final concentration of 109 CFU/mL (OD700 = 1). SP-A 25 µg/mL 
was added to 150 µL of this solution and it was incubated for 30 min at 37 ºC with 30 seconds 
of gentle shaking each 5 min. The aggregation was determined by monitoring the changes in 
absorbance at 700 nm during 2h at 37ºC without shaking, in a spectrophotometer DU-800 
(Beckman Coulter, Fullerton, USA). The results are shown as percentage of absorbance 
versus absorbance at time 0 (100%). 
K. pneumoniae 52145 and mutant strains expressing GFP were used to visualize bacterial 
aggregation by fluorescence microscopy (Leica TCS SP2 Confocal System).  
In addition, a suspension of 1 mL from K. pneumoniae 52145 and mutant strains re-
suspended in HBSS buffer and adjusted to a final concentration of 109 CFU/mL were 
incubated in culture tubes with SP-A 25 µg/mL in the same conditions above mentioned, for 
direct visualization of bacterial aggregation by turbidity and bacterial pellet formation. 
3.2. Inhibition of Bacterial Growth 
10 µL bacteria on stationary-phase were diluted 1/200 in 200 µL LB in the absence or 
presence of 25 µg/mL SP-A to perform the experiment at the beginning of the growing-phase. 
Tubes were shaken at 250 rpm and 37ºC for up to 6 hours. Bacterial density was monitored by 
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measuring light scattering at 400 nm in an ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, USA) at 1-hour intervals. 
3.3. Bacterial Killing 
To evaluate the microbicidal activity of SP-A, AMPs or both, colony count on plate assay 
was used. Bacteria were grown in corresponding medium (BHI for H. influenzae and LB for 
the other ones) at 37ºC with continuous shaking to exponential phase. The bacteria were 
harvested from broth by centrifugation at 500 g for 10 min, and the pellet was washed twice 
with 10 mM PBS (pH 7.2), re-suspended in PBS and adjusted to a final concentration of 5 x 
105 CFU/mL. Aliquots of this suspension (5 µL) were mixed with SP-A (100 µg/mL) alone in 
5 mM Tris (pH 7.2), 150 mM NaCl and 2 mM CaCl2, or with AMPs (different 
concentrations) in the absence or presence of 100 µg/mL of SP-A in 10 mM PBS (pH 7.2), 
1% TSB and 100 mM NaCl for 1h at 37ºC. In the case of SP-BN, bacteria were incubated with 
SP-A (100 µg/mL), SP-BN (10 µg/mL) or both in 20 mM phosphate buffer, pH 7.0, or 2 mM 
sodium acetate buffer, pH 5 for 1 h at 37 °C, in the absence and presence of 150 mM NaCl 
with or without 2 mM Ca2+. In all cases the final volume of incubation was adjusted to 30 µL. 
After incubation, bacteria were plated on agar plates and incubated for 18 h at 37ºC. Viable 
bacteria were estimated by colony count and results are expressed as survival percentages 
with respect to bacteria not exposed to antibacterial agents.  
3.4. Microscopic examination of bactericidal activity of SP-A 
Bacterial membrane integrity and direct bactericidal activity of SP-A against K. 
pneumoniae and mutants were also assessed by staining bacteria with the membrane-
impermeant fluorescent probe, propidium iodide. K. pneumoniae 52145 and deep rough 
mutant strains expressing GFP were harvested from broth by centrifugation at 500 g for 10 
min, and the pellet was washed twice with 10 mM PBS (pH 7.2), re-suspended in 5 mM Tris 
(pH 7.2), 150 mM NaCl and 2 mM CaCl2 and adjusted to a final concentration of 108 
CFU/mL. Aliquots of 100 µL were incubated with or without 100 µg/mL of SP-A for 1 h at 
37°C. PMB (5 µg/mL) was used as positive control of killing. After treatment, samples were 
stained with propidium iodide at 30 µM for 15 min in the dark. Bacteria were pelleted, and re-
suspended in the same buffer to one-tenth the original volume and mounted on a glass slide. 
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Living (green color) and dead/dying bacteria (red color) were visualized by fluorescence 
microscopy (Leica TCS SP2 Confocal System). 
3.5. Phagocytosis of bacteria by macrophages 
To determine the ability of SP-A to enhance phagocytosis of bacteria by itself, MH-S 
cells were seeded in 24-well tissue culture plates at a density of 5x105 cells per well 15 h 
before the experiment. Macrophages were infected with Klebsiella pneumoniae 52145 wt or 
Rc LPS nonexpressing CPS (multiplicity of infection = 50) in HBSS and bacterial 
phagocytosis assay in the presence of 100 µg/ml SP-A was performed with three different 
approaches: a) Bacteria were pre-incubated 2h with SP-A before infection, b) Macrophages 
were pre-incubated with SP-A 2h before infection and, c) macrophages were infected with a 
suspension of bacteria and SP-A. 
To examine the synergistic activity of SP-A and AMPs to increase phagocytosis, MH-S 
or Raw 264.7 cells were pre-incubated 4h with or without SP-A, SP-BN or with both proteins, 
before infection with Klebsiella pneumoniae 52145 (5 X 107 CFU). 
To synchronize infection in both cases, plates were centrifuged at 200 g for 5 min. Plates 
were incubated at 37°C in a humidified 5% CO2 atmosphere. After 1h of infection, monolayer 
cells were washed 3 times with PBS and incubated with RPMI containing 10% FCS, 10 mM 
Hepes, gentamicin (300 µg/mL) and polymyxin B (15 mg/mL) for 90 min. to kill extracellular 
bacteria. Cells were extensible washed again to remove gentamicin and polymyxin, and lysed 
with 0.5% saponin re-suspended in PBS. The intracellular bacteria were serial diluted for 
CFU enumeration on agar plates. 
Immunofluorescence of phagocytosis was performed as previously described (336). MH-
S cells were seeded on 12 mm circular coverslips in 24-well tissue culture plates. Infections 
were carried out as described before with K. pneumoniae 52145 and decapsulated deep rough 
mutant strain expressing GFP. After 1h, cells were washed three times with PBS, and fixed 
with 3.7% paraformaldehyde in PBS pH 7.4. The actin cytoskeleton was stained with 
Rhodamine-Phalloidin diluted 1:100 and DNA was stained with 1 µg/ml 4’,6-diamidino-2-
phenylindole. Stains were carried out in 10% horse serum, 0.1% saponin in PBS for 15 min. 
Coverslips were washed twice in PBS containing 0.1% saponin, once in PBS and once in 
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H2O, mounted on Mowiol 4-88 containing 2.5% (w/v) 1,4-diazobicyclo-[2.2.2]-octane 
(DABCO) and analyzed with a Leica TCS SP2 Confocal System.  
4. Antimicrobial Activity in vivo Assays 
4.1. Intratraqueal Administration 
For in vivo experimental approaches, all bacterial infection and treatments were delivered 
via intratracheal (Fig. 8). Briefly, isoflurane was administered to mice until adequate 
anesthesia was achieved. Anesthetized mice were hanged vertically by their two upper 
incisors on a horizontally suspended string on a plastic supportive table. This position was 
maintained during the entire administration procedure. The tongue was extended with 2 
pipette tips and held in place with one of them. With the mouth open, 50µl of bacteria and/or 
proteins were injected into the pharynx while covering the nose with the thumb. After 2-3 
deep mouth inhalations the thumb was removed, and mice were taken down and allowed to 
recover from anesthesia. This procedure is highly effective to deliver proteins and cells to the 
lungs and avoids tracheal incision and cannulation. 
	  
Figure 8. Illustrative image of intratracheal administration procedure. Mice are anesthetized with 
isoflurane and hung vertically by their upper incisors. 2 pipette tips are used to extend the tongue and 
open the mouth of the animal. While tongue is kept extended with one pipette tip, bacteria and/or 
proteins are then injected into the pharynx while covering the nose with the thumb. 
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4.2. Bacterial Killing in vivo 
Preliminary experiments identified a dose of intratracheal K. pneumoniae K2 that caused 
some inflammation with minimal mortality in wt FVB/N mice. Ten thousand CFUs of K. 
pneumoniae were then administered intratracheally as mentioned above. This bacterium is 
heavily encapsulated and particularly virulent in mice. To minimize variability in virulence, 
all bacteria were selected from aliquots of the same passage stored at -70°C in 16% 
glycerol/trypticase soy broth (TSB), and prepared as previously described (337). For each 
experiment, a trypticase soy agar (TSA) (Difco, Detroit, MI) plate was streaked with an 
inoculum from the glycerol stock and incubated overnight at 37°C. A single colony was 
inoculated into 1 mL of TSB, incubated at 37°C with vigorous shaking for 10 hours, 
transferred to 50 ml of LB medium and grown to mid-logarithmic phase at 37°C with 
vigorous shaking. The bacteria were harvested from the broth by centrifugation at 200g for 10 
min, washed, and re-suspended in sterile PBS. The number of viable bacteria was determined 
by plating serial dilutions of the stock on TSA plates and counting the number of CFU after 
overnight incubation at 37°C. The bacterial suspension was stored at 4°C and used within 48 
hours. For each experiment, the dose was confirmed by plating an aliquot from the bacterial 
suspension that was injected intratracheally. 
To examine the potential synergistic protection of SP-A and SP-BN in vivo, a 
combination of K. pneumoniae K2 and 100 µg SP-A, 20 µg SP-BN or both proteins re-
suspended in 50 µL of 5 mM Tris and 150 mM NaCl were administered intratracheally to 
mice. For therapeutic application of SP-A/SP-BN, mice infected with Klebsiella pneumoniae 
K2 were treated with both proteins in combination 6h or 24h after the bacterial challenge. 
Mice were exsanguinated after a lethal dose of sodium pentobarbital i.p at 24 h or 48 h post-
infection, respectively. In both applications, after infection time, left lungs were harvested, 
weighed and homogenized in 1 mL sterile PBS. Dilutions of lung homogenates were plated 
on LB agar plates and the number of CFUs determined after an overnight incubation at 37°C. 
Each experimental group included 6 mice and data were expressed as CFU ± SEM/mouse. 
4.3. Bronchoalveolar lavage cell count 
Right lungs of mice infected and treated as mentioned in bacterial killing in vivo 
experiments were used to obtain bronchoalveolar lavage fluids (BALFs) as described 
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previously (337). The lungs were lavaged three times with 1-mL aliquots of PBS, BALF was 
centrifuged at 200 g for 10 min to precipitate BALF cells, and the cell pellet was re-
suspended in 1 mL of PBS. A 50-mL aliquot was stained with an equal volume of 0.4% 
trypan blue (Life Technologies) for total cell count on a hemocytometer. Differential cell 
counts were made on cytospin preparations stained with the May-Grünwald Giemsa stain 
(Scientific Products, McGraw Park, IL). 
 
4.4. Lung Histopathology 
Mice were exsanguinated after a lethal dose of sodium pentobarbital i.p. and their lungs 
inflation-fixed with 4% paraformaldehyde 6 or 24 h following intratracheal instillation of 5 
mM Tris and 150 mM NaCl or K. pneumoniae with or without SP-A+SP-BN, as mentioned 
above. Serial 5-µm paraffin lung sections from each lobe were loaded onto polylysine-coated 
slides (Fisher, Atlanta, GA) and stained with hematoxylin and eosin (Sigma). 
 
4.5. Cytokine levels in lung homogenates 
At 6 or 24h after treatment, levels of cytokines associated with severe lung injury (mouse 
interleukin [IL]-1β, IL-6, IL-17a, tumor necrosis factor-α [TNF-α], and macrophage 
inflammatory protein (MIP)-2) were assessed in lung homogenates by enzyme-linked 
immunosorbent assay (ELISA) using MilliplexTM Multiplex kits (Millipore, Billerica, MA) 
according to manufacturer’s protocol. Briefly, cytokine levels presents in the lung were 
measured by an indirect ELISA where the secondary antibodies were conjugated with 
horseradish peroxidase. The quantity of cytokines bound to the inmunosorbent was assayed 
by the addition of streptavidin-RPE. Samples were read using luminex technology on the Bio-
PlexTM (Bio-Rad, Hercules, CA). Concentrations were calculated from standard curves using 
recombinant proteins and expressed in pg/mL. All samples were assayed in duplicate. The 
limits of sensitivity as described by the manufacturer are <3.2, <3.2, <0.64, <3.2 and <16 
pg/mL, respectively.  
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5. Experimental Approaches for Mechanism of Action of SP-A 
and AMPs 
5.1. Binding Assays 
5.1.1. SP-A binding to Bacteria 
To explore the ability of SP-A alone to bind to Klebsiella pneumoniae 52145 and mutant 
strains, or to Klebsiella pneumoniae 52145 in the presence of AMPs, binding assays were 
performed as previously described (338). Microcentrifuge tubes were filled with PBS 
containing 10% fetal bovine serum (FBS) for 24 h at 4°C to block nonspecific binding of SP-
A to plastic. Next day, bacteria were grown at 37ºC in 5 mL of LB, harvested (500 g for 10 
min) on log-phase and re-suspended to a concentration of 107 CFU/mL in 5mM Tris buffer 
pH 7.4 containing 150 mM NaCl and 2 mM Ca2+. Bacteria were then incubated on blocked 
microcentrifuge tubes with several concentrations of biotinylated SP-A in the absence or 
presence of PMB (5 µg/mL), PMBN (5 µg/mL), SP-BN (10 µg/mL) or human serum albumin 
(HSA) (5 or 10 µg/mL) at room temperature (RT) for 30 min. with gentle shaking. 
Suspensions were then centrifuged (500 g for 10 min) to pellet bacteria, washed twice with 
PBS and re-suspended in 200 µL of carbonate buffer 0.1 M pH 9.5. Bacteria-associated SP-A 
was then measured by solid-phase binding as described below. 
The concentration of biotinylated SP-A bound to bacteria was determined by solid-phase 
binding assay. Samples were applied to a 96 well-plate maxisorp (Nunc, Rochester, NY, 
USA) and allowed to bind 1 h at 37°C. Controls in absence of bacteria were performed to 
estimate the nonspecific binding of SP-A to plastic. The plate were blocked 1 h at 37ºC with 
5mM Tris containing 10 % FBS. After extensive washing with PBS, streptavidin-horseradish 
peroxidase (1:2000) was added to the wells and incubated for 1h at RT. The bound biotin-
labeled SP-A was detected by adding 3,3’,5,5’-tetramethylbenzidine liquid substrate (TMB; 
Sigma). The colorimetric reaction was stopped with 4 M sulfuric acid, and the absorbance in 
each well was read at 450 nm on an ELISA reader (DigiScan; Asys HiTech GmbH, 
Eugendorf, Austria). A standard curve was generated with 156 ng/mL to 1.2 µg/mL of SP-A 
in 0.1 M buffer carbonate pH 9.5. Results obtained were expressed as nanograms of SP-A per 
concentration of bacteria. 
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5.1.2. SP-A binding to AMPs 
Intrinsic Fluorescence experiments. Fluorescence measurements were carried out in 5 x 5 
quartz cuvettes using an SLM-Aminco AB-2 spectrofluorimeter equipped with a thermostated 
cuvette holder (±0.1 °C; Spectronic, Waltham, MA, USA). Fluorescence emission spectra of 
SP-A (10 µg/mL) in the absence or presence of increasing concentrations of AMPs were 
measured at 25 °C in 5 mM Tris-HCl buffer (pH 7.4), 150 mM NaCl. Blanks and protein 
were excited at 295 nm. Emission spectra were recorded from 305 to 400 nm, and the slit-
widths were 4 nm for the excitation and emission beams. 
The apparent dissociation constants (Kd) at 25 ºC for the complex SP-A/AMP were obtained 
by analyzing the change in the fluorescence of SP-A at 337 nm upon addition of increasing 
amounts of AMPs. The data from equilibrium binding titrations of SP-A were analyzed by 
nonlinear least-squares fitting to equation [1]: 
 
 
 
, where ΔF is the change in fluorescence intensity at 337 nm relative to the intensity of free 
SP-A; ΔFmax is the change in fluorescence intensity at saturating AMP concentrations; Kd is 
the apparent equilibrium dissociation constant; [AMP] is the molar concentration of free 
AMP; and n is the Hill coefficient.   
Dynamic light scattering (DLS). DLS, as we have seen before, allows measuring the size 
distribution of molecules dissolved in a liquid by measuring the proportion of the incident 
light that is scattered. The Brownian motion of the scattering particles causes fluctuations in 
light scattering intensity. The velocity of the Brownian motion of the particles can be 
calculated and related to their hydrodynamic size (326). 
The hydrodynamic diameters of AMPs and SP-A, as well as mixtures of these 
components, were measured at 25°C in a Zetasizer Nano S (Malvern Instruments, Malvern, 
UK) equipped with a 633-nm HeNe laser. Six scans were performed for each sample, and all 
of the samples were analyzed in triplicate. The hydrodynamic diameter was calculated using 
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the general purpose algorithm available from the Malvern software for dynamic light 
scattering analysis, which correlates the diffusion coefficient to the hydrodynamic diameter 
through the Stokes-Einstein equation [2]:  
  
 
, where Kβ is the Boltzmann constant, T is the temperature, η is the viscosity, and D is the 
translational diffusion coefficient. The multiple narrow modes algorithm was also used to 
verify the results obtained by the general purpose method. The interaction of SP-A with AMP 
in solution was measured by the addition of different AMP concentrations to 15 nM SP-A in 
5 mM Tris buffer (pH 7.4) in the absence or presence of 150 mM NaCl. 
Solid-phase binding assay. Solid-phase binding assay was also performed with biotinylated 
SP-BN to explore whether SP-BN binds to immobilized SP-A. Wells of a 96-well maxisorp 
microtiter plate (Nunc, Rochester, NY, USA) were coated with either SP-A (25µg) or human 
serum albumin (25 µg) in 0.1 mM sodium bicarbonate buffer, pH 9.5, overnight at 4°C. Wells 
were washed (5 mM Tris HCl, pH 7.4, containing 150 mM NaCl, 2 mM CaCl2 and 0.1% 
Tween 20) and blocked with washing buffer containing 2.5% nonfatty dried milk for 2 h. 
Following washing, biotinylated SP-BN in concentrations ranging 0 to 12 µM was added to 
the wells in the same buffer. Incubations were performed for 1 h at room temperature. To 
detect the bound biotin-labeled SP-BN, streptavidin-horseradish peroxidase was added to the 
wells and absorbance was read in the same conditions mentioned in 5.1.1. Results obtained 
were expressed as OD450nm of biotinylated SP-BN. 
5.2. Experiments on Model Bacterial Membranes 
5.2.1. Bacterial Model Membrane preparation 
Total bacterial phospholipid extract (BPL) and Re-LPS were used to prepare bacterial 
model membranes. Bacterial stock solutions of PL in chloroform/methanol (3:1, v:v) and Re 
LPS in chloroform/methanol/water (17:7:1, v:v:v) were prepared and stored at -20ºC. The 
sample solution was prepared by mixed stocks solutions of the BPL and Re-LPS, to achieve 
the desired Re-LPS/PL ratio. The organic solvent was then evaporated to dryness under a 
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stream of nitrogen, and traces of solvent were subsequently removed by evacuation under 
reduced pressure overnight. Multilamellar vesicles of Re-LPS/BPL (8/2, w/w) were prepared 
by hydrating the dry lipid film in a saline buffer and allowing them to swell for 1h at a 
temperature above the transition temperature (Tm). After vortexing, the resulting 
multilamellar vesicles (MLVs) were used for different assays. Unilamellar vesicles were used 
for spectroscopic measurements to reduce light scattering artifacts. To obtain them, MLVs 
were sonicated during 4 min at 390 w/cm (burst of 0.6 s, with 0.4 s between bursts) in a UP 
200S sonifier with a 2mm microtip. 
 
5.2.2. Monolayer experiments 
Monolayer experiments were performed at 25°C using a thermostated Langmuir-Blodgett 
trough (102M micro Film Balance; NIMA Technologies, Coventry, UK) equipped with an 
injection port and magnetically stirred. The trough is equipped with two symmetrical movable 
barriers controlled by an electronic device. The subphase buffer employed was 5 mM Tris 
buffer (pH 7.4), 150 mM NaCl containing 0.175 mM CaCl2. A concentrated solution (1 
mg/mL) of Re LPS dissolved in chloroform/methanol 3/1 (v/v) was used for monolayer 
experiments. For penetration studies, monolayers were formed by spreading different 
volumes of a concentrated solution of Re LPS at the air-water interface to give the indicated 
initial surface pressures (from 0 to 40 mN/m). After organic solvent evaporation, the 
monolayer was allowed to stabilize for a few minutes before 100 µL of PMBN (1 µg/mL), 
SP-A (1.25 µg/mL), or the mixture PMBN+SP-A was injected into the subphase without 
disturbing the lipid monolayer. Then, protein-induced changes in the monolayer surface 
pressure at constant surface area were measured. 
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Figure 9. Schematic representation of a Langmuir balance. A monolayer of Re-LPS is deposited at the 
air-liquid interface at a given initial pressure. SP-A, PMBN or both are injected into the subphase 
while going by monitoring changes in surface pressure induced by the insertion of these molecules in 
the Re-LPS monolayer. 
 
5.2.3. Fluorescence Experiments 
Fluorescence experiments were carried out using an SLM-Aminco AB-2 
spectrofluorimeter equipped with Glam prism polarizers and a thermostated cuvette holder 
(±0.1ºC) (Thermo Spectronic, Waltham, MA, USA). We have used 5X5 mm path-length 
quartz cuvettes. 
5.2.3.1. DPH fluorescence measurements.  
The required amounts of Re-LPS/BPL (8/2 w/w) were mixed with DPH at a probe/lipid 
molar ratio of 1:200 (final lipid concentration of 1 mg/mL) as previously described (339). 
DPH concentration was determined spectrophotometrically by absorbance at 350 nm, using a 
molar extinction coefficient in methanol of 88000 M-1cm-1. MLVs of Re-LPS/BPL (8/2, w/w) 
were prepared in 5 mM Tris buffer (pH 7.4), 150 mM NaCl. To reduce the size of these 
particles, MLVs were sonicated as described before to form LUVs. Exposure to light was 
minimized throughout the preparation of Re LPS/PL aqueous dispersions doped with DPH.  
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To study the effect of PMBN, SP-A or both on bacterial model membrane, measurements 
of fluorescence intensity and fluorescence emission anisotropy of DPH were done.  
Fluorescence emission anisotropy. For each sample, fluorescence emission intensity data in 
parallel and perpendicular orientations with respect to the exciting beam were collected ten 
times each and then averaged. Background intensities in DPH-free samples due to the vesicles 
and proteins were substracted from each recording of fluorescence intensity. Excitation and 
emission wavelengths were set at 360 and 430 nm, respectively. Anisotropy, r, was calculated 
as [3]: 
 
,where III and I˔ are the parallel and perpendicular polarized intensities measured with the 
vertically polarized excitation light and G is the monochromator grating correction factor. 
DPH fluorescence intensity measurements. The emission spectra were recorded with the 
emission polarizer set at the magic angle (m= 54.7°) relative to the vertically polarized 
excitation beam. This was done to reduce contributions from scattering due to Re-LPS/BPL 
dispersions and to avoid intensity artifacts due to molecular rotation during the lifetime of the 
excited state (340). Moreover, background intensities in probe-free samples were subtracted 
from each re-cording of fluorescence intensity.  
5.2.3.2. LAURDAN GP Function 
Re-LPS/BPL (8/2, w/w) liposomes were mixed with the amphiphilic fluorescent probe 
LAURDAN at a probe/phospholipid molar ratio of 1:100. LUVs were prepared in 5 mM Tris 
buffer (pH 7.4), 150 mM NaCl and then steady-state fluorescence emission spectra of 
LAURDAN were measured at 25°C in the absence and presence of different PMBN and/or 
SP-A concentrations. The LAURDAN emission maximum is near 440 nm in the lipid gel 
phase but is red-shifted to 490 nm in the liquid-crystalline phase (341). To quantify these 
emission spectrum changes, the excitation generalized polarization (GPex) of LAURDAN was 
calculated according to Parasassi et al. (341), using Eq. [4]: 
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,where IB and IR are the intensities at the blue (440 nm) and red (490 nm) edges of the 
emission spectrum (λex = 364 nm). 
 
5.2.4. Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) is a technique, which measures the 
thermodynamic properties of temperature-induced phase transitions. A sample and an 
appropriate reference material (usually the same buffer in which the sample has been 
prepared) are simultaneously heated in different cells at the same predetermined rate. If the 
sample undergoes a thermally induced phase transition, absorption or release of heat takes 
place (depending on whether the process is endothermic or exothermic). The instrumental 
control system has to supply more (or less) heat to the sample cell to maintain its temperature 
equal to that of the reference cell. 
 
The recorded parameter in a DSC scan is the excess heat capacity (Cp) of a sample with 
respect to the reference as a function of temperature. Endothermic transitions are represented 
as positive peaks. Three thermodynamic parameters can be directly determined from the 
thermogram (Fig. 10). Firstly, the phase transition temperature, Tm, corresponds to the 
maximum Cp of the peak. For symmetric curves, Tm represents the temperature at which the 
transition is half complete. Secondly, the relative cooperativity of the process is related to the 
sharpness of the peak, which is commonly expressed as the temperature width at half-height 
of the peak, ΔT1/2. And finally, the enthalpy of the transition (ΔH) can be calculated by 
integrating the area below the thermogram (342, 343). 
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Figure 10. DSC thermogram for a two-state endothermic process. Tm is the phase transition 
temperature, ΔT1/2 is the temperature width at half-height of the peak, and ΔH is the enthalpy of the 
thermodynamic event. 
 
 
Biological membranes undergo a temperature-induced phase transition from a relatively 
ordered crystalline-like state (gel phase (Lβ)) to a relatively disordered fluid-like state (liquid-
crystalline phase (Lα)). The properties of the gel-to-liquid phase transition of different lipid 
mixtures can be therefore studied by DSC. 
Calorimetric measurements were performed as previously reported (144, 339) in a 
Microcal VP differential scanning calorimeter (Microcal Inc., Northampton, MA, USA) at a 
heating rate of 0.5 ºC/min. Multilamellar vesicles of Re-LPS/PL (8/2, w/w) (0.5mM) prepared 
in 5 mM Tris buffer (pH 7.4), 150 mM NaCl, were loaded in the sample cell in the absence 
and presence of different amounts of PMBN (1.25 µg/mL to 95 µg/mL) or/and 1.25 µg/mL 
SP-A. Buffer alone was loaded in the reference cell of the microcalorimeter. Four calorimetric 
scans were collected from each sample between 10ºC and 60ºC. The standard Microcal Origin 
software was used for data acquisition and analysis. The excess heat capacity functions were 
obtained after subtraction of the buffer-buffer baseline. 
5.2.5. Analysis of liposomal permeability 
An assay was developed to assess the effect of SP-A, PMBN and the mixture SP-
A/PMBN on the permeability of model bacterial membranes. The fluorophore ANTS and its 
collisional quencher DPX were co-encapsulated into Re-LPS/BPL (8/2, w/w) vesicles. Re-
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LPS/BPL (8/2, w/w) dry lipid film was rehydrated in a buffer containing the probes to form 
MLVs (5 mM Tris buffer (pH 7.4), 150 mM NaCl, 12.5 mM ANTS, 45 mM DPX). Then, 
sample was subjected to 5 freeze-thaw cycles (liquid N2) and passed through an extruder to 
obtain LUVs (100 nm pore membrane). Free probes were removed in a sephadex G50 
chromatography. Then, 300 µl of vesicles were loaded in 5x5 mm path-length quartz cuvettes 
to measure fluorescent intensity as a function of time using excitation and emission 
wavelengths of 353 nm and 520 nm, respectively. These experiments were carried out using 
an SLM-Aminco AB-2 spectrofluorimeter equipped with Glam prism polarizers and a 
thermostated cuvette holder (±0.1ºC) (Thermo Spectronic, Waltham, MA, USA).  
After leakage of aqueous contents by addition of a potential lytic peptide (SP-A, PMBN 
or both), the probes will dilute into surrounding medium, and ANTS fluorescence will 
increase because quenching by DPX will be diminished. Triton X-100 was used as positive 
control. We have also obtained the emission spectra of the samples at the beginning and at the 
end of the experiments to measure the percentage of leakage according to this equation [5]:  
 
 
 
,where F0 is the fluorescence at 520 nm of the sample before adding any protein, Fp is the 
fluorescence after the addition of proteins, and F100 is the fluorescence obtained after the 
addition of triton X-100 (total permeabilization). 
 
6. Statistical analysis 
Means were analyzed by Student´s t-test for unpaired samples or analysis of variances 
following by Bonferroni test when appropriate. p value <0.05 was considered statistically 
significant. Analyses were performed using Prism 5 program for MAC OS X (GraphPad 
Software, Inc. La Jolla, CA).  
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1. ABSTRACT 
Pulmonary surfactant protein-A (SP-A) is a large protein secreted to the alveolar fluid 
that has been proven to have macrophage-independent antimicrobial activity in vivo. In this 
study, we explore the effect of SP-A on aggregation, growth, and viability of several 
pathogenic Gram-negative bacteria as well as SP-A’s possible synergistic action with several 
antimicrobial peptides (AMPs). Results indicate that SP-A was able to aggregate, inhibit the 
growth of, and kill isogenic decapsulated Klebsiella pneumoniae (serotype K2:O1) mutants 
expressing deep rough lipopolysaccharide on their outer membranes. Conversely, SP-A did 
not bind or have any effect against capsulated or decapsulated K. pneumoniae K2:O1 
expressing smooth lipopolysaccharide or capsulated deep rough K. pneumoniae mutants. 
However, we found that SP-A acted synergistically with exogenous cationic AMPs 
(polymyxin B and colistin) as well as with endogenous cationic AMPs (human β-defensins 2 
and 3) present in the alveolar fluid. SP-A enhanced AMP microbicidal activity on different 
pulmonary pathogen strains (K. pneumoniae K2, P. aeruginosa O1, and nontypeable 
Haemophilus influenzae), which are resistant to SP-A. In addition, we found that AMPs 
facilitate the binding of SP-A to bacteria that did not interact with SP-A alone through a 
protein-protein interaction mechanism. These results indicate that the synergic action of SP-A 
with AMPs might be important in lung defense against infection. 
2. INTRODUCTION 
The alveolar epithelium in the organism is continuously exposed to inhaled particles such 
as, allergens, contaminants and pathogens. To protect the host against pathogens reaching the 
alveoli during inspiration, there must be some effective defense mechanisms.  Klebsiella 
pneumoniae is a common Gram-negative bacterium that infects the respiratory tract of 
immune compromised patients (344). One of the main virulence factors of this kind of 
bacteria is the lipopolysaccharide (LPS) present in its outer membrane (OM), which is 
composed by a highly conserved and amphipathic fraction called lipid A, an oligosaccharide 
core and a variable domain of repeated units of polysaccharides called O-antigen (345). The 
LPS core domain is usually divided into inner and outer core and it is frequently named as 
smooth LPS (S-LPS), when it contains all the structure mentioned; or rough LPS (R-LPS), 
when it lacks the O-antigen, but keeps the lipid A and the oligosaccharide core which could 
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be progressively shorter, depending on the rough phenotype (Ra-, Rb-, Rc-, Rd- and Re-LPS) 
(346). 
K. pneumoniae expresses S-LPS and two major core structures in their OM (type 1 and 
2), which differ only in the outer-core region (347). In addition, Klebsiella usually develops a 
prominent capsule polysaccharide (CPS) composed of complex repeating subunits of acid 
polysaccharides. The CPS, consisting of four to six sugars and, very often, uronic acids (as 
negatively charged components), can be classified into 77 serological types, being K1 and K2 
the most virulent serotypes (344). LPS and CPS structure of K. pneumoniae have been shown 
to be involved in their pathogenicity and resistance to antimicrobial factors in the alveolar 
fluid (348, 349).  
The innate immune system in the alveolar space is composed, besides a cell component, 
by multiple soluble factors able to recognize and eliminate pathogens, through direct 
bactericidal action, or indirectly by increasing their phagocytosis by phagocytic cells present 
in the alveolar space (350). Among these factors, there are antimicrobial peptides (AMPs) like 
cathelicidins or defensins, and proteins like C-reactive protein, lactoferrin, lysozyme, 
galectins, complement proteins and pulmonary surfactant collectins (SP-A and SP-D), which 
are all secreted by the alveolar epithelium, alveolar macrophages and/or neutrophils (12). 
Several evidences show that host lung defense against bacterial infections is partly due to the 
presence of these antimicrobial factors in the airways (12, 350).  
Surfactant protein-A (SP-A) belongs to the collectin family and is the most abundant 
protein of pulmonary surfactant (by weight) (12). It is able to modulate and facilitate alveolar 
immune cells response, to opsonize microbes and also exerts direct bactericidal activity 
against some Gram-positive and -negative bacteria, virus and fungi (351).  Wu and co-
workers (2003) have shown that SP-A decreases the growth of Gram-negative bacteria by 
increasing membrane permeability (16). Moreover, it has been reported that SP-A -/- mice are 
more susceptible than WT mice to lung infections (352) and that macrophages-free 
bronchoalveolar lavages from SP-A +/+ mice showed a bactericidal effect greater than 
lavages from SP-A -/- mice, suggesting a direct microbicidal role of SP-A in vivo (353). In 
this point, the antimicrobial ability of SP-A is well established. However, multiple bacterial 
resistance factors to SP-A have been reported, being bacterial strain and the LPS and CPS 
types the most important ones (354). In general, Gram-negative bacteria susceptible to SP-A 
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have a truncated (deep R-LPS) or abbreviated OM like Escherichia coli J5 or K12 (17, 353, 
355). However, the highly virulent respiratory pathogens like K. pneumoniae K2 or P. 
aeruginosa O1, which express more complex OM, have been shown to be resistant to SP-A-
mediated membrane permeabilization or SP-A binding (356, 357). Due to the wide variety of 
Gram-negative strains and serotypes, the real bacterial killing spectrum of SP-A needs more 
clarification. 
In addition to SP-A, the immune system in the alveolar space is also composed by AMPs, 
which are small cationic or anionic peptides involved in the innate and adaptive immune 
systems that show antimicrobial activity against bacteria, virus and fungi (350). AMPs can be 
endogenous (part of the innate immune system) and exogenous, which are administered for 
the treatment of infections (358). Among the endogenous cationic AMPs (CAMPs) present in 
the alveolar fluid are the human beta-defensins (HBDs) (273). Several HBDs have been 
described, but the most studied are HBD-1, -2 and -3. In the alveolar space, HBD-1 is 
constitutively expressed, while HBD-2 and HBD-3 are expressed by cytokine induction or the 
presence of pathogens. These beta defensins show a higher antimicrobial activity than HBD-1 
(29). On the other hand, the exogenous CAMPs Polymyxin B and colistin (PMB and PME, 
respectively) are polypeptide antibiotics capable of killing Gram-negative bacteria. They 
became available for clinical use in the 1960s, but they were replaced by antibiotics 
considered less toxic (359). However, due to the ability of polymyxins and naturally 
occurring defensins to kill multidrug-resistant (MDR) Gram-negative pathogens, they have 
gained considerable attention and clinical interest (26, 121).  
Given the rising phenomenon of microbial resistance among important pathogens (360), 
several studies have suggested the importance of cooperative actions between different 
soluble factors with microbicidal activity in vitro and in vivo (22, 361). Consequently, it is 
possible that SP-A may act synergistically or cooperatively with different AMPs in the 
alveolar space to strengthen the microbicidal activity of each factor alone. The study of these 
interactions would allow the development of new therapies against MDR Gram-negative 
bacteria. 
Therefore, in this work, we proposed to evaluate the ability of SP-A to enhance or block 
the microbicidal activity of several CAMPs (PMB, PME, and HBDs) against three respiratory 
pathogens, as well as to determine some of the mechanism by which these proteins are able to 
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act synergistically. For this purpose, we firstly characterized the individual antimicrobial 
activity of SP-A, using a clinic strain of K. pneumoniae and several isogenic mutants 
expressing truncated OM.  
3. EXPERIMENTAL DESIGN 
K. pneumoniae K2 is a common and high virulent Gram-negative bacterium that infects 
the respiratory tract of immune compromised patients. To study the potential protective effect 
of SP-A against this bacterium and/or its mechanism of resistance to SP-A, chromosomal in-
frame nonpolar waa deletions were generated in order to obtain K. pneumoniae mutant strains 
with defects in LPS core. Thus, we used the next smooth and rough strains (Fig. 1): i) the 
clinic strain K. pneumoniae 52145, which express S LPS and CPS (Kp wt); ii) the isogenic 
mutant 52145-ΔwabK (Kp Rc+CPS), which express Rc LPS and CPS; iii) the isogenic mutant 
52145-ΔwcaK2-ΔwabK (Kp Rc-CPS), which does not express CPS and express Rc-LPS; and 
the isogenic mutant 52145-ΔwaaC (Kp Re-CPS), which does not express CPS and express 
Re-LPS.  
To determine the antimicrobial action of SP-A against these bacteria (Fig 1), a single 
colony of bacteria was inoculated into 10 ml of LB, incubated at 37°C with vigorous shaking 
O.N., transferred to 5 ml of LB medium and grown to mid-logarithmic phase at 37°C. 
Bacteria were, then, harvested (500 g for 10 min), the pellet was washed twice with PBS, pH 
7.2, re-suspended in corresponding buffer, and incubated with SP-A to determine its ability 
to: 
1. Aggregate bacteria: evaluated by changes in bacterial suspension absorption at 700nm, 
by microscopic examination of bacteria expressing GFP and by direct visualization of 
bacterial pellet formation. 
2. Kill bacteria: determined by CFU counts and staining of bacteria expressing GFP with 
the membrane-impermeant fluorescent probe, propidium iodide following 
fluorescence microscopy. 
3. Enhance phagocytosis of bacteria: assessed by intracellular CFU count on the cell line 
of mouse alveolar macrophages MH-S. 
4. Bind to bacteria: estimated by solid-phase binding assays of bacteria incubated with 
biotinylated SP-A. 
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Fig. 1. Experimental design used to determine the individual antimicrobial action of SP-A. K. 
pneumoniae 52145 (Kp wt) OM structure is based on a published study (331). Dashed lines denote the 
truncation level for the different core biosynthetic gene mutations, which were used to obtain the 
several rough strains for this study.  
 
 
To elucidate the potential synergistic activity of SP-A with AMPs (Fig. 2), both 
exogenous (polymyxin B and E) and endogenous CAMPs (human beta defensin-1, -2 and -3) 
were used. SP-A in the absence and presence of CAMPs was incubated with the respiratory 
pathogens K. pneumoniae (Kp wt), P. aeruginosa O1 (PAO1) and non typable H. influenzae 
(NTHi) and bacterial killing assays were assayed by CFU count. In addition, the ability of SP-
A to bind to K. pneumoniae in the presence of AMPs was investigated by solid-phase binding 
assay. Finally, the potential molecular interactions between SP-A and CAMPs were 
determined using dynamic light scattering (DLS) assays and changes in the intrinsic 
fluorescence of SP-A (Fig. 2).  
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Fig. 2. Experimental design used to determine the synergistic action of SP-A with cationic 
antimicrobial peptides. CAMPs: cationic antimicrobial peptide; PMB: polymyxin B: PME: 
polymyxin E; hBD: human beta-defensin.  
 
 
4. RESULTS 
4.1. SP-A antimicrobial effect on K. pneumoniae 52145.  
Since K. pneumoniae is a common lung pathogen and an important cause of nosocomial 
infections (344), we investigated the potential antimicrobial activity of SP-A against this 
microorganism, determining its ability to: a) aggregate bacteria, b) inhibit bacterial growth, c) 
cause bacterial death, and d) increase phagocytosis by alveolar macrophages. Several studies 
have shown that SP-A interacts with bacteria expressing preferably rough LPS (17, 131, 362). 
Thus, we have used different isogenic mutants of K. pneumoniae expressing different LPS 
phenotypes, from smooth LPS with CPS to deep rough Re-LPS without CPS, in order to 
examine its antimicrobial activity. 
Bacterial aggregation assays in vitro were performed with Kp wt, Kp Rc+CPS, Kp Rc-
CPS and Kp Re-CPS. The spectrophotometry results showed that SP-A, in the presence of 
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calcium, was able to aggregate Rc and Re strains nonexpressing CPS over 2h incubation at 
37ºC (Fig. 3A and B). In contrast, there was no significant difference in the monitoring of the 
Kp wt and Kp Rc+CPS strains in the presence or absence of SP-A (Fig. 3A and B).  
 
 
 
Figure 3. SP-A aggregates deep rough decapsulated K. pneumoniae. Kp wt, Kp Rc+CPS, Kp Rc-
CPS and Kp Re-CPS were incubated in the absence or presence of SP-A 25 µg/mL Hank’s balanced 
salt solution (HBSS) buffer. A) Aggregation was determined by monitoring the changes in absorbance 
at 700 nm during 2h at 37ºC without shaking. B) Percentage of aggregation at 120 min. is shown as 
absorbance at that time versus time 0. Absorbances of strains incubated in the absence of SP-A are 
around 100% (data not shown). Data represent mean ± SD (n=3, each one in duplicate) and significant 
differences between control and treatments are indicated by asterisks, where *** p <0.001 vs control. 
C) SP-A aggregation was visualized by fluorescence microscopy using Kp wt and Kp Rc-CPS 
expressing GFP. D) SP-A bacterial aggregation of Kp Rc-CPS but not Kp wt was also visualized by 
turbidity and bacterial pellet formation (white arrow) after 2h of incubation with SP-A (25 µg/mL).  
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The SP-A ability to aggregate deep rough strains of K. pneumoniae lacking CPS but not 
smooth capsulated strains was also observed by fluorescence microscopy using bacteria 
expressing GFP (Fig. 3C). Similarly, it is shown in culture tubes containing Kp wt and Kp 
Rc-CPS, untreated or treated with SP-A, 
where deep rough strain aggregation is 
confirmed in form of bacterial pellet and 
culture transparency. In contrast, for the wt 
strain, no bacterial pellet was detected and 
culture turbidity remained after 2h of 
incubation with SP-A, which indicates that 
the protein does no induce the aggregation 
of Kp wt (Fig. 3D).  
Some studies have shown that SP-A 
inhibits the growth of several Gram-negative 
strains (355). Therefore, we also 
investigated whether SP-A has this ability 
against the strains used in this study. Our 
results showed that SP-A produced a 
significant decrease in the growth of the Re-
CPS strain, starting at 4 hours of incubation, 
as seen by optical density decline of the 
strain at 400 nm, in the presence of SP-A. 
However, SP-A had no effect on the growth 
of Kp wt and Kp Rc+CPS (Fig. 4A and 4B). 
Next, we tested the direct killing of SP-A 
by colony-forming units (CFU) count on 
LB-agar plates. These experiments 
demonstrated that deep rough decapsulated 
strains of K. pneumoniae showed 
susceptibility to SP-A by a 2-fold decrease 
in the CFU count of the treated samples. 
Figure 4. SP-A inhibits the growth of K. 
pneumoniae 52145 expressing deep rough 
LPS and non-expressing CPS. 200 µl of a 
suspension of bacteria Kp wt, Kp Rc+CPS or 
Kp Re-CPS in the beginning of the growing-
phase were incubated 6h at 37ºC and 250 rpm 
in the absence or presence of 25 µg/ml of SP-
A. A) Growth inhibition was monitored by 
measuring the absorbance at 400 nm each 
hour. B) Also is shown the percentage of 
inhibition by plotting the percentage of 
decrease in absorbance at 4 hours from 
treated samples compared to untreated control 
at the same time. Bars represent mean ± SD 
(n=3, each one in duplicate) and significant 
differences between control and treatments 
are indicated by asterisks, where * p < 0.05. 
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However, the absence of a decrease in the number of CFUs for Kp wt and Kp Rc+CPS strains 
indicates the resistance of these strains to SP-A (Fig. 5A).  
 
Figure 5. SP-A directly kills decapsulated strains K. pneumoniae Rc and Re expressing deep 
rough LPS. A) Bacteria (105 CFUs/mL) were incubated 1h at 37ºC in the absence or presence of SP-
A 100 µg/mL 5 mM Tris (pH 7.2), 150 mM NaCl, 2 mM CaCl2 buffer and immediately plated on LB 
agar for CFU count after 18h of incubation at 37ºC. The survival of bacteria in the presence of SP-A is 
shown as a percentage of the number of colonies of the same strain not exposed to agent. Bars 
represent mean ± SD (n=3, each one in duplicate) and significant differences in survival between 
control and treatments are indicated by asterisks, where **p < 0.01 and *p <0.05. B) K. pneumoniae 
wt and Rc-CPS both expressing GFP (to visualize living bacteria in green) were incubated with or 
without 100 µg/mL SP-A or 5µg/mL of PMB, as positive control of killing, for 1h at 37ºC. After that, 
both strains were stained with propidium iodide (stains dead/dying bacteria in red) following by 
fluorescence microscopy to assess viability (original magnification 50X).  
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The killing of deep rough decapsulated strains of K. pneumoniae by SP-A was also 
determined using the membrane-impermeant DNA-specific dye propidium iodide. Following 
incubation with SP-A, Kp Rc-CPS strain formed aggregates and most of bacteria were stained 
with propidium iodide (Fig. 5B). This indicates cell death, which is in agreement with the 
60% of killing determined by the CFU count assay (Fig. 3A). In contrast, Kp wt neither 
aggregated nor was stained with propidium iodide in the presence of SP-A. Both strains were 
stained with propidium iodide after treatment with 5µg/mL of PMB as positive control of cell 
death. 
Finally, we explored the ability of SP-A to enhance the phagocytosis of Kp wt as well as 
its isogenic mutant Kp Rc-CPS by mouse alveolar macrophages (MH-S) using an intracellular 
CFU count assay. In the absence of SP-A, after 1h of incubation, the uptake of Kp Rc-CPS 
bacteria by MH-S cells was greater than that of the wt bacteria, as previously seen by others 
(363) (Fig. 6A). Bacterial phagocytosis assays in the presence of SP-A were performed with 
three different approaches: a) Bacteria were pre-incubated 2h with SP-A before infection, b) 
macrophages were pre-incubated with SP-A 2h before infection, and c) macrophages were 
infected with a suspension of bacteria and SP-A. In the last two approaches, the presence of 
100 µg/mL of SP-A did not increase the uptake of any of these bacteria by alveolar 
macrophages after 1h of infection (data not shown). However, when bacteria were pre-
incubated with SP-A 2h before infection, SP-A was able to increase phagocytosis of the 
isogenic mutant Kp Rc-CPS, but not of the Kp wt strain (Fig. 6A). This is in agreement with 
the microscopic observation of intracellular bacteria expressing GFP (green) on alveolar 
macrophages, in which cytoplasm was stained with rhodamine-phalloidin (red) and nucleus 
with DAPI (blue). At the same conditions for intracellular CFUs count, higher numbers of 
intracellular Kp Rc-CPS compared to Kp wt were observed by confocal microscopy (Fig. 
6B). In addition, these data suggest that enhanced phagocytosis of the mutant strain was due 
to the opsonic effects of SP-A, and not to a direct stimulatory effect of SP-A on macrophages. 
This is consistent with the ability of SP-A to aggregate Kp Rc+CPS (Fig. 3). 
Taken together, our results suggest that SP-A has no antimicrobial effect on K. 
pneumoniae 52145 wild type strain and this could be due to the structure of its OM, since 
deep rough strains nonexpressing CPS are susceptible to SP-A. As K. pneumoniae is one of 
the lung pathogens that are isolated more frequently in patients with ARDS (196), it is 
conceivable that this bacterium has developed mechanisms to evade the bactericidal activity 
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of different soluble factors present in the alveolar space. One of these mechanisms could be to 
avoid being recognized and bound by SP-A present in the alveolar space. Hence, we 
evaluated the ability of SP-A to bind to Kp wt. 
 
 
 
Figure 6. SP-A increases alveolar macrophages phagocytosis of decapsulated K. pneumoniae 
52145 expressing Rc-LPS. A) Macrophages were infected 1h with Klebsiella pneumoniae 52145 wt 
or Rc-LPS nonexpressing CPS (multiplicity of infection = 50) pre-incubated with or without 100 
µg/mL SP-A during 2h before infection, and treated with gentamicin (300 µg/mL) and PMB (15 
µg/mL) during 90 min. to kill extracellular bacteria. Cells were lysed with 0.5% Saponin re-suspended 
in PBS and intracellular bacteria were serial diluted for CFU enumeration on agar plates. Bars 
represent mean ± SD (n=3) and significant differences between control and treatments are indicated by 
asterisks, where ** = p < 0.01. B) Immunofluorescence confocal microscopy of mouse alveolar 
macrophages infected with Kp wt and Rc-CPS both expressing GFP. Actin cytoskeleton was stained 
with Rhodamine-Phalloidin (red) and DNA was stained with DAPI (blue) to visualize cells with 
intracellular bacteria expressing GFP (green). Images are representative of three independent 
experiments. 
 
4.2. SP-A Binding to K. pneumoniae 52145 strains.  
The ability of SP-A to bind to the different K. pneumoniae strains used in this study was 
assessed by a solid-phase binding assay. K. pneumoniae and isogenic mutants were incubated 
30 min. with increasing concentrations of biotinylated SP-A (0 to 1.25 µg/mL), and the 
amount of bacteria-associated SP-A was measured. As our previous results suggested, SP-A 
showed greater binding ability to decapsulated deep rough strains (Kp Rc-CPS and Re-CPS) 
and this binding was in a dose-dependent manner (Fig. 7). The fact that SP-A was unable to 
CHAPTER1 
	  
130 
recognize and bind to the wt strain would explain why this protein does not present 
microbicidial activity against it. 
 
 
Figure 7. SP-A binds to decapsulated K. pneumoniae 52145 expressing deep rough LPS. K. 
pneumoniae strains (107 CFU) were re-suspended in 5 mM Tris pH 7.4 with 150mM NaCl and 2 mM 
Ca2+ and incubated with biotinylated SP-A (0 to 1.25 µg/mL) at room temperature for 30 minutes. 
Total Klebsiella-associated SP-A was measured by solid-phase binding and expressed as total 
nanograms of SP-A/107 bacteria. Bars represent mean ± SD (n=3, each one in duplicate). 
 
So far, our results have shown that SP-A lacks of a direct antimicrobial effect against K. 
pneumoniae 52145 wt. However, in vivo studies have demonstrated that SP-A has 
antimicrobial activity against in vitro SP-A-resistant strains (20, 364). Since the SP-A is not 
alone in the alveolar fluid, the second objective of this study was to investigate whether SP-A 
was able to collaborate with antimicrobial peptides, both endogenous as exogenous 
modulating its microbicidal activity against various Gram-negative respiratory pathogens.	   
4.3. Synergistic action of SP-A with exogenous cationic antimicrobial peptides.  
To evaluate whether SP-A is able to modulate the antimicrobial activity of exogenous 
cationic antibiotics with potential clinical use, we used PMB and E and three lung pathogens 
resistant to SP-A: K. pneumoniae 52145 wt (Kp wt), P. aeruginosa O1 (PAO1) and non-
typeable H. influenzae (NTHi).  
We performed survival bacterial assays by CFU count with different concentrations of 
PMB or PME in the presence or absence of SP-A. As it is known, PMB or PME alone showed 
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bactericidal effect in a dose-dependent fashion, being observed a decrease in bacterial survival 
according to the PMB or PME concentrations used (Fig. 8). SP-A alone (up to 100 µg/mL) 
had no effect in these bacteria; however, when bacteria were incubated with 100 µg/mL of 
SP-A and increasing concentrations of PMB (Fig. 8, upper graphs) and PME (Fig. 8, lower 
graphs) we obtained a higher bacterial killing for all pathogens studied. By contrast, when 
similar experiments were performed with lower concentrations of SP-A, up to 5 µg/mL, any 
synergistic effect was observed (data not shown). Thereby, we proved that SP-A significantly 
enhanced the polymyxin action, and it could increase the effect of these antibiotics in the 
alveolar space.    
 
 
 
Figure 8. SP-A acts synergistically with exogenous CAMPs to kill Gram-negative bacteria. 105 
CFUs/mL of K. pneumoniae 52145 wt (A), P. aeruginosa O1 (B) or non-typeable H. influenza (C) 
were incubated with different concentrations (0.07 µg/mL to 5 µg/mL) of PMB (upper line) and PME 
(lower line) in 10 mM PBS (pH 7.2), 1% TSB and 100 mM NaCl buffer in the absence (colored 
symbol) or presence (white symbol) of 100 µg/mL SP-A for 1h at 37ºC and immediately plated on LB 
agar for CFU count after 18h of incubation at 37ºC. The results are shown as % relative survival 
(percentage of live colony counts compared to untreated control). Data represent mean ± SD (n=4, 
each one in duplicate) and significant differences in survival between the two treatments are indicated 
by asterisk, where * = p < 0.05. 
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Since SP-A can act synergistically with CAMPs that do not belong to lung defense 
mechanisms, such as PME and PMB, we examined whether SP-A shows this effect on 
humans AMPs present in the alveolar fluid. 
4.4. Synergistic action of SP-A with endogenous cationic antimicrobial peptides.  
To clarify the SP-A role in the innate immune system of the alveolar space and given that 
most of the antimicrobial factors present in the alveolar fluid could act cooperatively (273), 
we used human β-defensins (HBDs) to evaluate the potential synergistic action of SP-A with 
endogenous CAMPs.  
  
Figure 9. SP-A acts synergistically with the endogenous cationic AMPs human β-defensin 2 and 
3 to kill K. pneumoniae 52145 wt. 105 CFUs/mL of K. pneumoniae 52145 re-suspended in in 10 mM 
PBS (pH 7.2), 1% TSB and 100 mM NaCl buffer were mixed with sublethal concentrations of HBDs 
(2.5 µg/mL HBD-1, 0.75  µg/ml HBD-2 and 1.5 µg/ml HBD-3) in the absence (white bars) or 
presence (red bars) of 100 µg/mL SP-A, incubated for 1h at 37 ºC and immediately plated on LB agar 
for CFUs count after 18h of incubation at 37 ºC. Results are shown as % relative survival (percentage 
of live colony counts compared to untreated control). Bars represent mean ± SD (n=3, each one in 
duplicate) and significant different in survival between the two treatments are indicated by asterisks, 
where * = p < 0.05. 
 
To verify whether SP-A is able to enhance the bacterial killing of HBDs, we used 
sublethal concentrations of defensins (that produced a 20-30% decreased survival of the 
bacteria). To establish these concentrations, mortality curves were performed for all HBDs 
against K. pneumoniae 52145 (data not shown). The results obtained indicated that 100 
µg/mL SP-A did not increase or block the bactericidal effect of HBD-1, while it significantly 
increased the bactericidal effect of HBD-2 and HBD-3 (Fig. 9). Therefore, the two inducible 
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variants with greater bactericidal effect of HBDs showed a synergistic effect with SP-A, 
similar to that found with the exogenous bactericidal peptides PMB and PME (Fig. 9). 
4.5. SP-A Binding to K. pneumoniae 52145 in the presence of AMPs.   
To explore the reasons why the presence of SP-A increases the bactericidal activity of 
these AMPs we performed solid-phase binding assays of SP-A to Kp wt in the presence or 
absence of AMPs. K. pneumoniae was incubated 30 min. with increasing concentrations of 
SP-A (0 to 1.25 µg/mL), with or without PMB (5 µg/mL) or HSA (5 µg/mL), and the amount 
of bacteria-associated SP-A was measured. As shown above (Fig. 7), SP-A alone did not bind 
to K. pneumoniae wt, not even in the presence of HSA (Fig.10). However, SP-A was able to 
bind to K. pneumoniae in the presence of PMB in a dose-dependent manner (Fig. 10). 
Therefore, these results suggest that AMPs facilitates the binding of SP-A to bacteria. 
 
Figure 10. SP-A is able to bind K. 
pneumoniae 52145 wt in the presence of 
polymyxin B. Increasing concentration of SP-
A were incubated with 107 CFU of K. 
pneumoniae 52145 wt in the absence (white 
symbol) or presence of PMB 5 µg/mL (black 
symbol) or HSA 5 µg/mL (red symbol) at 
room temperature for 30 minutes. Total 
Klebsiella-associated SP-A was measured by 
solid-phase binding and expressed as total 
nanograms of SP-A/107 bacteria. Bars 
represent mean ± SD (n=3, each one in 
duplicate). 
 
4.6. Interaction of SP-A with AMPs.   
Once proved that AMPs allow the binding of SP-A to bacteria with which SP-A alone 
cannot interact, we studied the potential interaction between SP-A and different AMPs in 
solution by measuring changes in the intrinsic fluorescence or in the hydrodynamic diameter 
of SP-A. Dynamic light scattering (DLS) studies showed that PMB alone has a unique peak 
(independent of the concentration), which corresponds to particles with a hydrodynamic 
diameter of 20 ± 3 nm (data not shown). For SP-A, two identifiable peaks were recognized for 
SP-A alone (15 nM), one corresponding to SP-A particles with a hydrodynamic diameter of 
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34 ± 5 nm (Fig. 11A, black line) and another corresponding to SP-A aggregates with a 
hydrodynamic diameter of 1000 nm (data not shown), according with previous data of our 
group (365). The addition of increasing concentrations of PMB (ranging from 0 to 75 µM) to 
a SP-A solution caused a PMB-concentration-dependent increase of the small size SP-A peak, 
up to a PMB molar concentration of 15 µM (Fig. 11A). This new peak (916 ± 22 nm for the 
highest amount of PMB added), is higher than the one determined for SP-A or PMB alone (at 
the same concentrations) and suggests the formation of a SP-A/PMB complex.  
 
Figure 11. SP-A interacts with polymyxin B and HBD-3. DSL analysis of the hydrodynamic 
diameter of SP-A (34 ± 5 nm) in the absence or presence of increasing concentration of PMB (left 
graphs), in 5 mM Tris buffer (pH 7.4), or HBD-3 (right graphs), in 5mM Tris buffer (pH 7.4) 
containing 150 mM NaCl. The y axis represents the relative intensity of the scattered light; the x axis 
denotes the hydrodynamic diameter of the particles present in the solution.  
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We also evaluated the possible binding between SP-A and AMPs by measuring changes in the 
intrinsic fluorescence emission spectrum of SP-A upon the addition of increasing 
concentrations of AMPs. In the absence of AMPs, the emission spectrum of SP-A is 
dominated by the contribution of two conserved tryptophan residues located at positions 192 
and 213 of the globular COOH-terminal domain (135), which are sensitive markers of 
conformational changes in this region (324). The emission spectrum of SP-A had a maximum 
at 338 nm, indicative of Trp residues partially exposed to solvent (Inset Fig. 11B) (366). The 
addition of increasing concentrations of PMB (0 to 150 µM) produced a concentration-
dependent decrease in the fluorescence intensity of SP-A without changes in its maximum 
wavelength (Inset Fig. 11B). This could indicate that PMB bound to the globular domain of 
SP-A or that conformational changes in SP-A (that exposed Trp residues to solvent) occurred 
due to the interaction with PMB. Figure 11 also shows the intensity data from titration of 15 
nM SP-A to PMB. Following the changes in fluorescence intensity as a function of PMB 
concentration, we obtained a estimated dissociation constant for the SP-A/PMB complex of 
Kd = 0.32 ± 0.04 µM. In addition, the Hill coefficient value was greater than 1, indicating a 
positive cooperative binding.  
 
Fig. 12. SP-A interacts with polymyxin B. A) Representative graph of the fluorescence emission 
spectra of SP-A (15 nM, black line) measured with or without increasing concentrations of PMB (0 to 
150 µM, colored lines) at 25 °C in 5 mM Tris buffer (pH 7.4) containing 150 mM NaCl. B) Results 
are also expressed as F/F0 in each PMB concentration at maximum emission of SP-A, where F is the 
observed intensity of SP-A and F0 is the observed intensity of SP-A+PMB. Results are means ± SD of 
4 experiments. 
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Binding experiments using DLS and changes in the intrinsic fluorescence of SP-A were 
also carried out to evaluate the binding of this protein to another AMPs, such as HBD3, 
estimating a binding constant which was similar to that described by Saito and coworkers 
(367) (data not shown).  
5. DISCUSSION 
In this study, SP-A neither bound nor showed bactericidal activity against the clinic 
isolate K. pneumoniae 52145 wild type, which expresses both smooth LPS and CPS on its 
outer membrane, not even against the deep rough K. pneumoniae mutants expressing CPS. 
Although SP-A exerts antimicrobial activity in several microorganisms (351), several studies 
on SP-A antimicrobial ability in vitro against Gram-negative bacteria indicate that it binds to 
and acts on strains that expresses rough LPS, especially deep rough phenotype Rc or Re (17, 
131, 355). This is consistent with our data, where SP-A was able to aggregate, kill and 
enhance phagocytosis by opsonization of Kp Rc-CPS and Re-CPS (Fig. 3-6), indicating that 
truncated LPS from inner core and the absence of CPS on K.pneumoniae 52145 made bacteria 
susceptible to SP-A.  
Multiple reports have shown the SP-A-resistance of different bacterial strains expressing 
S-LPS (356, 357, 368). LPS is generally thought to be a protective wall with two potential 
barriers, the hydrophobic barrier provided by the hydrocarbon chain region (inner core) and 
the hydrophilic part provided by the oligosaccharide core (outer core), which is densely 
packed (369). Since the surface polysaccharides molecular network is lower in rough strains, 
S-LPS could prevent or decrease the SP-A binding to its main ligand in Gram-negative 
bacteria, the lipid A (370), protecting bacteria against SP-A action. In fact, we found that SP-
A only had activity against decapsulated K. pneumoniae mutants expressing deep rough LPS, 
because it was able to bind these mutants (Fig. 7). 
With regards to the role of CPS in bacterial resistance, it has been shown that binding and 
action of SP-A against some K. pneumoniae strains depends on the sugar composition of the 
CPS (344). It is known that, among saccharides, SP-A binds preferably mannose and fucose 
residues and only binds to K. pneumoniae strains expressing manose-α2/3-manose sequence 
in their capsule (capsular serotype K21) which is not present in K. pneumoniae 52145 CPS 
(capsular serotype K2) used in this study (344, 356). This also might explains why SP-A 
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neither bound nor showed antimicrobial activity against this clinical strain and remarks the 
importance of CPS to confer bacterial resistance against SP-A.  
Taken together, these results highlight the importance of LPS and CPS in the bacterial 
resistance against SP-A, and confirm previous studies that indicate the SP-A preference to 
deep rough LPS bacteria(16). Finally, these findings provide new insights into the structural 
basis of SP-A/LPS interactions to the findings already reported (24). 
Although we have not seen bactericidal effect of SP-A against this clinical strain of K. 
pneumoniae, it has been reported that this protein has a protective role in K. pneumoniae 
infections since SP-A knock-out mice show a higher mortality index upon K. pneumoniae 
challenge (364). Furthermore, SP-A knockout mice are much more susceptible to bacterial 
infections and macrophages-free broncho-alveolar lavages from SP-A +/+ mice shown a 
greater bactericidal effect than lavages from SP-A -/- mice, suggesting a microbicidal role of 
SP-A in vivo, even on bacteria expressing CPS and smooth LPS and resistant to SP-A in vitro 
(20, 353). Thus, taken these findings together, they suggest a complex microbicidal role of 
SP-A in the innate immune system of the alveolar space.   
In this work, we show for the first time that SP-A, besides the bactericidal activity 
displayed against some pathogens, has another important role in the innate immune system, 
cooperating with AMPs present in the alveolar space to kill Gram-negative lung pathogens 
resistant to SP-A. Thus, we have shown that SP-A is able to act synergistically with 
antimicrobial peptides present in the alveolar fluid (such as HBD-2 and HBD-3). In this 
regard, it was observed an increase in the microbicidal activity of HBD-2 and -3 for K 
pneumoniae K2 strain against which SP-A showed no effect (Fig. 9). Among the innate 
immune system in the alveolar space, several reports have suggested the importance of 
cooperative actions between different soluble factors with microbicidal activity. It has been 
found that lactoferrin and lysozyme act synergistically in combination with HBD-2 (21), 
while HBD-2 and LL-37 have demonstrated an additive action against E. coli (22). Likewise, 
it has also found a synergistic activity in triple combinations of lysozyme, lactoferrin, and the 
proteinases inhibitor secreted by leukocytes (SLPI) (22). In addition, SP-A and SP-D have 
been shown to have additive neutralizing activity with human cathelicidin LL-37 against 
influenza A viruses susceptible to SP-A (371).  
CHAPTER1 
	  
138 
Moreover, we have shown that SP-A can also increase the bactericidal effect of two 
potent, but cytotoxic, bactericidal exogenous peptides, PMB and PME, against three different 
bacterial strains which SP-A did not have bactericidal effect, like K. pneumoniae K2, P. 
aeruginosa O1 or non-typable H. influenzae (Fig. 8). Since PMB and colistin are antibiotics 
of last resort against MDR microorganisms because of their high toxicity for the patient, and 
that this toxicity has been suggested to be dose dependent (372), their combinatorial use with 
SP-A would allow the use of a lower concentration of polymyxins, reducing their toxicity 
without decreasing their bactericidal effect. Therefore, the synergistic action found in this 
study, should be considered for the development of new therapies, though combinatorial use 
of SP-A and AMPs as therapeutic agents.  
The mechanism of action by which SP-A enhances the antimicrobial activity of these 
AMPs is still unknown and must be deeply investigated. A possible explanation could be that 
the presence of these AMPs facilitates the binding of the protein to SP-A resistant pathogens 
(with which SP-A alone cannot interact), since solid-phase binding assays showed that SP-A 
was able to bind K. pneumoniae K2 wt when PMB was added in the solution (Fig. 10). The 
ability of AMPs to facilitate the binding of SP-A to these bacteria could be through a protein-
protein interaction mechanism. Using dynamic light scattering and changes in the 
fluorescence of SP-A, we have demonstrated that SP-A interacts with PMB (Fig 11) and 
HBD-3 (data not shown) in a dose-dependent manner.  
SP-A ability to bind to antimicrobial peptides have been previously described. Saito et al 
determined that SP-A binds- to HBD3 with a binding constant of 17.3 µM, which was very 
similar to what we have observed, and it is able	  to block the cytotoxicity of hBD-3 without 
inhibiting its antimicrobial activity (at lethal concentrations) (367). In addition, we showed 
that SP-A increased its microbicidal activity (at sub-lethal concentration) (Figure 7). This 
suggests a complex interaction between both factors	  that would improve the activity of the 
innate immune system in the lung defense against pathogens. Currently, we are further 
examining the direct mechanisms of action by which these proteins kill synergistically 
bacteria. Perhaps, one of them is the previous bacterial OM disruption, since we have seen 
that SP-A killed or helped to kill bacteria when OM was perturbed by two different ways: 
mutational alteration of the LPS structure; and the use of drugs able to bind and perturb 
bacterial OM.	  In addition, AMPs might act as SP-A carriers, through direct interaction, in 
order to allow SP-A binding to its bacterial target, thus permitting its bactericidal activity. 
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In summary, we have found that SP-A has antimicrobial activity against pathogenic 
Gram-negative bacteria, when bacterial OM was mutated up to deep rough LPS without CPS. 
Moreover, in smooth LPS bacteria expressing CPS (as clinical strains of K. pneumoniae K2), 
which are capable to avoid the bactericidal activity of SP-A, SP-A is able to act 
synergistically with cationic AMPs, through a protein-protein interaction mechanism, 
enhancing the innate immune system in lung defense against Gram-negative lung pathogens. 
However, more antimicrobial in vitro experiments would be necessary to gain insight into the 
interaction mode of SP-A with AMPs, and in vivo studies that could confirm this finding at 
physiological conditions. On the other hand, biophysical and biochemical experiments to 
investigate mechanisms by which these factors kill bacteria would be necessary to better 
understand their role in the innate immune system. The study of synergistic activity between 
SP-A and AMPs may provide new insights to the development of new efficient therapeutic 
treatments against MDR pathogens.  
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1. ABSTRACT 
The anionic antimicrobial peptide SP-BN, derived from the N-terminal saposin-like 
domain of the SP-B proprotein, and SP-A are lung anti-infective proteins since SP-A-
deficient mice are more susceptible than WT mice to lung infections, and bacterial killing is 
enhanced in transgenic mice overexpressing SP-BN. However, SP-BN showed in vitro 
microbicidal activity only at middle acidic pH, and several microorganisms have been proven 
resistant to SP-A. Thus, we hypothesize that SP-BN and SP-A might act cooperatively in the 
alveolar fluid to strengthen each other’s microbicidal activity.  Our results indicate that both 
proteins acted synergistically in vitro against SP-A- and SP-BN-resistant capsulated Klebsiella 
pneumoniae (serotype K2) at neutral pH. SP-A and SP-BN were able to interact in solution 
(Kd = 0.39±0.02 µM), which enabled SP-A binding to bacteria with which SP-A or SP-BN 
alone could not interact. In vivo, we found that treatment of Klebsiella pneumoniae-infected 
mice with SP-A and SP-BN conferred more protection against K. pneumoniae infection than 
each protein individually. Relative to untreated infected mice, SP-A/SP-BN-treated infected 
mice showed significant reduction of bacterial burden, early neutrophil recruitment 
enhancement, and ameliorated lung histopathology. In addition, the concentrations of 
inflammatory mediators in lung homogenates increased early in infection in contrast with the 
weak inflammatory response of untreated K. pneumoniae-infected mice. Finally, we found 
that therapeutic treatment of SP-A and SP-BN after 6h or 24h of bacterial challenge conferred 
significant protection against K. pneumoniae infection. These studies show novel anti-
infective pathways that could drive development of new therapies for pulmonary infections.  
2. INTRODUCTION 
Lung infection is a frequent cause of morbidity and mortality especially in cystic fibrosis 
and other chronic lung diseases. Multidrug-resistant (MDR) bacteria strains are widespread 
and the pipeline for new antibiotics is insufficient to match the health burden posed by lung 
infection. Thus, the effectiveness of current therapeutic strategy against pneumonia is 
threatened (360).  
Klebsiella pneumoniae is a frequent cause of nosocomial infections and may be 
responsible for as much as 20% of respiratory infections in the neonatal intensive care unit 
(373). The emergence of MDR strains of K. pneumoniae has significantly complicated the 
management and treatment of infections involving this organism and it is contributing to 
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increased bacterial drug resistance, toxic effects and health care costs (373). In this regards, 
innate host defense proteins secreted into the airway are less likely to induce bacterial 
resistance that regular exogenous antibiotics, mostly since outer membrane (OM) is the main 
target of these proteins. Moreover, they have other desirable features as new classes of 
antibiotics, including a broad spectrum activity, neutralization of endotoxins, activity in vivo 
and possible synergy with antibiotics (374). Consequently, a variety of host defense proteins 
are gaining considerable attention and clinical interest, because of their importance in 
maintaining lung homeostasis in ambient conditions and their potential to kill MDR 
microorganisms (375). Among them, surfactant protein- (SP) A and the saposin-like domain 
derived from NH2-terminal propeptide of surfactant protein B (SP-BN) have been shown as 
potent lung innate immune molecules (6, 12). 
SP-A is a pulmonary protein member of the collectin family, which plays a key role in 
innate immunity through different activities. Directly interacts with and agglutinates various 
microbes and enhances phagocytosis by opsonization or direct phagocytes stimulation (376). 
It is able to regulate inflammatory mediator production depending upon the pathogen, the 
responding cell, and the cytokine environment (377). In addition, SP-A directly inhibits the 
growth of and kills some microorganisms by membrane permeabilization (362). In vivo, 
deficiency in SP-A in gene-targeted mice cause no apparent pathological changes but results 
in increased susceptibility to lung infections (352). Moreover, macrophage-free 
bronchoalveolar lavages from SP-A +/+ mice showed greater bactericidal activity against 
bacteria than those lavages from SP-A -/- mice (353). On the other hand, we recently 
discovered a new anionic AMP, SP-BN, derived from the proteolytic processing of the NH2-
terminal segment of the proprotein SP-B, which possess strong antimicrobial activity (6). 
Overexpression of SP-BN in the distal airway epithelium protects mice against infection with 
Pseudomonas aeruginosa and Streptococcus pneumoniae (6). In vitro, SP-BN indirectly 
promotes the uptake of bacteria by macrophage cell lines and directly kills bacteria at acidic 
pH, consistent with a lysosomal antimicrobial function (6). Despite the importance that these 
proteins have in lung defense against pathogens, there are limitations to consider: i) several 
studies have described the existence of SP-A-resistant microorganisms, including K. 
pneumoniae (chapter 1, (354, 378) and ii) SP-BN is secreted into the alveolar fluid, but is not 
able to kill microorganism at physiological pH (6).  
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We have previously shown that SP-A is able to act synergistically with AMPs against 
several respiratory pathogens resistant to SP-A (chapter 1). In addition, several reports have 
suggested the importance of cooperative interaction between antimicrobial factors of the 
alveolar space in order to strengthen the microbicidal defense of the lungs (22, 371, 379); 
even though, little is known about the in vivo interaction between these factors in innate host 
defense. Hence, SP-A and SP-BN may interact in the airways to aid in killing bacteria, even 
on resistant ones. 
We confirmed the bactericidal activity of both, SP-A and SP-BN, in vitro and assessed the 
potential therapeutic benefit of these proteins in combination to enhance host defense against 
a common cause of pneumonia, Klebsiella pneumoniae. Harnessing the host’s natural 
antimicrobial proteins might provide an adjunct to the current therapy for pneumonia. 
 
3. EXPERIMENTAL DESIGN 
For this work, both in vitro and in vivo potential synergistic activity of SP-A and SP-BN 
was evaluated. For in vitro experiments (Fig. 1), we firstly evaluated their direct microbicidal 
ability as well as their ability to enhance phagocytosis of capsulated K. pneumoniae K2. 
Killing was evaluated by CFU count on bacteria incubated with SP-A (100 µg/mL), SP-BN 
(10 µg/mL) or both in 20 mM phosphate buffer, pH 7.0, or 2 mM sodium acetate buffer, pH 
5, both buffers containing or not 150 mM NaCl with or without 2 mM Ca2+. For phagocytosis 
assays, alveolar and peritoneal mouse macrophages (MH-S or Raw 264.7 cells) were infected 
with a suspension of bacteria and SP-A and/or SP-BN and uptake of bacteria were enumerated 
by CFU count of intracellular bacteria after macrophages lysis. On the other hand, the ability 
of SP-BN to bind to K. pneumoniae at acidic and neutral pH as well as the ability of SP-A to 
bind to this bacterium in the presence of SP-BN was investigated by solid-phase binding 
assay. Finally, as determined in chapter 1 for CAMPs, the potential molecular interactions 
between SP-A and SP-BN were determined using DLS assay and changes in the intrinsic 
fluorescence of SP-A.  
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Fig. 1. In vitro experimental design used in chapter 2. 
 
 
For in vivo experiments (Fig. 2), 10,000 CFUs of K. pneumoniae K2 re-suspended in 100 
µL of 5 mM Tris/150 mM NaCl were intra-tracheally co-administered with SP-A, SP-BN or 
both, in wild type FV/BN mice. Then, after 6, 24 or 72h of infection, on one hand, the left 
lobe of the lungs was harvested and homogenized in 1 mL of sterile PBS to assay lung 
bacterial burden by CFU count or to determine cytokines expression by ELISA. On the other 
hand, the right lobes were used to obtain the bronco-alveolar lavage (BAL). Total cell counts 
from BAL fluid were counted in a hemocytometer, and then, a suspension of cells was 
cytocentrifuged to analyze the types of cells by staining of cytospin preparations. In some 
experiments, lungs were inflation-fixed with 4% paraformaldehyde 6 or 24 h following intra-
tracheal instillation of bacteria and proteins, and lung sections from each lobe were loaded 
onto polylysine-coated slides and stained with hematoxylin and eosin for analysis of lung 
histopathology. For therapeutic application of SP-A/SP-BN, mice infected with 10,000 CFUs 
of K. pneumoniae K2 were treated with both proteins in combination 6 or 24h after the 
bacterial challenge and sacrificed at 24 or 48 h post-infection, respectively. Then, lung 
bacterial burden and total cell numbers and type of cells were analyzed as mentioned above. 
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Fig. 2. In vivo experimental design used in chapter 2. CFU: colony-forming units; PFA: 
paraformaldehyde; BALF: bronchoalveolar lavage fluid; H&E: Hematoxylin & eosin 
 
 
4. RESULTS 
4.1. SP-A and SP-BN are able to act synergistically against Klebsiella pneumoniae K2 at 
neutral pH in vitro 
To assess potential synergistic interaction between SP-BN and SP-A in bacterial killing, 
in vitro killing assays were performed using the common and highly virulent pathogen K. 
pneumoniae (serotype K2).  Bacteria were incubated with SP-A and/or SP-BN at pH 7 (Fig. 
2A) or pH 5.5 (not shown). As previously reported by us, SP-BN and SP-A was unable to kill 
Klebsiella pneumoniae K2 at neutral pH (chapter 1, (6)). However, we found that in 
combination, both proteins effectively killed K. pneumoniae at neutral pH, where neither of 
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these proteins had bactericidal activity individually. Addition of a buffer containing 150 mM 
NaCl enhanced SP-BN/SP-A mediated killing independently of the presence of calcium (Fig. 
3A), indicating that the presence of ionic strength in the medium is important but not essential 
for bactericidal activity. Given that SP-BN is able to kill bacteria at acidic pH (6), we also 
performed the experiment under these conditions. However, at this pH, the bactericidal action 
of SP-BN was not increased by the presence of SP-A, with or without NaCl or Calcium (data 
not shown). 
 
 
 
Figure 3. SP-A and SP-BN are able to kill synergistically K. pneumoniae K2 at neutral pH and 
enhance phagocytosis by macrophages. A) Bacteria (105 CFUs/mL) were incubated 1h at 37ºC with 
SP-BN (10 µg/mL), SP-A (100 µg/mL) or both in 20mM phosphate buffer, pH 7, containing or not 150 
mM NaCl and/or 2mM CaCl2. The number of viable bacteria was assessed by CFU count and results 
expressed as mean ± SD (n=4, each one in duplicate). B) RAW264.7 cells were pre-incubated with 
SP-BN (0 to 20 µg/mL) with or without SP-A (100 µg/mL) for 4 h. Cells were washed twice with PBS, 
and infected 1 h with K. pneumoniae (5 X 107 CFU). Bacterial uptake was assessed by quantitative 
culture of cell lysates. Results are means ± SD (n=4, each one in duplicate). ***p < 0.001 and **p < 
0.01 vs samples treated with proteins individually; ### p < 0.001 and ## p < 0.01 vs untreated 
samples. 
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4.2. SP-A acts together with SP-BN to enhance bacterial uptake in vitro 
Individually, SP-A and SP-BN enhance phagocytosis of several respiratory pathogens (6, 
380).  We tested the potential cooperative action between these proteins to enhance uptake of 
K. pneumoniae by the mouse macrophages cell lines MH-S and Raw 264.7. Pre-incubation of 
bacteria with both proteins prior to infection or infection of macrophages with a suspension of 
bacteria and SP-A and/or SP-BN did not increase phagocytosis after 1 h of infection (data not 
shown), suggesting that both proteins did not directly promote the uptake of this bacteria. In 
contrast, pre-incubation of MH-S (data not shown) or RAW264.7 cells (Fig. 3B) with SP-A 
(100 µg/mL) in combination with increasing amount of SP-BN (5 to 20 µg/mL) for 4 h prior 
to the addition of bacteria resulted in a dramatic increase in intracellular bacteria, compared 
with untreated cells or cells treated with SP-A or SP-BN alone (Fig. 3B). Therefore, these data 
suggest that SP-A and SP-BN act in conjunction to indirectly increase phagocytosis of 
Klebsiella. 
4.3. SP-A is able to bind K. pneumoniae in the presence of SP-BN 
As we have seen in Chapter 1, SP-A is only capable of recognizing and binding to Kp wt 
in the presence of other AMP (chapter 1, Fig. 10). Thus, we proposed to study if SP-BN could 
also facilitate the binding of SP-A to bacteria. To this end, we firstly analyzed the ability of 
SP-BN to bind to this bacterium at both pH 7 and 5.5. Bacteria were incubated with 
biotinylated SP-BN (0 to 2.5 µg/mL) and Klebsiella-associated SP-BN was assessed by solid-
phase binding assay. Fig 4A shows that SP-BN was able to bind to K. pneumoniae at acidic 
pH, but not at neutral pH, which is in accordance with its ability to kill bacteria only at acidic 
pH (6). On the other hand, binding of biotinylated SP-A (0 to 1.25 µg/mL) to bacteria in the 
presence or absence of SP-BN (10 µg/mL) or HSA (10 µg/mL) was also evaluated. As 
previously shown (chapter 1, (356)), SP-A alone was unable to bind to K. pneumoniae K2, 
even in the presence of HSA (Fig. 4B). However, SP-A bound avidly to Klebsiella in a dose-
dependent manner when SP-BN was added to the solution (Fig. 4B), indicating that SP-BN 
facilitates binding of SP-A to bacteria even at neutral pH. 
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Figure 4. SP-A binds to K. pneumoniae K2 in the presence of SP-BN. A) Biotinylated SP-BN were 
incubated at RT for 30 minutes with K. pneumoniae K2 (107 CFU) in 20mM phosphate buffer, pH 7 
(red symbol), or 5mM sodium acetate buffer, pH 5.5 (blue symbol), both containing 150 mM NaCl 
and 2mM CaCl2. Total Klebsiella-associated SP-BN was measured by solid-phase binding and 
expressed as total nanograms of SP-BN per 107 bacteria. B)	   Increasing concentration of SP-A were 
incubated alone (white symbol) or in the presence of SP-BN (10 µg/mL) (red symbol) or HSA (10 
µg/mL) (black symbol) in the same conditions above mentioned. Total Klebsiella-associated SP-A 
was measured by solid-phase binding and expressed as total nanograms of SP-A/107 bacteria. Results 
are means ± SD of 4 experiments, each one in duplicate.	  	  
 
4.4. SP-A and SP-BN interact directly 
We next determined the mechanism by which the combination of SP-A and SP-BN are 
able to bind and kill K. pneumoniae. First, we studied the potential interaction between SP-BN 
and immobilized SP-A. Solid-phase binding assay showed that SP-BN interacted with 
immobilized SP-A (38 nM) in a dose-dependent (0 to 11 µM) and saturable (Kd = 0.42 ± 0.08 
µM) manner (Fig. 5A, red circles). SP-BN did not bind to wells coated with HSA (Fig. 5A, 
black circles) or wells containing buffer alone. 
Interaction of SP-A and SP-BN in solution was next examined by monitoring changes in 
the intrinsic fluorescence of SP-A. The fluorescence emission spectrum of SP-A in the 
absence of SP-BN showed a maximum at 338 nm, indicating that Trp residues (positions 191 
and 213 of the globular domains) are partially exposed to solvent (381). Addition of 
increasing concentrations of SP-BN (0 to 5.5 µM) significantly decreased in amplitude of the 
emission spectrum of SP-A, without changes in its maximum wavelength, in a dose-
dependent manner (Fig 5B). These data suggest that the interaction of SP-BN with SP-A takes 
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place in tryptophans region or that the binding produces conformational changes in SP-A 
resulting in the quenching of the two SP-A tryptophans (324). 
 
 
Figure 5. SP-A and SP-BN interact in a dose-dependent manner. A) 25µg of SP-A (red symbol) or 
HSA (black symbol) was coated onto microtiter plate wells and biotinylated SP-BN (0 to 11 µM) was 
then added to the wells. The level of bound SP-BN was determined with streptavidin-horseradish 
peroxidase. Results are means ± SD of 4 experiments. B) Fluorescence emission spectra of SP-A (15 
nM) was measured with or without increasing concentrations of SP-BN (0 to 5.55 µM) at 25 °C in 5 
mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl. Results are expressed as F/F0 in each SP-BN 
concentration at maximum emission of SP-A, where F is the observed intensity of SP-A and F0 is the 
observed intensity of SP-A with SP-BN. Results are means ± SD of 4 experiments. In addition, inset 
graph shows a representative graph of fluorescence emission spectra of SP-A in the absence (black 
line) and the presence of increasing concentrations of SP-BN (colored lines).  
 
Using the Hill equation according to (chapter 1), an estimated Kd value for the SP-A/SP-
BN complex was obtained by measuring the changes in the fluorescence intensity of SP-A at 
338 nm upon the addition of increasing concentrations of SP-BN. This dissociation constant 
(Kd = 0.39 ± 0.02 µM) was quite similar to that one calculated by solid-phase binding assay. 
4.5. Killing of K. pneumoniae in mice treated with SP-A and SP-BN 
To determine an appropriate bacterial dose for in vivo studies, 103 to 105 CFUs of K. 
pneumoniae K2 (6 mice/group) in wild-type FVB/N mice were inoculated intratracheally. 
Administration of Klebsiella was well tolerated, and all animals survived the 72-h study 
period at the 104-CFUs dose. Alterations in activity or physical appearance of the animals 
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were not detected until 72 h post-infection. K. pneumoniae K2 was co-administrated with SP-
A, SP-BN or both to wt FVB/N mice and bacterial burden was assessed. At 6 hours post-
infection, lung bacterial burden was decreased 2.5-fold in SP-A- or SP-BN-treated mice 
(p=0.02) and 6.6-fold in SP-A+SP-BN-treated mice, p=0.001 (Fig. 6). Bacterial burden was 
also significantly decreased at 24 h when mice were treated with SP-A (2-fold), SP-BN (4-
fold) or SP-A+ SP-BN (9-fold) (Fig. 6), indicating that these proteins are more effective when 
they are co-administrated. Although SP-A and SP-BN treatment slowed down bacterial 
growth, total bacterial burden increased from 6 to 24 hours post-infection and by 72 hours 
post-infection. There was no difference among the groups at that last time post-infection. 
These data suggest that exogenous SP-A and SP-BN are consumed after 24 hours and that 
retreatment and/or higher doses will be required to control infection. 
 
 
 
Figure 6. SP-A and SP-BN treatment enhances bacterial clearance following intratracheal 
instillation of K. pneumoniae K2. K. pneumoniae K2 (104 CFUs) was co-administrated with SP-A 
(100 µg), SP-BN (20 µg) or SP-A (100 µg) + SP-BN (20 µg) in wt FVB/N mice and lungs were 
harvested, weighed, and homogenized at indicated time points. The numbers of viable bacteria were 
assessed by colony counting and expressed as CFUs/Mouse (n=6 mice/group/time point). Results are 
means ± SEM (n=6); ***p < 0.001 and *p < 0.05 vs untreated mice. 
 
4.6. Inflammation in SP-A and SP-BN-treated mice after K. pneumoniae infection 
A mild increase in the total cells in BALF of untreated mice was observed 6 h and 24 h 
after infection with K. pneumoniae, compared to uninfected mice (Fig. 4A). Total cell 
numbers in BALF from SP-A- or SP-BN-treated groups were significantly increased 
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compared to untreated animals. Combined SP-A/SP-BN treatment further enhanced cell 
recruitment at 6 and 24 h post-infection (Fig. 4A). Histologic examination of lung sections 
showed mild alveolar infiltration in lungs of infected mice at 6h post-infection, which was 
higher in mice infected and treated with SP-A+SP-BN (Fig. 4B). By 24h, alveolar infiltration 
increased in both groups of infected mice (Fig 4B), and areas of lobular pneumonia were 
detected, especially in untreated mice (Fig 4B, black arrows).  
 
Figure 7. SP-A and SP-BN treatment increase total cells in BALF and ameliorate lung 
histopathology of mice infected with Klebsiella pneumoniae. A) wt FVB/N mice were instilled with 
buffer or infected with 104 CFUs of K. pneumoniae K2 co-administrated with SP-A (100 µg), SP-BN 
(20 µg) or SP-A (100 µg)+SP-BN (20 µg), and sacrificed at 6h or 24h to assess total cell count. Six 
mice were evaluated for each group at each time point. Results are means ± SEM (n=6), ***p < 0.001 
and *p < 0.05 vs untreated mice. B) Lung sections from uninfected mice or mice instilled with K. 
pneumoniae (104 CFUs) with or without SP-A(100µg)+SP-BN(20µg) were stained with hematoxylin 
and eosin after 6 h (upper line) or 24 h (lower line) of administration. Representative lung histology 
from each group is shown. Arrows indicate lobular pneumonia. 
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Analyses of cell types in BALF from uninfected mice revealed that nearly all cells were 
alveolar macrophages while practically there were no neutrophils (Fig. 8). In infected mice, 
both treated and untreated ones, we could observe an increase in the recruitment of 
neutrophils, both at 6h and 24h post-infection (Fig. 8A and B). Neutrophil recruitment was 
significantly greater in mice treated with SP-A/SP-BN compared to mice treated with SP-A or 
SP-BN (Fig. 8A and B). In contrast, administration of both molecules in uninfected mice only 
promoted a minimal inflammation (data not shown). 
 
 
 
 
Figure 8. SP-A and SP-BN treatment enhances early neutrophils recruitment in infected mice. wt 
FVB/N mice were instilled with buffer or infected with 104 CFUs of K. pneumoniae K2 co-
administrated with SP-A (100 µg), SP-BN (20 µg) or SP-A (100 µg) + SP-BN (20 µg).  Mice were 
sacrificed at 6h (A) or 24h (B) and total macrophages and neutrophils count in bronchoalveolar lavage 
fluid (BALF) were assessed. Six mice were evaluated for each group at each time point. Results are 
means ± SEM (n=6). ***p < 0.001 and **p < 0.01 vs untreated mice. 
   
 
Moreover, neutrophil recruitment was strongly associated with elevated levels of TNF-α, 
IL-1β, IL-6, IL-17α, and MIP-2 (Fig. 9). The cytokine response was only detected in animals 
treated with SP-A/SP-BN and was transient, returning to baseline 24h after treatment.   
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Figure 9. Levels of cytokines in lung homogenates after intratracheal co-instillation of K. 
pneumoniae K2 and SP-A/SP-BN. wt FVB/N mice were instilled with 5 mM Tris, 150 mM NaCl 
buffer (black bars) or 104 CFUs of K. pneumoniae K2 without (white bars) or with (purple bars) 100 
µg of SP-A + 20 µg of SP-BN. Lungs were harvested and homogenized at 6h and 24 hours after 
infection and concentrations of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, IL-17α and 
macrophage inflammatory protein-2 (MIP-2) were quantitated by ELISA (n = 5 mice for each group). 
Results are means ± SEM, ***p < 0.001 and *p < 0.05 vs untreated mice. 
 
4.7. Therapeutic effect of SP-A and SP-BN in mice with an established infection 
Once we have verified that both proteins are able to act in conjunction in vivo, we asked 
if they could be used as treatment once infection was established. To assess the therapeutic 
potential of SP-A/SP-BN treatment, wt FVB/N mice were first infected with K. pneumoniae 
and subsequently treated with exogenous proteins 6 or 24h post-infection. Lung bacterial 
burden and BALF cells were analyzed 24h post-infection for animals treated at 6h, and 48h 
post-infection for animals treated at 24h.   
SP-A/SP-BN treatment reduced bacterial burden when administered 6h or 24h post-
infection (Fig. 10A). Reduced bacterial burden was associated with increased cell infiltration 
(Fig. 10B) with neutrophils being the predominant cell type (Fig. 10B and 10C).  Therefore, 
therapeutic treatment of SP-A and SP-BN was also protective against K. pneumoniae 
infections. 
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Figure 10. Therapeutic application of SP-A/SP-BN increased bacterial clearance and neutrophils 
recruitment in mice with an established K. pneumoniae K2 infection. wt FVB/N mice were 
instilled with PBS (black bars) or 104 CFUs of K. pneumoniae K2 and instilled with Tris 5mM NaCl 
150mM pH 7 (white bars) or SP-A (100 µg) + SP-BN (20 µg) (purple bars) 6h (A) or 24h (B) after the 
bacterial challenge. Mice were then sacrificed at 24h or 48 hours post-infection, respectively, to assess 
lung bacterial burden in lungs (left graphs) and macrophages and neutrophils count in BALF (right 
graphs). Six mice were evaluated for each group at each time point. Results are means ± SEM (n=6). 
***p< 0.001 vs uninfected mice. ###p< 0.001 vs untreated mice. 
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5. DISCUSSION 
Due to the emergence of multi-resistant bacteria and the ineffectiveness of current 
treatments (360), research is focusing on naturally occurring lung proteins that may provide 
novel adjunctive therapies. SP-A and SP-BN have been shown to have in vivo anti-infective 
role individually. Overexpression of SP-BN in targeted mice is associated with a significant 
protective effect and survival following infection (6) and SP-A -/- mice are more susceptible 
to lung infection (352). In the current study, we demonstrated in vivo cooperative action 
between SP-A and SP-BN against MDR-K. pneumoniae infection, which corroborates 
previous data showing synergistic in vitro activity between antimicrobial soluble factors of 
the alveolar space (22, 371).  
SP-A and SP-BN have shown several in vitro antimicrobial activities. Both proteins alone 
enhance bacterial uptake and killing by macrophages (151, 152). Microbicidal role of SP-A 
has been demonstrated by in vitro (16) and in vivo (14) studies showing bactericidal activity 
in Gram-negative bacteria. However, several SP-A-in vivo-susceptible microorganisms (20, 
176) have been shown resistant to SP-A in vitro (16, 19) (Chapter 1), and we reported that 
SP-A acts synergistically with the cationic antimicrobial peptides human beta-defensin 2 and 
3 to aid in killing K. pneumoniae K2 (Chapter 1), suggesting that SP-A might require 
collaboration with AMP in the alveolar space. On the other hand, the anionic saposin-like 
peptide SP-BN kill bacteria only at acidic pH, but it is has been shown to be secreted into the 
alveolar fluid (6), where could cooperate with another antimicrobials factors, like SP-A. In the 
current study, we found that in vivo protection of SP-A/SP-BN treatment against Klebsiella 
pneumoniae K2 was consistent with a combinatorial antimicrobial activity between these 
proteins. Therefore, we found that SP-A and SP-BN further enhanced macrophages-mediated 
phagocytosis of Klebsiella pneumoniae in combination and were able to kill bacteria 
synergistically in vitro at neutral pH, whereas neither of these proteins had bactericidal 
activity individually. In this sense, several reports have found synergistic and additive 
interactions between antimicrobial factors of the alveolar fluid, including synergistic 
combination between lactoferrin and lysozyme against E. coli (22) and additive antiviral 
activity of SP-A with human cathelicidin LL-37 (371).  
This collaboration in bacterial killing seems to be in connection with SP-A ability to bind 
Klebsiella, since only occurs in the presence of SP-BN and probably through the interaction of 
SP-A with SP-BN (Kd=0.39±0.3 µM). Ability of collectins, such as SP-A and SP-D, to bind 
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several ligands, including proteins, has been widely studied (365, 367). They showed several 
effects, from additive or antagonist (361, 382) to anti-cytotoxicity ones (367), which suggest 
complex interactions between alveolar soluble factors. Thus, in our case, protein-protein 
interaction showed synergistic activity and appears to be essential for this activity. The 
mechanisms by which SP-A and SP-BN produce bacterial death synergistically remain 
unknown. It has been reported that SP-A is able to permeabilize bacterial outer membrane 
(14, 30) and suggested that SP-BN might kill bacteria via pore formation, given the striking 
similarities with the anionic AMPs amoebapores, including saposin-like folding and pH- and 
oligomerization-dependent bactericidal activity (6). Therefore, it is possible that both proteins 
could enable each other to perturb bacterial OM through the interaction between them, which 
permit binding to bacterial LPS. However, additional experiments are necessary to confirm 
this presupposition. 
The ability of SP-A and SP-BN to enhance clearance of K. pneumoniae in vivo appears to 
be related to their capability to modulate host inflammatory response, since SP-A and SP-BN 
were able to enhance early immune response to Klebsiella. SP-A and SP-BN enhanced the 
expression of several pro-inflammatory cytokines, including IL-17, which is widely 
implicated in host response against infection by K. pneumoniae (383); as well as the 
expression of an important chemokine implicating in neutrophils recruitment, MIP-2 (384). 
Consequently, SP-A and SP-BN promoted an increase in early neutrophil recruitment in 
BALF during infection with Klebsiella, which was greater in combination. In contrast, 
instillation of SP-A and SP-BN in uninfected mice only promoted a minimal inflammation 
(data not shown).  
Although data supporting the role of SP-BN in inflammation are sparse, anionic AMPs 
have been shown to induce cytokine and chemokine production. Dermcidin is an 
antimicrobial peptide secreted into sweat, which shares some features with SP-BN, such as 
anionicity, antimicrobial activity at acidic pH and constitutive expression (385). Dermcidin-
derived peptides have been shown to activate normal human keratinocytes by inducing pro-
inflammatory and chemoattractive mediators (386). In addition, AMPs have been reported to 
promote chemotaxis (8), both indirectly by stimulating the expression of well-known 
chemokines, like CXCL8/IL8 and CCL2/MCP1(227); and directly by acting as chemokines 
themselves to recruit a variety of immune cells (229). On the other hand, even though the 
main role of SP-A in inflammation seems to be anti-inflammatory (18), it has been also 
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shown to increase inflammation and modulate host innate defense in a context-dependent 
manner (34). SP-A stimulates production of pro-inflammatory cytokines during the early 
phase of lung injury (387). SP-A enhances chemotaxis of inflammatory BAL neutrophils 
toward chemokines such as MIP-2 (167) or the stimulation of neutrophil chemotactic factors 
release (168). In addition, influx of neutrophils into bronchoalveolar lavage fluid and pro-
inflammatory cytokine expression was enhanced after exogenous administration of SP-A in 
mechanically ventilated preterm lambs (169). Thus, according to our results, SP-A and SP-BN 
could collaborate in vivo to immunomodulate host immune response during infection. 
The collaboration between both factors in the alveolar space might also depend on the 
bacterial pathogen or toxin that is attacking the host. Evidence indicated that Klebsiella 
infections are characterized by lacking an early inflammatory response, because K. 
pneumoniae antagonizes the activation of NF-kB in order to subvert the host inflammatory 
response in its own benefit (388, 389). In addition, several reports have demonstrated that 
activation of an inflammatory response is essential to clear Klebsiella infections (383, 390-
392). In our case, SP-A and SP-BN seem to counteract the anti-inflammatory response 
induced by this bacterium, since mice treated with both proteins showed an increase in early 
inflammation and neutrophils recruitment. In fact, studies involving mice infected with K. 
pneumoniae have found that the marked reduction of bacterial loads in response to the AMP 
a-defensin-1 is attributed to the increased accumulation of leukocytes at the site of infection 
(393). In addition, it is possible that the lower bacterial burden found in the lungs contributed 
to this increase in pro-inflammatory response, due to the presence of fewer bacteria to 
suppress the cytokine response. In any case, our data suggest that SP-A/SP-BN treatment 
might enhance endogenous protective mechanisms to aid in the clearance of K. pneumoniae.  
In summary, we found that two surfactant components, SP-A and SP-BN, act in 
conjunction to protect the lungs against Klebsiella pneumoniae infection. These findings are 
consistent with an SP-A+SP-BN-mediated increase in: 1) microbicidal activity; 2) bacterial 
phagocytosis; 3) neutrophil recruitment in BALF and 4) host early inflammatory response. 
Given the alarming increase in MDR Gram-negative bacteria in the face of a paucity of new 
antibiotics (376), we have shown that naturally occurring lung proteins may provide a novel 
model of adjunctive therapy for Gram-negative infections. 
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1. ABSTRACT 
Surfactant protein A (SP-A), the most abundant protein of the alveolar fluid, has been 
proven to directly kill some microorganisms; however, several bacteria are resistant to SP-A. 
In this study we investigate whether a nontoxic nonapeptide derived from polymyxin B 
(PMBN) cooperates with SP-A in killing Gram-negative bacteria and the mechanism by 
which both molecules exert their action. We found that, although PMBN and SP-A did not 
exhibit antimicrobial activity against Klebsiella pneumoniae K2:O1 and Pseudomonas 
aeruginosa PAO1, the combined action of both proteins resulted in efficient bacterial killing.  
PMBN was able to interact with SP-A (Kd =0.26 ± 0.02 µM), which allowed SP-A to bind to 
bacteria with which SP-A alone could not interact. To identify the mechanism of bacterial 
killing mediated by PMBN/SP-A, we measured the capability of these proteins to insert into 
bacterial outer membranes. We found that PMBN and PMBN/SP-A, but not SP-A, were able 
to insert into LPS monolayers, and PMBN insertion significantly increased in the presence of 
SP-A. Membrane disturbances induced by SP-A/PMBN, but not by SP-A or PMBN alone, 
resulted in membrane permeabilization of vesicles composed of bacterial outer membrane 
lipids. In contrast, the presence of SP-A did not have any influence on PMBN-induced 
permeability of bacterial inner membranes. Taken together, these results indicate that SP-A 
and PMBN cooperate in killing bacteria because they are jointly able to disturb and 
permeabilize the outer membrane of Gram-negative bacteria. 
2. INTRODUTION 
Polymyxins are pentacationic lipopeptides isolated from Bacillus polymyxa (394) that are 
well-known clinically used antibiotics (242, 317). Among them, polymyxin B (PMB) and 
polymyxin E, also called colistin, have been used in clinical practice since 1950s. Polymyxins 
are highly bactericidal against Gram-negative organisms, which are increasingly used as the 
last-line therapeutic options for treatment of infections caused by multidrug-resistant (MDR) 
Gram-negative bacteria, particularly Pseudomonas aeruginosa, Acinetobacter baumannii, and 
Klebsiella pneumoniae (26, 395). 
To understand the mechanisms of antibacterial activity of the polymyxins and their 
resistance, it is crucial to have knowledge of their chemical structures (217, 247). Polymyxins 
are cyclic lipopeptides that can be characterized by the general structure illustrated in figure 1. 
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Their decapeptide sequence contains an intramolecular cyclic heptapeptide loop between the 
amino group of the side chain of the diaminobutyric acid (Dab) residue at position 4 and the 
carboxyl group of the C-terminal threonine residue at position 10. Polymyxins also have 
several other distinguishing structural features, including: five nonproteogenic Dab residues, 
which makes them polycationic at pH 7.4; hydrophobic residues at positions 6 and 7; and an 
N-terminal fatty acyl group (238).  
 
Like many others antimicrobial peptides, the mixture of lipophilic and hydrophilic groups 
makes polymyxins amphipathic, a chemophysical property that is essential for their 
antibacterial activity (191, 238). Polymyxins are membrane surface-active proteins, which 
bind to lipid A, an important polymyxin-binding target in the outer membrane of Gram-
negative species (238). The mechanism of action of polymyxins is based on self-promoted 
uptake system and it was explain in detail by Robert E Hancock (217) and Martti Vaara (247). 
It purports that the amphipathic nature of polymyxins is crucial to enable uptake of the 
polymyxin molecule across the outer membrane barrier (216), also permitting the passage of a 
variety of molecules, including hydrophobic compounds and small antimicrobial proteins. 
 
Polymyxins are considered drugs of last resort because of their high neuro- and 
nephrotoxicity (236, 267, 396). In an attempt to counter this, a derivative from PMB, called 
polymyxin B nonapeptide (PMBN), was synthesized (246, 247). This derivative is 
characterized by the absence of the fatty acid tail and the N-terminal amino acyl residue Dab 
(Fig. 1). PMBN thereby lost the bactericidal activity of polymyxin B and is noticeably far less 
toxic (397-399). PMBN does, however, still possess endotoxin-binding activity via interacting 
with the anionic groups of LPS (400), although the deacylated derivative is also less active in 
its anti-endotoxin activity than that of its parent compound (401). By such interaction at the 
surface of viable Gram-negative bacteria, this nonapeptide facilitates the insertion of the 
membrane attack complex of the complement system into the bacterial membrane. In 
addition, the outer membrane-disorganizing effect of PMBN was described to enhance the 
permeability of the bacterial membrane for hydrophobic antibiotics (250, 255). 
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Fig. 1. Generation of polymyxin B nonapeptide. PMBN is obtained by proteolytic removal of the fatty 
acid tail of PMB.  Taken from (249). 
 
Surfactant protein A (SP-A) is a pulmonary collectin, which has been widely studied 
partly because of its antimicrobial properties in the lungs (12). Therefore, SP-A is able to 
aggregate, inhibit the grown and kill some microorganisms among Gram negative and 
positive bacteria, virus and fungi (18).  We have recently shown that one function of the 
surfactant protein A (SP-A) in the alveolar innate immune system is its ability to act 
synergistically with antimicrobial peptides (AMPs), facilitating the clearance of various lung 
pathogens, even if they are resistant to the direct antimicrobial activity of SP-A (chapter 1 and 
2). To this extent, we have seen that SP-A acted synergistically with cationic AMPs, both 
exogenous (PMB and colistin) and endogenous (HBD-2 and -3) presents in the alveolar fluid, 
leading to high bactericidal action against Klebsiella pneumonia K2 (which is resistant to SP-
A). In addition, is important to notice, that there is also a synergistic action between SP-A and 
SP-BN, which do not exhibit bactericidal activity alone at neutral pH. This synergistic action 
is possible because AMPs facilitate the binding of SP-A to bacteria (with which SP-A alone 
cannot interact), probably through a protein-protein interaction mechanism (chapter 1 and 2). 
Despite having lost their bactericidal capacity, PMBN maintains the ability to bind to 
bacterial outer membranes by interaction with LPS (400) and it is able to act collaboratively 
with complement proteins and other hydrophobic antibiotics (250), suggesting that PMBN 
could act in collaboration with SP-A. Moreover, we have shown that SP-A interacts with 
PMB increasing its antimicrobial activity, most likely through a of protein-protein interaction 
mechanism. Therefore, in this work, using a variety of biophysical techniques, we propose to 
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study the effect that these proteins together have on bacterial model membranes in order to 
determine the mechanism by which SP-A kills synergistically bacteria with polymyxins. For 
this purpose, we firstly evaluate whether the derivative from polymyxin PMBN could act in 
collaboration with SP-A to cause bacterial death, although none of them possesses 
bactericidal capacity separately.  
3. EXPERIMENTAL DESIGN 
For this work, we have used the exogenous CAMP polymyxin B nonapeptide, to 
investigate the mechanism by which SP-A and AMPs act synergistically. As mentioned 
before, PMBN is a derivative from polymyxin B, which lack of the acid fatty tail and is 
unable to kill bacteria but retains its ability to bind and disrupt bacterial OM. Then, the 
integrity and properties of bacterial model membranes of Re-LPS/BPL after incubation with 
SP-A and PMBN was assessed. First, we evaluated the potential synergistic killing of SP-A 
and PMBN against K. pneumoniae K2 and P. aeruginosa O1 by CFU count. In addition, to 
mimic condition of biophysical experiments, its synergy was also determined on K. 
pneumoniae K2 mutant expressing Re-LPS (Fig. 2).  
For the study of mechanisms of action, as used for the other AMPs, we firstly determined 
the ability of SP-A to bind to K. pneumoniae K2 in the presence of PMBN by solid-phase 
binding assay as well as the potential molecular interactions between SP-A and PMBN by 
DLS and changes in the intrinsic fluorescence of SP-A (Fig. 2). Next, we tested the ability of 
PMBN together with SP-A to insert into monolayers of Re-LPS by measuring increases in the 
surface pressure of the monolayer after addition of PMBN, SP-A or both.  
To obtain further information about mechanism of SP-A- and PMBN-promoted bacterial 
membrane disruption, we employed liposomes containing Re-LPS and bacterial phospholipid 
extract (BPL) composed of PE/PC/PG. Liposomes were prepared by mixed stocks solutions 
of the BPL and Re-LPS to achieve the desired Re-LPS/BPL ratio (80/20, w/w). Dry lipid 
films were hydrated in a saline buffer and allowing them to swell for 1h at a temperature 
above the transition temperature (Tm). After vortexing, the resulting multilamellar vesicles 
(MLVs) were used for measuring the thermotropic behavior of Re-LPS/PL vesicles in the 
absence or presence of both proteins by differential scanning calorimetry (DSC). Unilamellar 
vesicles, obtained by sonication of MLVs, were used for spectroscopic measurements to 
CHAPTER 3 
	  
167 
reduce light scattering artifacts. To determine membrane fluidity of bacterial model 
membranes in the absence and presence of SP-A and PMBN, the hydrophobic membrane 
fluorescent probes DPH as well as the amphiphilic fluorescent dye LAURDAN were used 
(Fig. 2). Changes in their fluorescence emission are indicative of membrane perturbation. 
Finally, the fluorophore ANTS and its collisional quencher DPX were co-encapsulated into 
Re-LPS/BPL or BPL vesicles to assess the ability of SP-A, PMBN or both to permeabilize 
bacterial model membranes by measuring the increase of the ANTS fluorescence after 
leakage of the aqueous contents by addition of a potential lytic peptide (Fig. 2) 
 
 
 
 
Fig. 2. Experimental design used in chapter 3. Fluorescent probes = DPH, LAURDAN, 
ANTX/DPX. DLS: dynamic light scattering; DSC: differential scanning calorimetry. BPL: 
phospholipid extract; LUVs: large unilamellar vesicle; MLVs: multilamellar vesicle. 
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4. RESULTS 
4.1. Synergistic activity of SP-A and PMBN  
Previous studies from our group showed that SP-A had no bactericidal activity against 
Klebsiella pneumoniae K2, but nevertheless was able to act synergistically with polymyxin B 
and colistin increasing their antimicrobial activity (chapter 1). In addition, it was also capable 
of acting in collaboration with SP-BN, an anionic antimicrobial peptide present in the alveolar 
fluid, against pulmonary pathogens resistant to SP-A, reducing the bacterial burden and 
increasing the early inflammatory response (chapter 2). Consequently, for this work, we 
firstly confirmed synergistic interaction between SP-A and PMBN against two Gram-negative 
bacteria, K. pneumoniae (serotype K2) and Pseudomonas aeruginosa O1 using an in vitro 
bacterial killing assay. As previously reported, neither SP-A nor PMBN possessed 
antimicrobial activity against Klebsiella or Pseudomonas (chapter 1,(247)). In contrast, we 
found that in combination, SP-A and PMBN effectively killed these two Gram-negative 
bacteria (Fig. 3A).   
Due to the difficulty of working with smooth LPS in vitro, to make bacterial model 
membranes we have used a rough LPS. Therefore, we tested the synergistic activity of SP-A 
and PMBN using an isogenic mutant of K. pneumoniae expressing deep rough LPS in its 
bacterial outer membrane. We have previously described that deep rough decapsulated strains 
of K. pneumoniae showed susceptibility to SP-A (chapter 1), which agrees with several 
studies showing that SP-A preferably interacts with bacteria expressing rough LPS (16, 17, 
131). To see the synergistic effect of both proteins, without any of them taking effect 
separately, it was necessary to decrease the concentration of SP-A. Thus, in figure 3B we can 
see that SP-A at 25 µg/ml did not have bactericidal effect on deep rough decapsulated strains 
of K. pneumoniae. Neither PMBN showed bactericidal effect by itself on this strain. 
However, PMBN and SP-A together demonstrated antimicrobial effect on this K. pneumoniae 
strain.  
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Figure 3.  SP-A and PMBN are able to kill synergistically Gram-negative bacteria expressing S 
LPS or Re LPS. A) 105 CFUs/ml of K. pneumoniae K2 (left graph) or P. aeruginosa PAO1 (right 
graph) were incubated with increasing concentrations of PMBN in the absence (black symbol) or 
presence (colored symbol) of 100 µg/mL of SP-A in 10 mM PBS (pH 7.2), 1% TSB and 100 mM 
NaCl for 1h at 37ºC and immediately plated on LB agar for CFUs count after 18h of incubation at 
37ºC. B) 105 CFUs/ml of K. pneumoniae K2 expressing Re-LPS were mixed with several 
concentrations of PMBN in the absence (black symbol) or presence (blue symbol) of 25 µg/ml SP-A 
in the same conditions above mentioned. Results are shown as % relative survival (percentage of live 
colony counts compared to untreated control). Bars represent mean ± SD (n=4, each one in duplicate), 
*p < 0.05, **p < 0.01 ***p <0.001 vs control. 
 
 
4.2. PMBN facilitates binding of SP-A to bacteria through a protein-protein interaction 
mechanism 
To gain insight into the mechanism by which SP-A and PMBN were able to act 
synergistically against K. pneumoniae, whereas neither of these proteins had bactericidal 
CHAPTER 3 
	  
170 
activity individually, we tested the ability of these proteins to bind to bacteria surface. It has 
been described that PBMN lacks antimicrobial activity, but retains its ability to bind to LPS 
(247). In this work, we have performed solid-phase binding assays to examine the ability of 
SP-A to bind K. pneumoniae wild type in the presence of PMBN. Bacteria were incubated 30 
min. with increasing concentrations of biotinylated SP-A (0 to 1.25 µg/mL) in the absence 
and presence of PMBN (1 µg/mL) or HSA (1 µg/mL) and then bacteria-associated SP-A was 
measured. As we previously reported (chapter 1), SP-A alone did not bind K. pneumoniae wt, 
even in the presence of HSA. However, SP-A was able to bind Klebsiella surface in the 
presence of PMBN in a dose-dependent manner (Fig. 4).  
 
Figure 4. SP-A interacts with K. pneumoniae 
K2 only in the presence of PMBN. Increasing 
concentration of SP-A were incubated with 107 
CFU of Kp wt in the absence (white symbol) or 
presence of PMBN 5 µg/ml (red symbol) or HSA 
5 µg/ml (black symbol) at room temperature for 
30 minutes. Total Klebsiella-associated SP-A 
was measured by solid-phase binding and 
expressed as total nanograms of SP-A/107 
bacteria. Error bars represent standard deviations 
from the mean of three experiments, each one in 
duplicate. 
 
 
To try to understand how PMBN facilitates the binding of SP-A to bacteria, we evaluated 
potential interaction between both proteins in solution by monitoring changes in the intrinsic 
fluorescence or in the hydrodynamic diameter of SP-A.  
Emission spectra for SP-A were recorded from 300 to 400 nm after excitation at 295 nm. 
It was characterized by a maximum at 338 nm (Fig. 5A), due to the contribution of two 
conserved tryptophan residues located at positions 191 and 213 of the globular COOH-
terminal domain (135). Addition of increasing concentrations of PMBN (0 to 200 µM) 
resulted in a concentration-dependent decrease in fluorescence intensity (Fig. 5A and 5B) of 
SP-A, indicating that there is an interaction between these proteins. Following the changes in 
fluorescence intensity as a function of PMBN concentration we could obtain a dissociation 
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constant for the SP-A/PMBN complex of Kd =0.26 ± 0.02 µM. The dissociation constant 
obtained is similar to that obtained for the SP-A/PMB complex (chapter 1), indicating that the 
binding between the SP-A and PMB does not take place through the fatty acid tail. In 
addition, the Hill coefficient value was greater than 1, indicating a positive cooperative 
binding. 
 
 
Figure 5.  SP-A interacts with polymyxin B nonapeptide. A) Representative graph of the 
fluorescence emission spectra of SP-A (15 nM, black line) measured with or without increasing 
concentrations of PMBN (0 to 200 µM, colored lines) at 25 °C in 5 mM Tris-HCl buffer (pH 7.4) 
containing 150 mM NaCl. B) Results are also expressed as F/F0 in each PMBN concentration at 
maximum emission of SP-A, where F is the observed intensity of SP-A and F0 is the observed 
intensity of SP-A+PMB. Results are means ± SD of 4 experiments.  
 
Interaction of SP-A and PMBN in solution was also determined by dynamic light 
scattering. These experiments were carried out with the same buffer of in vitro killing assay, 
even though self-aggregation of SP-A occurs in the presence of calcium and/or NaCl (136). 
SP-A alone showed two peaks, the major one corresponds to SP-A aggregates with a 
hydrodynamic diameter of 421.25 ± 37.54 nm (Fig. 6A) and another corresponding to higher 
SP-A aggregates with a hydrodynamic diameter of >1000 nm (data not shown). In contrast, 
PMBN showed a unique peak of 441.26 ± 57.63 nm (Fig. 6A).  
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Figure 6.  SP-A interacts with polymyxin B nonapeptide. Binding of SP-A and PMBN was also 
examined by DLS in 5 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl. A) DSL analysis of 
the hydrodynamic diameter of SP-A (15 nM) and PMBN (4 µM). B) DSL analysis of the 
hydrodynamic diameter of SP-A (15 nM) in the absence (black line) or presence (colored lines) of 
increasing concentration of PMBN (0-4µM). The y axis represents the relative intensity of the 
scattered light; the x axis denotes the hydrodynamic diameter of the particles present in the solution. 
  
It is known that PMB and PMBN have a different structure in solution that coupled with 
bacterial membrane. The solution structure of LPS-bound PMB was elucidated as an 
envelope-like fold of the peptide ring and a β-turn type II for the free peptide (238, 402). This 
structure of the free peptide could favor the formation of aggregates in solution, which would 
explain the size we get from DLS measurements. Figure 6B shows that the addition of 
increasing concentrations of PMBN (ranging from 0 to 4 µM) to a SP-A solution (15 nM) 
caused a PMBN concentration-dependent increase of the SP-A peak. This new peak, could 
exhibit a hydrodynamic diameter higher than that observed for SP-A or PMBN alone, 
depending on the PMBN concentration. These results are consistent with a cooperative 
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binding. Its important to notice that in the presence of SP-A, PMBN aggregates become 
dissociated and they hide their hydrophobic residues through its binding to the SP-A. 
Consequenlty, changes observed in SP-A size in the DLS would be due to the formation of 
different SP-A/PMBN complexes. 
Together, these data suggest that PMBN permits binding of SP-A to bacteria, probably 
through a protein-protein interaction mechanism, similarly to what happened with polymyxin 
B (chapter 1). 
 
 
4.3. SP-A increase PMBN insertion into Re LPS monolayers 
Studies involving lipid monolayers at the air/water interface, which mimic biological 
membranes, have been widely used for the study of protein-membrane interactions (403). The 
penetration of proteins into monolayers of Re-LPS gives information that can be significant to 
understand the mechanism of action of these proteins on the OM of Gram-negative bacteria. 
We tested the ability of SP-A and PMBN to insert into Re-LPS films by measuring the 
increase in the lipid monolayer surface pressure at a given initial pressure.  An increase in 
pressure (π) is indicative that protein is able to insert into the monolayer, resulting in a more 
tightly packed film. For these experiments, SP-A, PMBN or both were injected into the 
aqueous sub-phase of Re-LPS monolayers at several initial surface pressures (πi). Pressure 
increase was measured until equilibrium adsorption pressure (πe) (steady-state pressure after 
the addition of the proteins) is reached. By plotting the surface pressure increase induced by 
the insertion as a function of initial surface pressure  (Δπ = πe - πi), the maximum insertion 
pressure (MIP) for each protein can be obtained by extrapolation of the regression line to a 
surface pressure increase equal to zero. This pressure indicates the maximum πi above which 
no more protein molecules are able to penetrate into a membrane and increase surface 
pressure.  
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Figure 7. SP-A increases PMBN insertion into Re LPS monolayers. Re LPS monolayers were 
formed by spreading 10 µL of a concentrated solution of Re LPS  (1 mg/mL) at the air-water interface 
of the subphase buffer (5 mM Tris buffer, pH 7.4, 150 mM NaCl and 0.175 mM CaCl2) to give the 
indicated initial surface pressures (0 to 50 mN/m). PMBN (1 µg/mL), SP-A (1.25 µg/mL), or the 
mixture PMBN+SP-A was injected into the subphase and protein-induced changes in the monolayer 
surface pressure at constant surface area were measured using a thermostated Langmuir-Blodgett 
trough. Straight line was obtained by linear regression. 
 
 
Considering that the estimated lateral pressure for a biological membrane is between 30-
35 mN/m (404, 405), we can see in figure 7 that SP-A was not able to be inserted into a 
bacterial membrane where it reaches a MIP about 15 mN/m. Clausell et al. (239) described 
that PMB and different polymyxin B analogues are able to bind LPS, thus inserting between 
the molecules and expanding the lipid film. These experiments were performed at an initial 
pressure of 20 mN/m, which is lower than the estimated lateral pressure for biological 
membranes. We have extended these measurements for the PMBN, determining that it had a 
MIP value of 42 mN/m, indicating that PMBN would be able to insert into the bacterial outer 
membrane. When both proteins are together, the reaching MIP value is greater (51mN/m) 
indicating that SP-A is able to increase PMBN insertion into bacterial model membranes 
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4.4. PMBN and SP-A fluidize bacterial model membranes 
DPH fluorescence 
Given that PMBN inserts into bacterial model membranes, we investigated whether 
PMBN influences membrane fluidity using the highly hydrophobic fluorescent dye DPH. 
This probe is very sensitive to polarity and fluidity of the membrane. Its fluorescence 
decreases rapidly in the presence of water, indicating changes in membrane properties. 
Decrease in DPH steady-state anisotropy can be due by two reasons: i) a reduction of the lipid 
molecular order surrounding DPH and a consequent hastening in DPH rotational diffusion, 
which indicate fluidization; or ii) changes in DPH fluorescence lifetime and hence, changes in 
DPH steady-state fluorescence intensity, indicating membrane perturbation and water entry 
(406). Figure 8A shows that addition of increasing concentrations of PMBN to Re-LPS/BPL 
(8/2, w/w) unilamellar vesicles resulted in a significant decrease in the steady-state emission 
anisotropy of DPH incorporated in bacterial model membranes.  
 
 
 
Figure 8. PMBN and SP-A increase membrane fluidity. A) Effect of increasing PMBN 
concentrations on steady-state anisotropy of DPH embedded in Re-LPS/BPL vesicles (1 mg/mL). 
Values are expressed as means ± SD of 3 experiments. B) Representative graph of the effect of 
different amounts of PMBN on the fluorescence emission spectra of DPH in Re-LPS/BPL (1 mg/mL) 
vesicles upon excitation at 340 nm.  
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To find out the reason by which PMBN decreases DPH steady-state anisotropy in Re-
LPS/BPL (8/2, w/w) vesicles, we determined the effect of different amounts of PMBN on the 
fluorescence emission spectra of DPH in Re LPS/BPL (8/2, w/w) vesicles upon excitation at 
340 nm. The lack of changes in the fluorescence emission of DPH with increasing amounts of 
PMBN (Fig. 8B), allows us to infer that PMBN decreases the lipid order of these bacterial 
model membranes. 
LAURDAN fluorescence 
To further examine whether PMBN affects membrane properties near the bilayer surface, 
we used the amphiphilic fluorescent dye LAURDAN. This probe is localized near the polar 
head groups of lipids and displays high sensitivity to the polarity of its environment, this is, 
its fluorescence emission intensity and maximum emission wavelength depends on the 
number and/or mobility of water molecules present at the membrane interface (341, 407). 
When the local environment of LAURDAN is a membrane, its emission depends strongly on 
the packing of the lipid chains. At temperatures below the phase transition (gel state), the 
emission maximum is near 440 nm. At temperatures above the phase transition (liquid 
crystalline state), the emission maximum is red-shifted to 490 nm (341).  
The steady-state fluorescence parameter known as the LAURDAN generalized 
polarization (GP) quantitatively relates LAURDAN spectral changes by taking into account 
the relatively fluorescence intensities of the blue and red edge regions of the emission and 
excitation spectra, respectively (341). 
Figure 9A shows that the emission spectrum of LAURDAN in Re LPS/PL vesicles (8/2, 
w/w) in the absence of PMBN showed a maximum centered at 440 nm, denoting that these 
membranes contain a high percentage of ordered phase. Addition of increasing PMBN 
concentrations caused a decrease in the fluorescence emission intensity at 440 nm and a red 
shift of the spectra. Figure 9B shows that the LAURDAN GP values decreased with 
increasing PMBN concentrations. This clearly indicates that PMBN is fluidizing these 
bacterial model membranes. 
Additionally, pre-incubation of 50 µg/ml of PMBN with different SP-A concentrations 
before addition to Re LPS/PL vesicles (8/2, w/w) resulted in a higher decrease of LAURDAN 
GP values with respect to those obtained with PMBN alone (Fig. 9C). This indicates that the 
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fluidizing activity of PMBN is enhanced in the presence of SP-A, which is consistent with 
DPH data.  
 
 
 
Figure 9. LAURDAN fluorescence to ascertain PMBN- and SP-A-fluidizing effects on Re 
LPS/PLliposomes. A) Representative graph of the effect of increasing PMBN concentration on the 
fluorescence emission spectrum of LAURDAN embedded in Re LPS/PL vesicles at 25 ºC. B) Effect 
of increasing PMBN concentrations on the GP values of LAURDAN. C) GP values of LAURDAN 
embedded in Re LPS/PL vesicles after addition of PMBN (50 µg/mL) in the absence or presence of 
increasing concentrations of SP-A (1, 5 and 10 µg/mL). Inset graph shows the representative graph of 
the effect of increasing SP-A concentrations on the fluorescence emission spectrum of LAURDAN.  
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DSC measurements  
For a more detailed analysis of the thermotropic properties, DSC experiments were 
performed with Re LPS/PL (8/2, w/w) in the absence and presence of PMBN at different 
concentrations. The thermal transition of Re LPS/PL (8/2, w/w) was characterized by gel to 
fluid main transition temperature (Tm) of 22.54 ± 0.43 ºC and a transition enthalpy of 2.81 ± 
0.98 kcal/mol (Fig. 10A). Addition of increasing amount of PMBN (1.25 µg/mL to 96 
µg/mL) caused a decrease in the main transition temperature of these membranes until it is 
completely abolished at 96 µg/mL (Fig. 10A and Table 1). This is probably indicating a 
destabilization of the gel phase. Additionally, at a concentration of 1.25 µg/mL of PMBN, a 
shoulder in the endotherm was observed. Brandenburg et al. have observed something similar 
with Re LPS in contact with polymyxin B, and have suggested a demixing of the phase due 
the formation of endotoxin-peptide clusters (408). 
  
Figure 10. PMBN decreases the main transition temperature of Re LPS/PL multilamellar 
vesicles. A) Effect of PMBN on DSC heating scans of Re LPS/BPL liposomes (8/2, w/w). B) 
Multilamellar vesicles were also studied in the presence of 1 µg/mL SP-A alone (red line),1.25 µg/mL 
PMBN (dark red line) or both (blue line). Calorimetric scans were performed at a rate of 0.5°C/min. 
Three consecutive scans were recorded for each sample. One representative experiment of 3 is shown. 
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In contrast, when SP-A was added to Re-LPS/BPL (8/2, w/w), no SP-A-induced effects 
on the Tm were observed (Fig. 10B). This might be because at this concentration of SP-A (1 
µg/ml) there are electrostatic repulsions between negative charges in the SP-A surface and the 
negatively charged Re LPS molecules, which would prevent the interaction of the protein 
with Re LPS (30). Finally, in figure 10C we can see that the effect of PMBN over Re LPS/PL 
(8/2, w/w) membranes was higher in the presence of SP-A. This thermal phase transition was 
also characterized by a complex double-peak due to electrostatic interactions between the 
positively charged PMBN and the anionic LPS, but it is more shifted to lower temperatures, 
indicating that PMBN/SP-A fluidized bacterial model membranes more than PMBN alone.  
 
Table 1: Thermodynamic data of  MLV (0.5mM) composed of Re LPS/PL (8/2, w/w) in the 
absence or presence of  increasing concentrations of PMBN (1.25, 27, 54 and 96 µg/mL). 
 
Data are means ± SD of 3 experiments.  
 
4.5. Ability of SP-A and PMBN to destabilize and permeabilize inner and outer 
bacterial model membranes 
DPH fluorescence 
As mentioned before, DPH fluorescence is very sensitive to the polarity of the membrane 
environment. This probe has a low quantum yield and a very short lifetime when exposed to 
water. Thus, its fluorescence is sensitive to the amount of water that penetrates into the lipid 
bilayer. Thus, we found that addition of increasing concentrations of SP-A causes a decrease 
in the fluorescence intensity of DPH membranes inserted in Re-LPS/BPL (8/2, w/w) (Fig. 
11A), due to water penetration in the Re-LPS bilayer as a consequence of SP-A-induced Re 
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LPS membrane destabilization (30). As seen in Figure 9B, this destabilization of bacterial 
model membrane is greater in the presence of PMBN, which alone does not decrease DPH 
fluorescence (Fig. 11B). 
 
Fig. 11. A) Representative graph of the effect of different amounts of SP-A on the fluorescence 
emission spectra of DPH in Re-LPS/BPL (1 mg/mL) vesicles upon excitation at 340 nm. B) Effect of 
increasing concentrations of SP-A on fluorescence intensity of DPH embedded in Re-LPS/BPL 
vesicles (1 mg/mL) in the absence and presence of PMBN (50 µg/mL). Values are expressed as means 
± SD of 3 experiments. 
 
Leakage of ANTS/DPX probes  
We have seen how the two proteins are capable of insert into bacterial model membranes 
and destabilize them when they are together. The next step is to see if the destabilization 
arising in the membrane is sufficient to produce bacterial permeabilization and death. 
Experiments were performed to characterize the direct permeabilizing effects of SP-A 
and/or PMBN on liposomal membranes composed of bacterial phospholipids (BPL) in the 
presence and absence of Re-LPS. Unilamellar vesicles were loaded with a set of self-
quenching probes (ANTS and DPX), which fluorescence as they diffuse apart. Experiments 
were performed with vesicles composed of BPL (PE/PG/CL) or Re-LPS/PL (8/2, w/w) as 
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models of inner and outer bacterial membrane, respectively. Triton-X100 was used as positive 
control of membrane permeabilization. 
We have seen that SP-A was able to destabilize bacterial model membranes, probably 
because favored the penetration of water molecules in Re-LPS membranes, disturbing Re-
LPS acyl chain packing by taking up Re-LPS molecules from the membrane (30). Although, 
this membrane perturbation is insufficient to cause membrane permeabilization (neither inner 
nor outer membrane), as we have seen by leakage experiments (Fig. 12 and 13). 
 
 
 
Figure 11. SP-A and PMBN synergistically induce membrane permeability of liposome 
mimicking bacterial OM. A) Representative graph of the fluorescence emission spectrum of ANTS 
after the exposure of Re-LPS/BPL vesicles (mimicking the OM of bacteria) to SP-A (25 µg/mL)+ 
PMBN (50 µg/mL) or TX100 (positive control). Experiments were performed in the presence of 0.150 
mM CaCl2. B) Changes in ANTS fluorescence during time. The arrow marks the moment when SP-A, 
PMBN or SP-A/PMBN were added.  
 
The fact that the SP-A was unable to permeabilize the inner membrane coincides with the 
data obtained by Kuzmenko et al (17) where they found that incubation of 100 µg/ml of SP-A 
with liposomes composed of POPE alone resulted in no changes from the background level of 
fluorescence. However, Kuzmenko and coworkers found SP-A was able to permeabilize 
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bacterial model membranes containing Re LPS in a calcium dependent way (17). Probably, 
the differences observed between our results were due to the calcium concentration that we 
have used in our experiments was very low (0.150 mM), in order to not interfere in the 
activity of PMBN, which is proposed to compete with LPS-bound calcium ions, to bind to 
and destabilize LPS adjacent molecules (396). 
Furthermore, while PMBN (50 µg/ml) was unable to permeabilize the bacterial outer 
membrane composed of Re-LPS/BPL (8/2, w/w) (Fig. 11), it was able to permeabilize 
vesicles mimicking inner membrane of Gram-negative bacteria (non-containing LPS), 
indicating that LPS confers protection to PMBN activity. According to equation 5, we could 
estimate that incubation with PMBN resulted in a 44.6 % of leakage, relative to triton-X100 
(100%) (Fig. 12).  
 
 
 
Figure 12. PMBN increase membrane permeability of liposome mimicking bacterial inner 
membrane. A) Representative graph of the fluorescence emission spectrum of ANTS after the 
exposure of BPL vesicles (mimicking the inner membrane of bacteria) to SP-A (25 µg/mL)+ PMBN 
(50 µg/mL) or TX100 (positive control). Experiments were performed in the presence of 0.150 mM 
CaCl2. B) Changes in ANTS fluorescence during time. The arrow mark the moment where SP-A, 
PMBN or SP-A/PMBN were added.  
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As we see in figure 11 the combined action of the two proteins (SP-A and PMBN) is 
required to produce bacterial outer membrane permeabilization (Re LPS/PL [8.2, w/w]), 
obtaining a 51.5 % of leakage. Furthermore, the combined action of both proteins did not 
improve the PMBN permeabilizing capacity on bacterial inner membrane (Fig. 12). 
5. DISCUSSION 
The global emergence of multidrug-resistant bacteria is an important clinical problem 
that is increasingly limiting the use of currently known antibiotics. This is related to the 
mechanism of action of traditional antibiotics, with five main specific targets: cell-wall 
synthesis, DNA gyrase, metabolic enzymes, RNA polymerase and protein synthesis (409). 
Bacteria can develop genetic resistance toward these mechanisms of action. The actual 
mechanism of action for PMB and its derivate is not yet fully understood but has been 
proposed to involved the formation of molecular contacts between the inner and outer 
membranes of the bacteria and the induction of lipid exchange, thus resulting in loss of the 
compositional specificity of the membranes and osmotic instability (410, 411). It is extremely 
difficult for the bacteria to generate genetic resistance to such a physical mechanism of action 
based on ionic and hydrophobic interactions. In fact, resistance to polymyxins is rare (412, 
413), a reason that explains the renewed interest in its clinical use (26, 395, 414). Although 
PMB is bactericidal to MDR Gram-negative bacteria and able to neutralize the toxic effects of 
released LPS, its therapeutic applications are very limited because of its relative high toxicity 
(415, 416). Because most of the toxic activity of PMB resides at the N-terminal fatty amino 
acid 6-methylheptanoic/octanoic-Dab, the removal of this segment by proteolytic cleavage, 
generated a nontoxic peptide named polymyxin B nonapeptide (399). 
PMBN is extremely poor antimicrobial compound, but it is still capable, like PMB, of 
binding to LPS (400). The binding of PMBN to LPS is therefore independent of the lipophilic 
acid tail of PMB and may be mediated by two processes: electrostatic interactions between 
the positives charges of the PMBN and the negative charges of the phosphates of LPS, and 
hydrophobic contacts of the D-Phe-Leu with the hydrophobic core of the lipid A moiety of 
LPS (238, 239, 402). 
Once PMBN is bound to its target, LPS, is able to disturb the bacterial membrane. It is 
commonly referred that the PMBN has “sensitizing activity”, thus rendering Gram-negative 
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bacteria susceptible to various hydrophobic antibiotics (246, 250, 417) against which the 
intact outer membrane is an effective barrier. A clear example of this was described by Ofek 
and coworkers who showed that PMBN was able to protect mice challenged with Klebsiella 
pneumoniae in combination with erythromycin (253). This ability for disturbing bacterial 
outer membrane points at a novel therapeutic direction. 
In this work we have studied the mechanism by which PMBN alters the bacterial outer 
membrane allowing it to act synergistically with other antimicrobial agents like SP-A. 
Although neither SP-A nor PMBN possess bactericidal activity against Pseudomonas 
aeruginosa or Klebsiella pneumoniae, in this chapter we show that they are able to act 
synergistically to produce bacterial death (Fig. 2) and we move into its mechanism of action. 
PMBN binds to LPS and is capable of insert at least partially into the bacterial outer 
membrane (Fig. 7). However, these processes are insufficient to permeabilize bacterial model 
membranes (Fig. 11), but might be sufficient to sensitize them. PMBN interaction with the 
membrane would give rise to the formation of clusters of PMBN/LPS as seen by calorimetry 
(Fig. 10). This would lead to destabilization of the gel phase becoming the bacterial 
membranes more fluid, which corroborates the data obtained by fluorescence anisotropy of 
DPH and GP of laurdan (Fig. 8A and 9A and B). It must take into account that every 
biological membrane has a certain fundamental biophysical characteristics for the 
performance of its functions (11, 144). Thus, changes in the lateral structure or fluidity of the 
membrane may be sufficient to sensitize it and turn it weaker to other antimicrobial agents. 
Besides being able to sensitize membranes against other agents, PMBN has another very 
important role, facilitating the binding of SP-A to bacteria. As we have seen in chapter 1 of 
this thesis, SP-A was unable to bind to Klebsiella pneumanie wild type. However, SP-A is 
capable of binding to bacteria in the presence of PMBN (Fig. 4), possibly through protein-
protein interaction mechanism (Fig. 5 and 6). Binding of SP-A to PMBN appears to be the 
first important step of their synergistic activity. Interaction of collectins, like SP-A and SP-D, 
with a variety of host defense molecules has been reported (13). SP-A is able to bind to beta-
defensins and polymyxins (chapter 1;(367)) while SP-D, has been reported to interact with 
alpha-defensins and LL-31 (361, 382). Now we have described that SP-A binds to PMBN, 
with a Kd which is very similar to that obtained for the SP-A/PMB complex (Chapter 1), 
showing that the fatty acid tail of PMB is not involved in its binding to the SP-A. SP-A-bound 
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PMBN would retain its ability to bind LPS, thus allowing SP-A access and binding to inner 
targets in OM, as lipid A, the main target of SP-A in Gram negative bacteria (192). Thus, SP-
A could overcome one of the most important factors involved in resistance to SP-A, Smooth 
LPS (16, 418) (chapter 1), in order to add in outer membrane permeabilization. 
Once SP-A comes in contact with the bacterial membrane, it has been reported to favor 
the penetration of water molecules in Re LPS membranes and to cause a sharp decrease of the 
overall transition enthalpy of these membranes (30). As we have seen, SP-A is unable to 
insert into Re-LPS membranes, probably because it is a large oligomeric protein (Fig. 7). 
Thereby, the observed changes must be due to protein-induced perturbation of the lipid 
packing, as we have demonstrated by the decrease in the fluorescence intensity of DPH 
induced by SP-A on bacterial outer model membranes. SP-A has been shown to extract LPS 
molecules of the membrane and to form supramolecular lattice-like protein-LPS aggregates in 
the bacterial membrane surface (30) that could explain the changes observed in bacterial 
membranes, and might be the initial step of its outer membrane disturbance, which was higher 
in the presence of PMBN. Despite this, SP-A alone was also unable to permeabilize bacterial 
model membranes (Fig. 11).  However, SP-A was able to act in collaboration with PMBN, 
enhancing even more the instability of the membrane caused by this peptide. SP-A increased 
peptide insertion into the membrane, probably favored by the extraction of LPS (Fig. 7) and 
the increase in fluidity caused by PMBN (Fig. 8-10), thus leading to the permeabilization of 
the bacterial OM (Fig. 11).   
Once the OM has been permeabilized, PMBN could translocate into the periplasmic 
space and from there, as seen above, permeabilizes the inner membrane (Fig. 12). Finally, 
PMBN would promote cell death by disruption of this membrane or/and translocation into the 
cytoplasm and interaction with intracellular targets. In addition, given that microbial cell 
membranes are responsible for multiple and essential functions (191), it is also likely that SP-
A add in killing bacteria, not only by increasing PMBN access through OM, but also by 
collaborating in OM destabilization, resulting in irreversible disruption in these vital 
functions. 
In this chapter, we have tried to approach into the mechanism by which SP-A and PMBN 
are capable of producing the death of Gram-negative bacteria, when separated neither of them 
can. We conclude that the binding between the two proteins may facilitates the interaction of 
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SP-A with the bacterial membrane. Once on membrane surface, both proteins increase its 
insertion, at least partially, leading to changes in the biophysical properties of the membranes, 
thus promoting membrane permeabilization and eventually bacterial death. There are still 
many unknowns in this process. We do not know if SP-A or PMBN cause permeabilization 
after the other factor weakened the bacterial OM or it is a combination of the membrane 
alterations produced by both proteins. Probably it would be necessary make more experiments 
about this. In any case, the fact that there is synergy with SP-A, causes that PMBN become 
relevant within the therapeutic field and could be used instead of PMB as a drug of last resort 
in the fight against MDR organisms such as Klebsiella pneumoniae. 
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The purpose of this doctoral thesis was to further investigate the antimicrobial role of SP-
A in airway host defense. The main finding of this thesis is that SP-A is able to protect host 
against infection by synergistic actions in the alveolar space, thus strengthening the 
antimicrobial potential of the lungs. Additionally, we elucidated some of the factors of 
bacterial resistance to SP-A as well as the mechanism by which SP-A act cooperatively with 
AMPs to kill bacteria. Therefore, our findings provide new insights to better understanding 
the complex role of this multifunctional protein during infection. 
SP-A is a pulmonary collectin with an essential role in host defense against infection. 
Bacterial agglutination and increase of phagocytosis are among the main roles of SP-A in 
innate host defense, as seen by extent in vitro evidences (12). Multiple reports have been 
published in which SP-A is able to bind and enhance phagocytosis of Gram-negative bacteria, 
including: 1) Escherichia coli J5 and K12 (19, 329), deep rough mutant strains; 2) mucoid 
and flagellated strains of P. aeruginosa (419), but not others isolates of P. aeruginosa (420, 
421); 3) Klebsiella pneumoniae strains expressing capsular serotype K21, but not K2 (147); 
4) and type a but not type b Haemophilus influenzae (148, 420). In addition, SP-A also 
enhances macrophages uptake of Gram-positive bacteria, such as Staphylococcus aureus 
(149, 422), Streptococcus pneumoniae (151) or Group A and B Streptococcus (420). The 
potential in vivo role of SP-A in innate defense, supported by in vitro findings, was proved 
once SP-A gene-targeted mice were successfully generated (137, 174). These mice were then 
infected with several of these respiratory pathogens showing more susceptibility than wt mice 
to these bacteria (18).  
After initial findings as opsonin, SP-A was then reported to directly kill Gram-negative 
bacteria in vitro (16) and ex vivo (14) by increase membrane permeabilization. SP-A showed 
preference by bacteria expressing rough LPS phenotype, including E. coli K-12 and J5, beside 
other rough strains of E. coli (16). SP-A was found to kill, aggregate and enhance 
phagocytosis only rough mutants of Bordetella pertussis and Bordetella bronchiseptica, 
unlike the wild-type strains, which was resistant to these activities (24). Comparative 
signature-tagged mutagenesis on Pseudomonas showed that mutants with reduced LPS and 
low outer membrane integrity were susceptible to SP-A membrane permeabilization, unlike 
the other ones (19). In the present thesis, we confirmed these previous studies in Klebsiella 
pneumoniae, a common Gram-negative bacterium that infects the respiratory tract of immune 
compromised patients, which only was susceptible to SP-A when was mutated to deep rough 
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LPS nonexpressing CPS. Thus, SP-A was only able to aggregate, kill and enhance 
phagocytosis of decapsulated Klebsiella mutants expressing deep rough Rc and Re LPS, 
indicating that truncated LPS up to inner core on K. pneumoniae made bacteria susceptible to 
SP-A.  
On the other hand, reports of bacterial killing activity of SP-A on bacteria with S-LPS 
phenotype are sparse. SP-A exhibited antimicrobial activity against two Enterobacter 
aerogenes species and two Klebsiella pneumoniae clinical isolates (with unknown serotype), 
all of them expressing smooth LPS (16). SP-A bound to and inhibited the growth of 
Legionella pneumophila, a respiratory pathogen that express S LPS and can replicate within 
human alveolar macrophages (184). In our case, SP-A did not have any activity against 
Klebsiella wt, which express S LPS and CPS. Accordingly, there are several reports of 
bacteria expressing S LPS that have been resistant to SP-A, including the mentioned 
Bordetella species, Pseudomonas aeruginosa (which also express exoproteases that are able 
to degrade SP-A) (19, 197) and E. coli O111 (16, 329). On the other hand, there are no reports 
of SP-A killing on several bacteria in which SP-A has been shown to interact and/or to 
enhance phagocytosis or clearance in vivo, such as K. pneumoniae, H. influenzae, S. aureus or 
Group B Streptococcus; suggesting that opsonization by SP-A may be not always linked to its 
direct bacterial action. 
A number of microbial surface components have been shown to be ligands for SP-A. For 
instance, SP-A binds to P2 outer membrane protein, found on particular H. influenza species 
(148), and flagellin, the major structural protein of the flagella of P. aeruginosa (421), thus 
enhancing phagocytosis of these pathogens. However, flagellum of Pseudomonas has been 
also reported to confer clearance resistance in vivo to SP-A, since mutants lacking flagella 
were attenuated in SP-A+/+ mice, but survived in SP-A KO mice (185). On the other hand, 
several studies involving LPS isolated from smooth and rough bacteria revealed that the main 
target ligand of SP-A in Gram-negative bacteria appears to be in the LPS membrane (13). SP-
A only bound to deep rough LPS, mainly through the lipid A, which is anchored in the outer 
leaflet of the outer lipid bilayer (131, 159, 192). In contrast, SP-A did not associate with 
smooth forms of LPS. This is consistent with our studies, since SP-A only bound to deep 
rough Klebsiella mutants, in which it had antimicrobial activity. In addition, SP-A has been 
shown to interact only with specific capsular polysaccharide of some K. pneumoniae 
serotypes expressing manose-α2/3-manose sequence (serotype K21), unlike our bacteria of 
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study, which express capsular serotype K2 and lacks of this sequence (147). In fact, it is 
though that Klebsiella serotypes, which do not express this sequence, are more virulent 
because they are able to avoid the antimicrobial activity of lectins (like SP-A) and 
macrophages, since they are not recognized by these immune components (196).  
Even though SP-A is unable to act against Klebsiella pneumoniae K2, SP-A KO mice have 
been shown to be more susceptible to this bacterium (176). In addition, these mice also 
exhibited delayed microbial clearance after intratracheal inoculation of P. aeruginosa (20), 
bacterium resistant to SP-A in vitro (19, 185, 197). One explanation of these disparate results 
is likely because SP-A have been shown to exert a multiple roles during infection, such as 
increase of phagocytosis or immunomodulation.  Thus, deficiency on SP-A could decrease 
some of these functions. It is also possible that respiratory pathogens display OM 
heterogeneity during infection (smooth or rough LPS, with or without CPS) depending on its 
needs to infect the host (423-425), which could make bacteria susceptible to SP-A bactericidal 
activity in vivo. On the other hand, clinical isolate used in several studies could have 
molecular adaptations that increase their resistance to antimicrobial activity of SP-A, such as 
expression of a more complex OM or proteases. In this thesis, we approached another 
possibility, regarding to a potential role of SP-A to cooperate with another antimicrobial 
factors of the alveolar space, in order to aid in killing bacteria to overcome infection.  
The microbicidal role of SP-A in vivo, where it shares location with another antimicrobial 
factors and surfactant phospholipids (to which SP-A is intimately associated), has been 
suggested by studies involving macrophages-free bronchoalveolar lavages from SP-A +/+ 
mice, which showed a greater bactericidal effect than lavages from SP-A -/- mice (14). In 
addition, since several bacterial strains showed resistance to SP-A in vitro, bacterial killing 
activity of SP-A in vivo was proposed to require the combinatorial interactions with other 
antimicrobial defenses in the airspace (16). In this sense, several reports have suggested the 
importance of cooperative interaction between antimicrobial factors of the alveolar space in 
order to strengthen the microbicidal activity of each factor alone. It has been found that AMPs 
representing each of the structural classes found in mammals demonstrated combinatorial 
activity against representative human pathogens (300). Lactoferrin and lysozyme acted 
synergistically in combination, while HBD-2 and human cathelicidin LL-37 demonstrated an 
additive action against E. coli (22). Likewise, it has also found synergistic activity in triple 
combinations of lysozyme, lactoferrin, and the proteinases inhibitor secreted by leukocytes 
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(22). In addition, SP-A and SP-D has been shown to have additive neutralizing activity with 
LL-37 against influenza A viruses susceptible to SP-A (382). 
Therefore, in the present thesis, we found that SP-A was able to act synergistically with 
endogenous components of the innate system, including the cationic AMPs β-defensin 2 and 
3 as well as the recently discovered anionic AMPs SP-BN. In the latter case, SP-A and SP-BN 
showed combinatorial bactericidal activity at neutral pH, whereas none of them had 
antimicrobial activity individually; and enhanced macrophages-mediated phagocytosis. In 
addition, we found that SP-A+SP-BN treatment in wt mice was more protective against K. 
pneumoniae K2 infection than administration of proteins individually. Thus, our findings 
indicate that SP-A is able to enhance host innate defense against infection, even on bacteria 
capable of escape from SP-A antimicrobial activity.  
The ability of SP-A, together with AMPs, to enhance clearance of K. pneumoniae in vivo 
seems to be also in connection with their capability to modulate host inflammatory response, 
since SP-A and SP-BN were able to enhance early immune response to Klebsiella. SP-A and 
SP-BN enhanced the expression of several pro-inflammatory cytokines, which are widely 
implicated in host response to infection (TNF-α, IL-1β, -6) (72), and specially, to K. 
pneumoniae one (IL-17) (383); as well as the expression of an important chemokine 
implicating in neutrophils recruitment, MIP-2 (384). Consequently, SP-A and SP-BN 
promoted an increase in early neutrophil recruitment in bronchoalveolar lavage fluid during 
infection with Klebsiella, which was greater in combination. In contrast, instillation of SP-A 
and SP-BN in uninfected mice only promoted a minimal inflammation (data not shown).  
Although data supporting the role of SP-BN in inflammation are sparse, anionic AMPs 
have been shown to induce cytokine and chemokine production. Dermcidin is an 
antimicrobial peptide secreted into sweat, which shares some features with SP-BN, such as 
anionicity, antimicrobial activity at acidic pH and constitutive expression (385). Dermcidin-
derived peptides have been shown to activate normal human keratinocytes by inducing pro-
inflammatory and chemoattractive mediators (386). In addition, AMPs have been reported to 
promote chemotaxis (8), both indirectly by stimulating the expression of well-known 
chemokines, like CXCL8/IL8 and CCL2/MCP1(227); and directly by acting as chemokines 
themselves to recruit a variety of immune cells (229). On the other hand, even though the 
main role of SP-A in inflammation appears to be anti-inflammatory (18), it has been also 
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shown to increase inflammation (13). SP-A stimulates production of pro-inflammatory 
cytokines during the early phase of lung injury (387). SP-A enhances chemotaxis of 
inflammatory BAL neutrophils toward chemokines such as MIP-2 (167) or the stimulation of 
neutrophil chemotactic factors release (168). In addition, influx of neutrophils into 
bronchoalveolar lavage fluid and pro-inflammatory cytokine expression was enhanced after 
exogenous administration of SP-A in mechanically ventilated preterm lambs (169). The 
majority of studies involving the pro-inflammatory role of SP-A have been performed with 
nonresident alveolar macrophages, unlike studies showing its anti-inflammatory role, which 
might indicate that SP-A exert several roles on inflammation depending of the target cell. 
The collaboration between antimicrobial factors in the alveolar space might also depend on 
the bacterial pathogen or toxin that is attacking the host. Evidence indicated that Klebsiella 
infections are characterized by lacking an early inflammatory response, because K. 
pneumoniae antagonizes the activation of NF-kB in order to subvert the host inflammatory 
response in its own benefit (388, 389). In addition, several reports have demonstrated that 
activation of an inflammatory response is essential to clear Klebsiella infections (383, 390, 
391). In our case, SP-A and SP-BN seem to counteract the anti-inflammatory response 
induced by this bacterium, since mice treated with both proteins showed an increase in early 
inflammation and neutrophils recruitment. In fact, studies involving mice infected with K. 
pneumoniae have found that the marked reduction of bacterial loads in response to the AMP 
α-defensin-1 is attributed to the increased accumulation of leukocytes at the site of infection 
(393). Therefore, our data suggest that SP-A/SP-BN treatment might enhance endogenous 
protective mechanisms to aid in the clearance of Klebsiella. Thus, SP-A and AMPs could 
collaborate in vivo to immunomodulate host immune response during infection. 
On the other hands, to the recently appearance of multi-drug resistant (MDR) Gram-
negative bacteria without new effective antibiotic non-toxic (100), we also found that SP-A is 
able to act synergistically with the exogenous cationic AMPs polymyxins against three 
respiratory pathogens. Thus, SP-A enhanced the bactericidal effect of two potent, but 
cytotoxic, exogenous antibiotic peptides, PMB and colistin against K. pneumoniae, P. 
aeruginosa and non-typable Haemophilus influenzae. Both polymyxins have been shown to 
enhance OM permeability to lipophilic and amphiphilic antibiotics like rifampin, macrolide 
antibiotics, fusidic acid and novobiocin, and kill MDR bacteria very efficiently (26). For this 
reason, and due to their associated toxicity for the patient, they are currently re-used as the 
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last resort against infections by MDR microorganisms in clinic (396). Since this toxicity has 
been suggested to be dose dependent (236), the combinatorial use with SP-A would allow the 
use of a lower concentration of polymyxins, reducing their toxicity without decreasing their 
bactericidal effect. Additionally, SP-A showed the same combinatorial effect with polymyxin 
B nonapeptide (PMBN), a derivative from polymyxin B, which lacks of antimicrobial activity 
but retains the polymyxin ability to bind bacterial outer membrane (OM) (246). As PMBN by 
itself has a lower toxicity than PMB and colistin, the use of SP-A in conjunction with PMBN 
could be very effective to treat infection by MDR bacteria.  
The mechanism of action by which SP-A enhances the antimicrobial activity of these 
AMPs is still unknown. In the present thesis, the major finding regarding this part is that SP-
A and AMPs might kill bacteria synergistically because SP-A/AMPs are able to promote 
changes on bacterial OM structure and permeability through a protein-protein interaction 
mechanism. Consistent with that, we elucidated some steps of the antimicrobial synergistic 
activity of these proteins.  
Through several experimental approached, we found that the first step of their 
combinatorial activity seems to be the interaction between both factors, which allow SP-A 
binding to bacteria. Thus, SP-A was able to bind to human beta-defensin-3 (HBD-3), SP-BN 
(Kd=0.39±0.3 µM), PMB (0.32 ± 0.04 µM), and PMBN (Kd =0.26 ± 0.02 µM) in a dose-
dependent manner, thus increasing its interaction with K. pneumoniae K2, a bacterium that is 
not recognized by SP-A (147). Interaction of collectins, like SP-A and SP-D, with a variety of 
host defense molecules has been reported (13). SP-A, unlike SP-D, bound to β-defensins 
(367). In addition, SP-D, but not SP-A, has been reported to interact with α-defensins and LL-
31 (361, 382). They showed several effects, from additive or antagonist (361, 382) to anti-
cytotoxicity ones (367), suggesting complex interactions between these factors. In our case, 
SP-A and AMPs binding had a synergistic effect and seems to be essential for this activity. 
Taken together, we found that AMPs facilitated the binding of SP-A to Klebsiella, probably, 
through a protein-protein interaction mechanism.  
The antimicrobial activity of cationic AMPs (CAMPs) has been shown to required three 
commons and independent steps, including peptide attachment; peptide insertion and 
membrane permeabilization; and cell death (15). The most accepted mechanism of peptide 
attachment to bacterial membrane is the initial electrostatic interactions between cationic 
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residues of the peptides and negatively charged structures of the bacterial surface, in order to 
gain access to the outer lipid bilayer, in Gram-negative bacteria. Thus, CAMPs are able to 
promote displacement of divalent cationic ions (Ca2+), which maintain CPS and LPS 
molecules of the OM closely packed. These displacements then promote disorganization of 
the bacterial LPS (191, 216). It is possible that the LPS-disorganizing and -binding ability of 
CAMPs allow SP-A access and binding to inner targets in OM, as lipid A, the main target of 
SP-A in Gram negative bacteria (192). Thus, SP-A could overcome one of the most important 
factors involved in resistant to SP-A, smooth LPS (16, 19, 24), in order to add in OM 
permeabilization. In the case of synergistic activity with SP-BN, not only SP-A but also SP-BN 
was unable to bind to Klebsiella at neutral pH separately. In contrast, SP-A was able to 
enhance its interaction in the presence of SP-BN, which only bind to Klebsiella and has 
activity at acidic pH. Several anionic AMPs have been shown to use metal ions to form 
cationic salt bridges with negatively charged components of microbial membranes (212). In 
addition, SP-BN and amaebopores have been proposed to permebealize bacterial membranes 
in a pH- and oligomerization-dependent manner (6, 294, 426). Thus, it is possible that both 
proteins could enable each other to bind to bacterial OM through conformational changes 
promoted by protein interactions. However, additional experiments are necessary to confirm 
this presupposition. 
The next step of the combinatorial action between SP-A and AMPs appears to be in 
accordance with their ability to insert into the OM. In this thesis, monolayers of Re-LPS were 
used to examine the mechanism by which SP-A and PMBN kills bacteria synergistically. 
Model membrane systems mimicking the interfacial environment of bacterial membrane have 
been extensively used to investigate how proteins interact with membranes (404). Thus, we 
found that PMBN binds to LPS and is capable of partially insert into the bacterial outer 
membrane, corroborating reports about PMBN insertion ability on LPS (239). In contrast, SP-
A did not insert into the monolayers, likely because it is a very large protein and it has been 
suggested to form supramolecular lattice-like protein-LPS aggregates in the bacterial 
membrane surface (30). However, the presence of SP-A significantly increased insertion of 
PMBN into monolayers of Re-LPS, which may indicate the initial step of their combinatorial 
killing activity.  
Once AMPs insert into the membrane of the target bacteria, they have shown to disrupt the 
bacterial membrane by different mechanisms, from transmembrane pore formation to 
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disruption in a detergent-like manner (7, 15). Polymyxins, once they cross LPS and arise to 
the outer lipid bilayer, bind to lipid A and insert into the bilayer through their hydrophobic 
part (fatty acyl tail and Phe and Leu hydrophobic domain), thus promoting disruption of the 
highly packed lipid A fatty acyl chains of the OM (238). In addition, it has been also proposed 
that PMB promote the formation of molecular contacts between the inner and outer 
membranes of the bacteria and the induction of lipid exchange, thus resulting in loss of the 
compositional specificity of the membranes and osmotic instability (410, 411). In the case of 
PMBN, the hydrophobic segment together with peptide accumulation into the OM, as well as 
stereospecificity is probably the cause of the OM perturbation (249, 258). However, 
deficiency of a higher amphiphaticity and hydrophobicity (due to the lost of the fatty acyl tail) 
is responsible for its absence of bacterial killing (247). We found that PMBN interaction with 
the membrane would give rise to the formation of clusters of PMBN/LPS, as we have seen by 
calorimetry. This would lead to destabilization of the gel phase becoming the bacterial 
membranes more fluid, which corroborates the data obtained by fluorescence anisotropy of 
DPH and GP of laurdan. It must take into account that every biological membrane has a 
certain fundamental biophysical characteristics for the performance of its functions (11, 144). 
Thus, changes in the lateral structure or fluidity of the membrane may be sufficient to 
sensitize it and turn it weaker to other antimicrobial agents. 
Regarding SP-A, it is reported that is able to extract LPS molecules from bacterial OM to 
perturb it (30), thus likely rendering membrane leaky and creating defects to permit small 
molecules, such as water, penetrate through the bilayer LPS. This is in accordance with the 
SP-A-induced perturbation of bacterial outer model membranes that we have seen by the 
decrease in DPH florescence intensity by SP-A. In addition, the presence of PMBN increases 
this SP-A-promoted destabilization, corroborating the collaboration of both proteins in 
membrane disturbance. Despite this individual action of SP-A, it was unable to permeabilize 
bacterial model membranes. However, SP-A acted in collaboration with PMBN, enhancing 
even more the instability of the membrane caused by this peptide. SP-A increased peptide 
insertion into the membrane, probably favored by the extraction of LPS and the increase in 
fluidity caused by PMBN, thus leading to the permeabilization of the bacterial OM. The 
presence of SP-A/PMBN complex increased membrane perturbation and permeabilization of 
bacterial outer membranes, as demonstrated by changes in DPH fluorescence and leakage of 
the encapsulated probes ANTS and DPX. In contrast, the presence of SP-A did not have any 
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influence on PMBN-induced permeability of the inner bacterial membrane composed of 
bacterial phospholipids (PE/PG/CL). Taken together, these results indicate that SP-A and 
PMBN cooperate in killing bacteria because they are jointly able to disturb and permeabilize 
the outer bacterial membrane. 
In this thesis, through several experimental approaches (differential calorimetry scanning, 
mobility of membrane probes and leakage of coated probe) on liposomes containing Re-
LPS/bacterial phospholipids, mimicking the bacterial OM, we proved that SP-A and PMBN 
were able to promote changes on outer bacterial membrane structure and permeability, which 
eventually might produce bacterial death. Thus, we demonstrated that SP-A/AMPs-mediated 
disturbance and permeabilization might be the last step of the synergistic activity of SP-A 
with AMPs.  
Since SP-A was shown to be an essential part of the host immune defense against 
infection, numerous efforts have been conducted in order to better understanding its functions 
in host immunity and its therapeutic potential. Therefore, the results presented in this thesis 
provide new insights, both in vitro and in vivo, about the role of SP-A as antimicrobial 
protein. More importantly, we have shown a new potential role of SP-A for futures clinical 
applications, since it is able to enhance the bactericidal activity of two potent but cytotoxic 
exogenous AMPs, currently used to treat MDR infections (396). In addition, in the face of the 
promising role of endogenous AMPs to treat respiratory infections (53, 121), we found that 
SP-A could be a very interesting partner of these AMPs as adjuvant therapy to overcome 
infections. Finally, we elucidated the mechanism by which SP-A act in conjunction with one 
AMP in order to optimize future treatment of these antimicrobials factor. Thus, we proposed 
the next mechanism of action of the synergistic activity between SP-A and AMPs:  
i) AMPs interact with SP-A permitting SP-A access to bacteria that express smooth LPS 
and/or capsule on its bacterial outer membrane (OM); ii) SP-A is now available to bind to 
LPS and extract LPS molecules to perturb OM; iii) SP-A/AMP-dependent increase of 
bacterial OM fluidity and destabilization increase OM permeabilization, which would 
enhance AMPs access to the inner membrane of Gram negative bacteria; iv) finally, AMPs 
promote cell death by disruption of this membrane or/and translocation into the cytoplasm 
and interaction with intracellular targets.  
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To conclude, given the alarming increase in MDR Gram-negative bacteria and the paucity 
of new effective antibiotics, a better understanding of the synergistic activity between 
naturally occurring antimicrobial factors, especially concerning physiological conditions in 
vivo, may provide new insights to the development of new efficient adjunctive therapies 
against infection by MDR bacteria. 
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El trabajo presentado en esta tesis doctoral revela nuevos detalles sobre el papel de la SP-
A en la defensa del pulmón frente a la infección por bacterias Gram negativas. Además, 
proporciona datos de interés para el desarrollo de nuevas terapias alternativas o adyuvantes 
para el tratamiento de infecciones respiratorias por patógenos multiresistentes (MDR). 
Tomando todos los resultados en consideración, concluimos que: 
1. La SP-A sólo presenta actividad antimicrobiana frente Klebsiella pneumoniae K2, 
cuando carece de capsula  y su membrana externa presenta LPS rugoso profundo. Estos 
resultados destacan la importancia del LPS completo (con antígeno O) y la capsula en la 
resistencia bacteriana a SP-A. 
2. La SP-A incrementa la capacidad bactericida de péptidos antibióticos con potencial uso 
clínico, tales como polimixina B (PMB) y colistina. Además, SP-A actúa de forma 
sinérgica sobre Klebsiella pneumoniae K2 con un derivado nonapeptídico de PMB 
(PMBN) que no tiene efecto bactericida pero mantiene su capacidad de unión 
membrana externa bacteriana.  
3. La SP-A también es capaz de actuar sinérgicamente con péptidos antimicrobianos 
(AMPs) endógenos tanto catiónicos (HBD-2 y -3), como aniónicos (SP-BN), frente a 
patógenos respiratorios Gram-negativos resistentes a SP-A. De este modo, la acción 
sinérgica entre SP-A y AMPs podría ser importante en la defensa del pulmón frente a 
infecciones por bacterias Gram negativas. 
4. El efecto cooperativo entre la SP-A y AMPs endógenos se ha demostrado también in 
vivo. La SP-A junto con SP-BN fue capaz de disminuir la infección provocada por el 
patógeno K. pneumoniae K2. La acción cooperativa de SP-A/SP-BN fue consistente 
con: 1) una aumentada actividad microbicida directa de SP-A/SP-BN; 2) un aumento de 
fagocitosis de Klebsiella pneumoniae K2 por macrófagos alveolares inducido por SP-
A/SP-BN; 3) un incremento en el reclutamiento temprano de neutrófilos en el fluido 
bronco-alveolar inducido por SP-A/SP-BN; y 4) una aumentada respuesta inflamatoria 
temprana del huésped. Además, SP-A y SP-BN fueron capaces de actuar sinérgicamente 
in vivo una vez que la infección por K. pneumoniae K2 estaba establecida, demostrando 
así su utilidad terapéutica. 
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5. La SP-A interacciona con PMB, PMBN, HBDs-2 y -3, y SP-BN con una Kd en el rango 
de 0.2 a 17 µM,  lo que facilita la unión de SP-A a bacterias capsuladas o con LPS liso 
(con las que no puede interaccionar) a través de un mecanismo de interacción proteína-
proteína. 
6. Utilizando membranas modelo de la membrana externa de bacterias Gram-negativas 
hemos estudiado el mecanismo de acción sinérgico de SP-A y PMBN. El complejo SP-
A/PMBN es capaz de unirse e insertarse en la membrana externa bacteriana, pero no la 
SP-A, provocando cambios en las propiedades físicas de las membranas y 
promoviendo, de este modo, la permeabilización de la membrana y, eventualmente, la 
muerte de la bacteria. 
La acción sinérgica entre la SP-A y AMPs demostrada en esta tesis puede ser la base para 
un nuevo modelo de terapia adyuvante en infecciones pulmonares. El uso de factores 
naturales del pulmón como agentes terapéuticos debería considerarse para aumentar la 
eliminación directa de patógenos invasivos, así como incrementar mecanismos de protección 
endógenos del huésped para combatir infecciones. Además, puesto que PMB y colistina son 
antibióticos de ultimo recurso frente a microorganismos multi-resistentes a antibióticos, y 
teniendo en cuenta su alta toxicidad para el paciente, su uso en combinación con SP-A 
permitiría disminuir la dosis de polimixinas, reduciendo así su toxicidad sin disminuir su 
efecto bactericida. En este caso, el uso de SP-A con PMBN podría resultar más efectivo, 
puesto que PMBN por sí mismo presenta una menor toxicidad que PMB o colistina, y 
nuestros datos indican una eficiente acción microbicida de PMBN en combinación con SP-A.  
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The research presented in this doctoral thesis reveals new insights about the role of SP-A 
in airway host defense. In addition, it provides interesting evidences concerning the 
development of new alternative or adjuvant treatments against respiratory infections by multi-
drug resistant pathogens. Taking all data into consideration, we conclude that: 
1. SP-A has antimicrobial activity against Klebsiella pneumoniae K2 only when the 
bacterium lacks the capsule (CPS) and its outer membrane (OM) expresses deep rough 
LPS. These results highlight the importance of smooth LPS and CPS in the bacterial 
resistance against SP-A.  
2. SP-A strengthens the microbicidal effect of antibiotics with potential clinical use, such 
as polymyxin B (PMB) and colistin. In addition, SP-A acts synergistically with a 
nonapeptide derivative of PMB (PMBN), which is not bactericidal, but retains its 
ability to bind to Gram-negative bacteria. 
3. SP-A is able to act synergistically with endogenous cationic AMPs (HBD-2 and -3) as 
well as anionic AMPs (SP-BN) against Gram-negative respiratory pathogens resistant 
to SP-A. Therefore, synergic action of SP-A with AMPs might be important in lung 
defense against infection.  
4. In vivo, SP-A was also able to collaborate with SP-BN to decrease bacterial infection 
by the respiratory pathogen Klebsiella pneumoniae K2. Cooperative action between 
these proteins was consistent with: 1) an enhanced SP-A/AMP microbicidal activity; 
2) an indirect increase of phagocytosis by alveolar macrophages; 3) an increase in 
early neutrophils recruitment in the alveolar fluid from infected SP-A/AMP-treated 
mice; and 4) an enhanced early host inflammatory response. 
5. SP-A is only able to kill Kp in the presence of cationic or anionic AMPs, because 
AMPs facilitate the binding of SP-A to bacteria (with which SP-A alone cannot 
interact) through a protein-protein interaction mechanism. 
6. Using model bacterial membranes of Gram-negative bacteria, we found that SP-
A/PMBN, but not SP-A alone, is able to insert into the bacterial outer membrane, 
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promoting changes on outer membrane structure and permeability, and eventually, 
bacterial death. 
The synergistic action found in this study between SP-A and AMPs may provide a novel 
model of adjunctive therapy for pulmonary infections. Combinatorial use of naturally 
occurring lung factors as therapeutic agents should be considered to enhance killing of 
invasive pathogens as well as to increase endogenous protective mechanisms of the host to 
overcome infection. Moreover, since PMB and colistin are antibiotics of last resort against 
MDR microorganisms, the combinatorial use with SP-A would allow the use of a lower 
concentration of polymyxins, reducing their toxicity without decreasing their bactericidal 
effect. In this case, the use of SP-A in conjunction with PMBN could be more effective, since 
both together showed efficient bacterial killing, and PMBN by itself has much lower toxicity 
than polymyxins. 
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